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Background: Motor neurone disease (MND) refers to a spectrum of rapidly progressive 
neurodegenerative diseases for which there remains no cure.  A recognised and crucial 
barrier to more accurate diagnosis, prognosis and treatment relates to phenotypic 
heterogeneity.  Recent discoveries in the genetic landscape of MND have resulted in an 
accelerated research investment exploring aetiology of disease and basis of phenotypic 
variation.  Scotland benefits from a culture of longstanding MND data capture and an 
integrated healthcare system.   
 
Methods: I helped to develop Clinical Audit Research and Evaluation of MND (CARE-MND), 
an evolution of the established Scottish MND Register.  CARE-MND is a national electronic 
platform for prospective, longitudinal monitoring of MND in Scotland.  All people with MND 
(pwMND) diagnosed in Scotland in 2015-17 were included in an epidemiological study of 
incidence and prevalence of the disease.  Patients who consented to sharing their medical 
records via the Scottish MND Register were included for phenotypic characterisation and 
prognostic modelling.  Patients also donated DNA samples for genetic research to the 
Scottish Regenerative Neurology Tissue Bank.  Two cohorts were genotyped: i) a pilot cohort 
of patients diagnosed 1989-2014 who were studied using a limited six-gene panel and ii) an 
incident cohort of patients diagnosed 2015-17 who were genotyped using an extended 49-
gene panel.  Genotype-phenotype correlations were explored and the impact of genetics 
included in prognostic models.  
 
Results: By the end of my study period, the CARE-MND electronic platform was fully 
integrated into routine clinical care across all 14 health boards in NHS Scotland.  Using 
capture-recapture statistics, coverage of the CARE-MND platform was 99% making it a 
reliable resource for further study.  Direct age-standardised incidence in 2015 was 
3.42/100,000 (95% CI 2.99–3.91); in 2016, it was 2.89/100,000 (95% CI 2.50–3.34).  This 
represents a rise in incidence in Scotland by 36.0% over a 25-year period.  The standardised 
incidence was also 66.9% higher than Northern European estimates.  Of 619 pwMND 
diagnosed 2015-17, 437 (70.6%) consented to shared their phenotypic data.  The following 
variables significantly predicted mortality: rapid decline in the ALS Functional Rating Scale 





Atypical MND phenotypes (PLS, PBP and PMA), a long time to diagnosis and having ever 
smoked predicted survival.  Genetic epidemiology of a historical cohort (diagnosed 1989-
2014) using a 6-gene panel revealed pathogenic or loss-of-function variants in 17%.  Using an 
extended panel, up to 22% had pathogenic variants or variants of uncertain significance with 
pathogenic potential (VUS-P).  The cohort was enriched for the Scottish p.I114T SOD1 
founder mutation.  Gene carrier status was associated with a family history of MND and other 
neurological conditions (including Parkinson’s disease and multiple sclerosis).  Having a 
C9orf72 repeat expansion was associated with an increased risk of cognitive impairment.  
Having a genetic mutation of any kind did not influence overall survival.    
 
Conclusions: Through CARE-MND, stratification of the MND population has facilitated 
participation in observational studies and has established a platform for recruitment into 
drug trials.  The epidemiological data show a changing landscape of MND in Scotland with a 
marked increase in incidence over 25 years.  This is likely attributable to ascertainment in the 
context of improved neurological services in Scotland.  Early disability, older age and a family 
history of MND are poor prognostic markers in the Scottish population, whereas a delay in 
time from onset to diagnosis, atypical subtypes of MND and a history of smoking are 
associated with longer survival.  Clinical trial design in Scotland needs to reflect and control 
for these factors.  Using an extended 49-gene panel, 22% of patients have a potentially 
pathogenic MND-associated variant.  Diagnostic genotyping should be considered to inform 










Motor neurone disease (MND) is a devastating neurological disorder, which results in rapidly 
progressive weakness, causing problems with speech, swallowing and breathing.  On 
average, patients typically do not survive more than 2.5 years from developing first 
symptoms.  People with MND can present with a wide spectrum of symptoms, depending on 
the part of the body affected.  Some progress very quickly and some live much longer than 
expected.  It is currently very difficult to predict the pathway each individual will follow.  In 
addition, memory and behaviour change have become increasingly recognised as a problem 
affecting patients.  About 10% of people with the condition have an inherited form, with 
symptoms caused by faulty genes (‘variants’) which can be passed to family members.   
 
My PhD project aimed to gather detailed information about all people living with MND in 
Scotland between 2015 and 2017.  With the consent of people with MND, I obtained 
information about the features of their disease. I also collected blood samples to test the 
DNA for abnormal genes that might have caused disease.  This information was stored in an 
anonymised database, anchored at the University of Edinburgh, called CARE-MND (Clinical 
Audit Research and Evaluation for MND).  Through this, I tried to answer four main questions: 
 
1.  How common is MND in Scotland? 
I answered this question by completing an ‘epidemiological’ study to investigate the number 
of people newly diagnosed with MND each year (incidence), and the number of people living 
with MND in Scotland at any one time (prevalence).  We now know that about 200 people 
are diagnosed in Scotland annually.  The number of people living with MND at any one time 
ranges between 400-430.  The incidence of MND in Scotland has increased (compared to 20 
years ago), and is higher than other European countries.  We think that the main reason for 
this is that our neurologists and nurses are better at diagnosing and recording MND.  Another 
reason might be that there are now better treatments for other diseases in Scotland, such as 
heart disease, so people are more affected by conditions like MND.   
 
2.  What factors affect survival? 
I looked at the clinical features that predict outcomes (‘prognosis’) in MND.  Using CARE-





Scotland (‘phenotypes’).  I found that having early disability, being older and having a family 
history of MND results in poorer outcomes.  However, having an unusual type of MND, having 
a long time from start of symptoms to diagnosis (ie. slowly progressive disease) and being a 
current or ex-smoker results in better outcomes.  Further studies are required to look at the 
influence of smoking in Scotland before coming to any conclusions about its impact.   
 
3. What gene variants affect people with MND in Scotland? 
I did two genetic studies in this PhD, collectively looking at DNA donated by 770 people with 
MND in Scotland.  The most important genes in Scotland are called C9orf72 and SOD1.  They 
can affect people with, or without, a family history of MND.  There is a specific fault that 
occurs in the SOD1 gene that is particular to Scotland.  This is important for us because 
awareness of the genetic fault can now be raised amongst healthcare teams and testing for 
the fault provided earlier.  It may be a potential target for drug treatments for a small 
proportion of people in Scotland (4%).  We can pick up a gene fault, including rare gene faults, 
in about two thirds of people with a family history of MND in Scotland.  Up to 23% of people 
overall may have a gene abnormality.  Knowing about gene faults is helpful as it can provide 
a more secure diagnosis of MND.  It is also important to look carefully for these gene faults 
as they may affect other family members.  
 
4. Are gene variants associated with particular phenotypes? 
I studied the influence of carrying a gene variant (‘genotype’) on the clinical characteristics 
(‘phenotype’) of MND (genotype-phenotype correlation).  I found that carrying any kind of 
gene variant is associated with a family history of MND, a family history of other neurological 
conditions, and a specific subtype of MND called Progressive Bulbar Palsy.  People with the 
C9orf72 variation are more likely to have problems with cognition.  The presence of a gene 
variant likely puts an individual at risk of developing MND, but does not influence duration 
of disease.   
 
In summary, information from this PhD thesis has allowed me to describe the clinical and 
genetic characteristics of people in Scotland.  Knowing about the numbers of people with the 
disease and factors which predict outcomes helps us to organise clinical services in hospitals 
and in the community to make sure people get the care that they need.  This information 
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This thesis is largely written in the passive voice.  However, when referring to “we” it is in the 
context of collaborative or published work.  “I” is used with reference to unpublished work 









1.1 CURRENT UNDERSTANDING OF MOTOR NEURONE DISEASE (MND) 
 
The Impact and Epidemiology of MND 
 
Motor neurone disease (MND) refers to a spectrum of neurodegenerative diseases for which 
there remains no cure.  All forms of MND involve progressive decay and death of motor 
neurones in the central nervous system (CNS).  Upper motor neurones (UMNs) in the cerebral 
cortex and lower motor neurones (LMNs) in the brainstem and cervical, thoracic or lumbar 
spinal cord can be affected.  This manifests clinically with a variety of symptoms including, as 
Jean-Martin Charcot first described, “paralysis and contracture”[1] (Table 1).  The most likely 
common features, however, are rapidly progressive disability and significantly shortened life 
expectancy.  People with a ‘typical’ form of MND usually have symptom onset in the seventh 
decade[2–4], a diagnostic delay from onset to diagnosis of 10-12 months[5,6] and a survival 
from diagnosis of 1-2 years[2,5,7].  During the short disease course, people with MND 
(pwMND) might expect to acquire difficulties with walking, speaking, eating and breathing, 
necessitating medical intervention to improve quality of life and help maintain relative 
independence in daily functioning.  Cognitive/behavioural change is also a recognised feature 
in about 50% of pwMND, with approximately 15% developing frontotemporal dementia 
(FTD)[8].   
 
In simple terms, there is currently a three-pronged approach to management of MND: i) 
pharmacological treatment with riluzole, ii) feeding management with insertion of a 
gastrostomy tube, and iii) respiratory assistance with non-invasive ventilation (NIV)[9,10].  
Other interventions are available for symptom control and comfort – including medications 
for sialorrhoea, emotional lability and spasms – and are part of the palliative approach to 
MND care.  Riluzole is currently the only licensed drug for MND in the UK.  It has a modest 
benefit: based on four Class I trials, it is thought to prolong survival by 2-3 months[10–13].  
Edavarone, an intravenous drug initially developed for the treatment of acute ischaemic 
stroke, was recently approved for use in MND in the USA and Japan[14].   However, the trials 





Gastrostomy tubes, including PEG (percutaneous endoscopic gastrostomy), RIG 
(radiologically inserted gastrostomy) and PIGG (per-oral image guided gastrostomy) tubes, 
are used to maintain weight and prolong survival[9,10,16,17].  NIV can be considered for 
symptomatic treatment of respiratory muscle weakness and has survival 
benefits[9,10,17,18].  These three management strategies all require careful consideration 
and adjustment.  They all come with risk of side effects and complications.  The urgency and 
volume of decisions and interventions is incredibly challenging for carers[19].    The 
consequent impact on individuals and families is tremendous.   
 
 
 Upper Motor Neurone (UMN)  Lower Motor Neurone (LMN) 
 








Limb Symptoms Pressure sores secondary to 
contractures 
Pain secondary to spasticity 
Cramps 
Bulbar Signs  Spastic dysarthria 





Bulbar Symptoms Emotional lability Dysarthria 
Dysphagia 
 
Table 1 Signs and symptoms associated with motor neurone disease 
 
 
Historically, MND has been considered a “rare” disorder with a European incidence rate of 
approximately 2 per 100,000 of the population[20].  The median prevalence of disease is 
about 5 per 100,000, reflecting the typically terrible prognosis[20].  However, recent 
evidence suggest a UK lifetime risk of 1 in 400 and a rising global disease burden[21–23].  The 
economic impact is considerable, with annual health services costs exceeding that of patients 
following a stroke and equalling that of patients diagnosed with dementia[24].     
 
In the context of this devastating disease, clinicians and clinician scientists have a duty to be 





and care of those living with the disease and ii) prospects for future pwMND.  Clinical 
research should ideally prioritise these goals equally, in parallel.  Better knowledge of disease 
phenotypes and disease progression would enable clinicians to inform pwMND of individual 
prognosis, helping to plan care and address future risks.  Better knowledge of disease 
aetiology would provide targets for early intervention, including pharmacological therapies, 






The Heterogeneity of MND Classifiers and Clinical Phenotypes  
 
MND is notoriously heterogeneous in clinical presentation[4,25].  Clinicians and researchers 
have defined the disease by certain phenotypic ‘classifiers’ and have attempted to 
prognosticate based on these markers.  The most common manifestation of MND is classified 
as amyotrophic lateral sclerosis (ALS), which typically involves UMN and LMN degeneration 
resulting in weakness, and eventual paralysis, of muscles in the limbs, bulbar region (muscles 
of speaking, chewing and swallowing) and respiratory system[1,26].  A diagnosis of ALS is 
currently based on consensus clinical criteria, reflecting degree of diagnostic certainty and 
supportive electrophysiology information (the Revised El Escorial criteria)[27–29](Table 2).  
Interpretation of electrophysiological parameters may further guide diagnosis, such as that 
applied in the Awaji-Shima Consensus Recommendations[30].  However, in clinical practice, 
ALS is often simply dichotomised into “limb-onset” and “bulbar-onset” disease.  The latter is 
thought preferentially to affect females and older individuals and is associated with poorer 
prognosis[31].  Classifying pwMND in this way aims to guide proactive management 
strategies such as early discussions regarding gastrostomy insertion to combat feeding 
difficulties.  However, this system is likely over-simplified, as patients can present with a more 
global picture of ALS.  Patients can present with respiratory symptoms, either acutely or 
insidiously[4,31,32].  Weight loss can also be a presenting feature, in the context of global 






ALS Definite ALS Probable ALS Possible 
Evidence of UMN + LMN signs in 
bulbar region and at least 2 spinal 
regions 
 
Evidence of UMN + LMN signs in 3 
spinal regions 
UMN + LMN signs in 2 regions but 
there must be UMN signs above 
the LMN signs 
UMN + LMN signs in 1 region 
 
UMN signs in 2 regions 
 
UMN signs above LMN signs, not 










Nomenclature of MND varies globally, with countries outside of the United Kingdom, Ireland 
and Australia using ALS interchangeably with MND.  For the purposes of this research, MND 
is an umbrella term, which covers ALS and more ‘atypical’ phenotypes (MND-subtypes).  ALS 
was first identified in 1887 by Jean-Martin Charcot[1] but since then four main MND-
subtypes have been described: 
 
i) Primary lateral sclerosis (PLS) 
 
Although the term PLS was first documented by Charcot in a case report[34], diagnostic 
criteria were only formally reviewed and defined in 2006[35].  A diagnosis of PLS can be made 
if there are features of UMN degeneration (a manifestation of the discriminate involvement 
of corticospinal and corticopontine motor neurones), absence of LMN degeneration (on 
examination and on electromyographic (EMG) studies) and signs and symptoms which are 
persistent for >4 years[35].  In spite of this, emergence of clinical and EMG-supported LMN 
signs have been described 7.5-27 years after onset[36].  Mill’s syndrome is thought to be a 
descriptive clinical identifier of a hemiplegic variant of PLS[37,38].   
 
ii) Progressive muscular atrophy (PMA) 
 
In contrast to PLS, PMA is an exclusively LMN disease affecting more than one body 
region[39].  However, PMA also has clinical overlap with ALS: a study reported that 22% of 
patients diagnosed with PMA developed UMN features (50% of these only one year after 
symptom onset)[39].  While the same study observed that patients who had persistently 
selective LMN disease did have phenotypic differences to people with ALS (longer survival), 
the pathological distinction between these two diseases remain unclear. 
 
iii) Progressive bulbar palsy (PBP) 
 
PBP refers to seemingly isolated bulbar-onset disease with no emergence of limb symptoms 
in the six month period after onset[40,41].  Patients are typically female, older and have 
rapidly progressive anarthria[40].  In reality, almost all of these individuals will develop limb 






iv) Flail limb MND 
 
First described in the context of upper limb disease, flail limb MND is a rare LMN predominant 
and localised presentation.  In contrast to PBP it is seen much more frequently in males than 
females (ratio 9:1) and tends to have a slower progression and subsequent better 
prognosis[43].   
 
Whilst being heterogeneous in presentation and survival, these MND classifiers clearly have 
significant phenotypic overlap.  The prognostic implications of such labels are therefore not 
clear-cut.   
 
Cognitive/behavioural change is now also a recognised feature of MND.  This corresponds 
with frontal atrophy observed on imaging[44] and neuropathological findings in extra-motor 
brain regions[45].  Other studies have characterised the cognitive phenotype and have 
correlated with that seen in frontotemporal dementia (FTD)[46,47].  In particular, planning 
(executive function), speech (perseveration) and behaviour control (impulsivity) are features, 
leading some to argue that the cognitive features are in fact ‘motor’ in origin[1].  Over 50% 
of people with ALS are now thought to develop cognitive impairment in the course of disease, 
with approximately 15% developing FTD (usually behavioural variant FTD)[8,48].  Similarly, 
10-15% of patients with FTD develop features of MND[48].  While the majority of studies in 
cognition include people with ALS only, there is evidence that people with PLS and PMA can 
develop cognitive impairment including frank FTD[49–51].  Co-existence of FTD has been 
shown to shorten life-expectancy and complicate decision-making[52].  The nature of 
behavioural change is such that families may describe a complete change in personality.  
These features, particularly apathy, impulsivity and disinhibition, are significant predictors of 
carer stress[53].  Identification and explanation of cognitive impairment and emotional 
lability are important i) to improve patient and carer understanding of disease, ii) to facilitate 
early and supported decision making and iii) to predict and plan for potentially shortened 
survival.    
 
Phenotypic determinants have also included age of onset and survival.  Juvenile MND 





harbour a genetic cause[54].  PwMND who are atypically “long surviving” are of interest as 
they may provide clues towards therapeutic targets or clinical interventions[55–57]; this 
population may constitute up to 20% of prevalent patients[58].  Within this group, age and 
site of onset are strong predictors of outcome[55].   
 
It therefore becomes difficult to disentangle MND ‘classifiers’.  It is possible that these 
phenotypic characteristics interact and collectively contribute to a poorer prognostic 
outcome.  For example, more widespread disease (ALS) may be associated with earlier-onset 
cognitive impairment; this, combined with bulbar-onset disease, may result in rapid 
progression and poor survival.   
 
 
Neuropathological Features of MND 
 
Typical neuropathological characteristics of MND include death of i) alpha LMNs from the 
anterior horn cells of the spinal cord and brainstem and ii) pyramidal UMNs (Betz cells) in the 
primary motor cortex[59].  This leads to amyotrophy of the muscles supplied and sclerosis of 
the corticospinal tracts, giving ALS its name[26].  On post-mortem examination, cytoplasmic 
ubiquitin deposits are a key signature of MND[60].  A particular breakthrough in 
understanding was the discovery of the 43kDa transactive response DNA binding protein 
(TDP-43) in both ALS and FTD cases, strengthening the argument for their being on a common 
spectrum of disease[61].  Mislocalised TDP-43 protein is now thought to be a signature of 
neuronal and glial pathophysiology in ~95% of MND cases (including MND-subtypes), leading 
us towards a classification of “TDP-43 proteinopathies”[61,62].  Further characterisation of 
pathological markers has occurred in parallel with genetic discoveries but there is a common 
theme of: misfolded proteins, abnormal protein aggregation and cytoplasmic/nuclear 
inclusion formation resulting in a toxic cellular atmosphere[63].   
 
Study of disease progression suggests that pathology is initial focal and stochastic but 
propagates contiguously to involve other regions[59].  Pattern of UMN and LMN involvement 
supports a theory of localised pathological spread.  For example, UMN signs and symptoms 
tend to progress from ipsilateral arm to leg, but LMN signs and symptoms progress from arm 





cord cells respectively[59,63].  MND-subtypes such as PLS and PMA, where UMN or LMN are 
selectively affected, have less pathological burden, consistent with their expected longer 
survival.  The theory of contiguous spread supports the hypothesis that MND may be a prion-
like disease[64].  However, some presentations are more “multi-focal”, suggesting that 
protein dysfunction is occurring randomly rather than through propagation[63].               
 
 
Genetics of MND 
 
Over the past decade, there has been a step change in our understanding of the inheritance 
and genetic aetiology of MND.  The term “familial MND” was first described by Gowers to 
suggest an inherited pattern of MND, in spite of there being no supportive genetic evidence 
at the time[1].  In the early nineties, however, an association was recognised between MND 
inheritance and the Cu/Zn superoxide dismutase 1 gene (SOD1)[65,66].  About 9-16% of MND 
is considered inherited/familial which has naturally given genetic research necessary 
momentum[67,68].  Since the discovery of SOD1, gene discovery in MND has increased 
exponentially, largely due to improved access to next generation sequencing platforms, in 
terms of both cost and technological advancement[69,70].  Genomic technology has evolved 
from candidate gene Sanger sequencing to extended panel sequencing, whole exome 
sequencing (WES) and whole genome sequencing (WGS).    
 
At the time of writing there are 126 genes associated (both strongly and tentatively) with 
MND[71,72].  The year 2011 marked the discovery of perhaps the most significant genetic 
mutation: expansion of a hexanucleotide GGGGCC repeat in intron one of the C9orf72 
(chromosome 9 open reading frame 72) region[73,74].  The threshold of repeat burden to 
reach pathogenicity has been difficult to quantify but it is currently accepted that more than 
30 repeats is associated with symptoms, though the majority of patients have repeats in the 
order of thousands[75,76].  The C9orf72 repeat expansion accounts for up to 10% of sporadic 
MND as well as being the most common mutation in familial MND[77].   
 
Over the past two decades the following key genes have been implicated in the aetiology of 
MND: ALS2 (alsin), TARDBP (encodes TDP-43 protein)[78], FUS/TLS (fused in 





associated protein B)[81], OPTN (optineurin)[82], UBQLN2 (ubquilin-2), PFN1 (profilin 1)[83], 
VCP (valosin-containing protein)[84], CHCHD10 (coiled-coil-helix-coiled-coil-helix domain 
containing 10).  During the course of this PhD, two further genes were newly  implicated in 
MND: TBK1 (TANK-binding kinase 1)[85–87] and NEK1[88–90]. Each are thought to account 
for a small proportion of cases.  The proposed molecular mechanisms of these genes are 





Figure 1 Molecular pathways implicated in motor neurone disease and associated genes.  Adapted 
from Van Damme et al. 2016[91] 
 
 
Oligogenic mutations are also reported, often in the context of the C9orf72 expansion plus 
another gene variant[92–97].  Other genes are thought to be risk factors for MND 
development, for example the CAG repeat intermediate expansion in the ataxin-2 gene 
(ATXN2) which is more commonly associated with spinocerebellar ataxia[98].   
 
Consequently, the clinical significance of SOD1, once thought to be a breakthrough discovery, 





characteristic of TDP-43 proteinopathy, suggesting that they are in fact MND-spectrum 
outliers[99]. 
 
Our understanding of the genetics of MND continues to evolve, with an estimated doubling 
of the number of known associated genes every four years[100].  Applying this knowledge 
on a population scale may help to delineate geographical variations and targets for focussed 
genetic counselling and drug development.    
 
 
Genetic Classifiers of MND: Familial and ‘Apparently Sporadic’  
 
Concomitant with this change in practice is a rich literature-base illuminating the genetic 
epidemiology of MND.  Whilst the majority of cases of MND present without a family history, 
variants in the same genes are thought to contribute to the genetic aetiology of both familial 
and ‘apparently sporadic’ cases.  Apparently sporadic genetic carriers (or simplex cases)  are 
thought to be indistinguishable from familial cases; they were first described in Scotland in 
1994[101].  In recent series, pathogenic variants in known genes have been found in 68% of 
cases with a family history and 11% of apparently sporadic cases[102].  The C9orf72 repeat 
expansion remains the most commonly identified mutation, thought to be causative in 10% 
of apparently sporadic cases, 30% of familial cases and up to 88% of cases of MND with 
FTD[100,103].  A recent meta-analysis calculated that SOD1 mutations were present in 18.9% 
(95% confidence interval (CI) 15.4-22.6%) of familial pwMND and 1.2% (95% CI 0.8-1.8%) of 
apparently sporadic cases[104].  Overall, approximately 10-15% of MND cases are now 
classified as having a monogenic aetiology in international case series/cohorts[77](see Table 
3).  These data lead us to believe that categorising people into “sporadic” and “familial” 
groups is partially artificial[100,105].  An important meta-analysis of “sporadic” MND-
concordant monozygotic twins estimated a heritability of disease of 0.61 (95% CI 0.38-0.78); 
the unshared environment contributed 0.39 (95% CI 0.22-0.62)[106].  This study suggests 









It may be possible to associate particular genetic mutations, or sets of mutations, with a 
particular phenotypic picture: “genotype-phenotype correlation”[105].  In this way, early 
genetic testing of an individual might help to confirm diagnosis and predict future outcome 
of the disease.  Some links have been postulated (genes listed in order of discovery; 
summarised in Table 3): 
 
 
i. SOD1    
In general, most people with a pathogenic/likely pathogenic SOD1 mutation are thought to 
develop a “classical” form of ALS which progresses rapidly[107].  Onset is usually in the lower 
limbs and associated cognitive impairment is very rare[108].  Case reports of rare 
presentations are documented, including autonomic failure[109], ataxia, neuralgia and 
bladder disturbance[108].  Most mutations are dominant but the p.D91A variant has been 
identified in both heterozygous and homozygous states[110].  The homozygous form of the 
mutation is thought to originate from a Scandinavian population and, interestingly, has a less 
aggressive course than the heterozygous mutation[110,111].  The p.H48R variant found 
predominantly in Japanese populations has similarly long survival with rare bulbar 
involvement[112].  Conversely, the p.A5V mutation, the commonest SOD1 variant in the USA 
and one of the first described, is characterised by rapid progression (survival <2 years from 
onset)[65,113,114].  Over 185 SOD1 variants have been reported so far covering all five exons 
of the gene[108].  With increasing global interest in genome sequencing, genotype-
phenotype associations will continue to become apparent.  For example, the p.D12Y variant 
was relatively recently associated with distal muscle involvement and very slow 
progression[115,116].   
 
ii. ALS2 
Recessive or compound heterozygous mutations in this gene cause MND at a very young age 
resulting in the following phenotypes: infantile ascending hereditary spastic paraplegia 
(IAHSP), juvenile PLS (JPLS) and juvenile ALS (JALS)[117,118].  Many of the ALS2 variant 





phenotypes, such as members of a family with a splice site mutation who had accompanying 
anarthria and dystonias[119].   
 
iii. VAPB 
VAPB mutations are rare and the phenotypic presentations heterogeneous and so no 
conclusive correlations have been postulated.  A detailed study of a particular kindred found 
a phenotype which represented most closely adult-onset spinal muscular atrophy with 
autonomic features and movement disorder (constipation, sexual dysfunction and 
tremor)[120].  This phenotype is very distinct from typical ALS and perhaps suggests a 
separate disease process. 
 
iv. TARDBP 
Individuals with TARDBP mutations have heterogeneous features but all usually fall within 
the ALS spectrum[107].  The p.A328T mutation has been particularly studied and is thought 
to be a Sardinian founder mutation, accounting for 28.7% of all cases of MND (familial and 
apparently sporadic) in the region[121].  Individuals with this variant have been reported to 
have extrapyramidal features; however, the authors acknowledge that other mutations or 
neuroleptic medications might also account for these findings[121].  TARDBP mutations have 
also been found to cause MND with FTD[122].   
 
v. FUS 
FUS variants have been associated with younger onset disease.  For example, the p.P525L 
variant is considered a particularly important cause of juvenile ALS (<25 years onset), with an 
aggressive disease course[123].  Although FUS mutations have been reported in atypical FTD 
(Basophilic Inclusion Body Disease)[124], cognitive impairment is not thought to be a feature 
of FUS MND[125].      
 
vi. OPTN 
Several OPTN variants have been reported in people with primary open angle glaucoma 
(POAG) and so it is important to separate these from those found in MND.  Most of the OPTN 








In 2010, an exome sequencing study identified individuals with ALS in families with 
multisystem disease including inclusion body myopathy with Paget disease of bone and 
frontotemporal dementia (IBMPFD)[84].  Manifestation of the VCP syndrome in family 
members is very variable, and ALS is now considered part of the wider phenotype.  VCP 
mutations causing MND, however, are rare in the UK[126].  As shown in Figure 1, VCP is 
involved in proteostasis and delivery of proteins to the autophagosome.  It operates with 
OPTN, TBK1 and UBQLN2 but yet has such a distinct clinical manifestation of disease.  This 
might allude to the fragility and vulnerability of these pathological pathways and provide 
some explanation for the wide phenotypic spectrum of MND disease.   
 
viii. C9orf72 
Ethnic origin is a strong factor in C9orf72 expansions: it is particularly enriched in the Finnish 
population, found in 28% of a population cohort of pwMND[73], but is relatively uncommon 
in Asian populations[127,128].  Indeed, the expansion is thought to originate from a single 
European founder mutation[129,130].  The phenotype of patients with the C9orf72 
expansion varies greatly within the literature.  Certainly it is associated with an increased risk 
of cognitive impairment and FTD[103,131,132] and it may also cause psychotic symptoms 
without dementia[133] and/or a neuropsychiatric prodrome of MND/FTD[134].  Some 
studies also suggest that it is significantly associated with younger age of onset and shorter 
survival[132], faster decline in respiratory function[135] and that males with spinal onset 
disease have shorter survival[136].  Meanwhile, others suggest that it has no impact on age 
of onset, survival[129], or site of onset[137].   
 
ix. UBQLN2 
The only known X-linked MND-associated gene, UBQLN2 mutations are also rare.  They can 
affect both males and females but males present earlier, likely due to the 
hemizygosity[107,138].  Variants in this gene are also associated with MND-FTD[138]. 
 
x. PFN1 
PwMND harbouring PFN1 mutations tend to be younger at onset, have limb-onset disease 







CHCHD10 is the only MND-associated gene that causes mitochondrial dysfunction.  
Individuals with these mutations can have cognitive impairment, as well as cerebellar ataxia 
and myopathy, but, again, they are rarely seen in UK cohorts[140,141]. 
 
xii. TBK1 
In 2015, a whole exome burden analysis newly identified an association between MND and 
the TBK1 gene[86].  The TBK1 protein interacts with products of OPTN and TARDBP, giving it 
a tantalising “narrative potential”[86].  TBK1 MND has been replicated in multiple 
populations; variants are also associated with cognitive impairment (approximately 50% in 
one study) and frank FTD[85,87,142].   
 
xiii. NEK1 
The latest genetic association with MND was a result of pooled efforts of genomic consortium 
members[88].  A single variant was enriched in a small Dutch population but otherwise 
genotype-phenotype correlations are unclear.   
 
 
Additionally, genetics have been used to refine the aforementioned definitions of “juvenile” 
MND by identifying those genes that cause MND before the age of 10 years (ALS2, SETX, 
SIGMAR1 and SPG11) and between 10-24 years (ANG, FUS, SETX, SOD1, SPG11, UBQLN2 and 
VAPB)[108].   
 
To complicate matters, however, gene mutations have been documented to result in variable 
phenotypic traits, even within the same family (genetic pleiotropy)[143].  Examples of this 
have been described in C9orf72, SOD1 and VCP carriers, with varying ages of onset, disease 
site of onset, rate of progression and burden of cognitive/behaviour change amongst first 
degree relatives with the same mutation[75,77,143,144].  As mentioned, phenotypes of 
genetic MND can also extend beyond the traditional spectrum of disease to other 
neurodegenerative disorders[1].  As well as FTD, Parkinsonism (tremor, rigidity and 
bradykinesia) is a well-reported feature which can coincide with or succeed MND signs and 
symptoms[145,146].  C9orf72 expansions have been observed in patients presenting with 





Huntington’s disease (HD)/HD phenocopy)[149].  The decision to consider these other 
neurodegenerative diseases as a “positive” family history is debatable[100] but certainly 

















SOD1 21 1993 Homodimeric 
metalloenzyme which 
catalyses removal of 
superoxide into oxygen 
and peroxide[108,151]  
Accumulation of 
misfolded protein/toxic 








ALS2 2 2001 Alsin comprises guanine-
nucleotide exchange 
factors (GEFs) that 
activate  GTPases[117]  
Loss of function of alsin 




Juvenile ALS, PLS 








VAPB 20 2004 A membrane protein that 
associates with 








Nil Unclear  Unclear  
TARDBP 1 2008 Active in RNA processing, 

































OPTN 10 2010 Inhibits activation of 
nuclear factor kappa B (NF-
kB)[82] 




OPTN and causing 







2010 Involved in maturation of 
ubiquitin-containing 
autophagosomes[84] 
Mutant VCP expression 







C9orf72 9 2011 Noncoding intronic 
hexanucleotide 
repeat[73,74] 




















PFN1 17 2012 Converts monomeric G-













CHCHD10 22 2014 Mitochondrial protein 
located in intracellular 
space[140] 
Thought to impair 
oxidative 
phosphorylation[140]  








TBK1 12 2015 Autophagy, 
phosphorylates optineurin 
(OPTN), role in innate 
immunity signalling 
through NF-kB pathway 
[100] 
Abrogates optineurin 
binding and may 










NEK1 4 2016 Formation and 
maintenance of cilia[100] 
Interacts with ALS2 and 
VAPB proteins; 
impaired cytoskeletal 
organisation; DNA and 













Phenotypes and Genotypes of MND: Conclusions from current understanding and 
unanswered questions 
 
In spite of the above characterisations, a clear aetiology of MND has evaded the research 
community for many years.  There is clear overlap between previously described 
classifications of disease, suggesting that this is insufficient.  We can therefore conclude that 
there is a phenotypic spectrum of disease, with heterogeneous presentation but eventual 
unifying end-organ damage to muscles and brain/corticospinal tracts.  There are 
commonalities in the neuropathological features of ALS and FTD, suggesting that FTD is also 
on the same spectrum.  Recent discoveries in the genetic landscape of MND have provided 
important clues, have resulted in an acceleration in research investment and have raised the 
public profile of the disease.  Causative genes have distinct pathological hallmarks suggesting 
that classification of disease by genotype, or proteinopathy, might provide the best clues for 
prognostication.  However, most genetic mutations that are thought to be causative are 
autosomal dominant and adult-onset.  This delay in onset suggests that the genetic burden 
imparts susceptibility, but that further triggers are required to overcome the disease 
threshold[63].  Recent studies support a multifactorial aetiopathogenesis with genetic 
and/or environmental risk factors: the “gene-time-environment (GTE)” hypothesis[143,160].  
However, the interplay of multiple phenotypic and genotypic classifiers on prognosis is 
largely unknown.  
 
Aetiological uncertainties have direct implications for provision of accurate diagnosis and 
prognosis, delivery of subsequent patient care, establishing appropriate services/clinical 
infrastructure, and crucially are a major obstacle to conducting clinically and genetically 
stratified clinical trials.  Consequently, it would seem prudent to understand the genetic 
epidemiology and environmental influencers of a clinical MND population, to appreciate the 









1.2 CHALLENGES IN GENOTYPES AND PHENOTYPES OF MND 
 
Challenges in identifying genotype-phenotype correlations 
 
Successful genotype-phenotype correlation relies on having access to a full and rich database 
of patient characteristics with optimal acquisition of DNA samples.  Historically this has been 
a major limiting factor in the discovery of potentially causative associations[108].  For 
example, in 2011 an Italian study proposed a link between UMN predominant MND and a 
particular single nuclear polymorphism within the kinesin-associated protein 3 (KIFAP3) 
gene[161].  These findings could not been replicated, however, due to poorly defined patient 
populations[105].  Variants in genes known to be associated with MND are not always 
‘pathogenic’, or disease-causing.  Supportive evidence requires information about the 
individual’s clinical phenotype and a detailed family history[100].  Indeed some of the 
previously reported pathogenic mutations are now thought to have been polymorphisms, for 
example, in the SETX gene[162].  This could very well be the case in other MND-associated 
genes.   
 
In spite of this, genotype-phenotype study remains challenging due to the rarity and breadth 
of the gene mutations concerned.  Study of the C9orf72 expansion has been possible due to 
its being the biggest monogenic contributor to MND.  However, multi-centre or meta-
analysed data are often required to reach conclusions[132,163,164].  Otherwise numbers are 
small and observations only hypothesis-generating, such as those speculated regarding 
particular SOD1 variants[109,112,165]. 
 
 
Challenges in clinical genetic testing in MND 
 
The growing acceptance of “genetic MND” has fuelled a need for routine clinical genetic 
testing.  Global collaboration in the field continues to generate massive patient databases, 
allowing for new gene discovery, validation of previous findings and use of whole exome and 
whole genome technology to its full potential.  In parallel, patient and clinician attitude to 





unknown aetiology[166].  Recent patient surveys suggest a move towards more proactive 
consultations, with 80% of patient responders having an understanding of MND genetics and 
59% being aware of clinical testing options[167].  Further, enquiries about clinical, pre-
symptomatic and pre-natal genetic testing are now being broached[168,169].   
 
Clinicians at point-of-care, as well as genetic counsellors, have a duty to facilitate informed 
discussions but also to emphasise associated complexities (Figure 2).  The European 
Federation of Neurological Sciences revised guidelines are clear that genetic testing is only 
recommended for individuals with a known family history of MND, or for individuals with 
symptoms in-keeping with the unusually slowly progressive phenotype seen in those with 
the SOD1 p.D90A mutation[170].  However, reporting of family history of disease can be 
clouded by adoption, non-paternity, incomplete recollection, family estrangement, lack of 
recognition of MND phenotype or death before onset of symptoms[169].  National guidelines 
from the USA and UK do not address genetic testing[9,10].  Although it is universally agreed 
that indiscriminate genetic testing is unhelpful to patients and their families, it has been 
suggested that clinicians, along with multidisciplinary experts,  introduce the concept of 
genetics and inheritance in all pwMND[166,168].  While 83% of pwMND agree with this 
approach, in reality only 35% of are offered genetic testing[167].  However, reservations exist 
due to perceived lack of benefit to patients and family members while genetically stratified 
treatments are not available.  Lack of genetic counselling support is cited as a barrier, 
especially where variants of uncertain significance (VUS) are identified[171].  Clinicians agree 
that consensus guidelines for genetic testing would encourage implementation[171].  The 
unmet need is starting to be addressed, with the recent publication of recommendations for 








Figure 2 Barriers to clinical genetic testing of patients with motor neurone disease 
 
 
Challenges in predicting outcomes in MND 
 
As is clear from the heterogeneous nature of disease and the multitude of gene associations, 
predicting patient outcomes is complex.  For pwMND, this is unsatisfactory.  In blunt terms, 
individuals diagnosed with MND are unable to foresee likely intervention requirements, or 
estimate time until death.  Further, identification of outcome predictors are essential for 
MND discovery.  Investment in MND research is leading to a wave of new foundations for 
targeted drug trials[173–176].  In preparation, clinical trial-ready well-characterised patient 
populations will be key.  Patient stratification for clinical trials depends on knowledge of key 
predictors of outcomes.   
 
For prediction models to be useful, they must be: 
 
i) Inclusive – all disease-relevant variables available for model development 
ii) Generalisable -  applicable to populations beyond the ‘test’ population 





iv) Clinically relevant – intuitive for clinicians and informative for patients 
 
Many previous prognostic modelling studies have focussed on clinical trial participants or 
patients recruited from tertiary referral centres[177].  However, these patients are known to 
be different to the general MND population, being typically younger, having longer survival 
and the cohorts are enriched for atypical (and longer surviving) phenotypes such as PLS and 
PMA[178].  A likely explanation for this is that these patients have milder or stable disease 
and they are therefore able to access site visits and engage in follow-up.  Younger patients 
are perhaps more likely to explore research opportunities online and have support networks 
to facilitate enrolment.  As such, models designed with trial/study data are likely not 
representative of the MND population and might fail to identify factors associated with 
rapidly progressive disease[179,180].        
 
Identification of an appropriate outcome for prognostic modelling is the first hurdle.  
Ultimately, the most reliable endpoint is death.  However, other markers have been explored 
such as time to NIV[181] and progression in the revised ALS Functional Rating Scale (ALSFRS-
R)[182,183].  The ALSFRS-R is a measure of limb, bulbar and respiratory function in daily 
living.  Although the course of decline in ALSFRS-R score is largely heterogeneous and 
unpredictable[183], its ease of use and acceptability to patients and care providers makes it 
an appropriate marker for clinical practice and research[184,185].  ALSFRS-R subscores may 
be more sensitive than patient self-report in predicting bulbar and limb symptoms; however, 
they do not appear to correlate well with respiratory function[186].  In view of its uncertain 
trajectory, its use as a prognostic endpoint is questionable.   
 
Prediction modelling is becoming a key research priority and several models have been 
proposed[6,143,183,187,188].  The largest and most generalisable of these models was 
recently described by Westeneng et al.[6].  This large, multi-centre study examined the 
influence of 16 phenotypic variables on a composite outcome of death, NIV use >23 hours 
per day, or tracheostomy insertion.  A backwards elimination process with bootstrapping was 
used to select predictors with imputation for missing data.  Eight predictors were selected 
for the model, including: age at onset, forced vital capacity (FVC), diagnostic delay, ALSFRS-R 
slope of decline, bulbar onset disease, definite ALS, presence of FTD and presence of the 





analysis could be conducted whereby results were trained on data with one site left out, and 
then tested on the remaining site.  These data were used to develop a tool for classification 
of patients into a likely survival outcome, ranging from very short to very long survival.  
However, riluzole use, NIV and gastrostomy insertion were not considered as predictor 
variables.      
 
There are many different statistical approaches for prediction modelling, from conventional 
statistics using binary and linear regression, to more advanced machine learning approaches.  
Regardless of the methods used, a priority from outset is to avoid a “sparse data bias” 
whereby there are insufficient individuals with the outcome of interest relative to the 
number of predictors (the Events Per Variable (EPV)[189].  An EPV of at least ten (the ‘one-
in-ten’ rule) is generally considered satisfactory though there are exceptions[189].  Reduction 
of the number of predictors requires care; one approach is to remove non-significant 
variables from the model in a stepwise fashion (backwards elimination) but this risks 
excluding important confounding variables which might suppress the effects of remaining 
variables, thereby resulting in over-inflated, biased results[189,190].  Another 
recommendation is the use of penalisation, whereby the model coefficient estimates are 
‘shrunk’ based on Bayesian theory, to reduce the variance within a model and ensure that 
the effects of a given variable are not inflated[189]. 
 
Further, missing clinical data in population databases are problematic, often because they 
are mishandled and therefore excluded, risking loss of valuable patient information[191].  For 
example, one population study of survival excluded 15% of pwMND because of missing 
data[7].  Missing data can be missing completely at random (MCAR), missing at random 
(MAR) or not missing at random (NMAR)[191,192].  Complete exclusion of MAR and NMAR 
data leads to systematic bias when predicting outcomes.  Statistical methodology to 
overcome missing data is becoming more widely recognised, and includes both single and 
multiple imputation methods[191,193,194].  Imputed values are obtained by examining 
relationships between and within variables, again using a Bayesian approach.  
 
Recent recommendations have been outlined by an expert committee for the reporting of 
prediction model methodology: the Transparent Reporting of a multivariable prediction 





these will now provide structure and rigour to future studies and will allow for better 
replication between populations.   
 
 
1.3 SCOTTISH MND INFRASTRUCTURE 
 
The medical infrastructure of Scotland makes it an ideal location for the detailed study of 
rare diseases.  We rely on three key strengths of Scotland: i) the National Health Service (NHS) 
in Scotland is a nationwide unified entity; ii) Scotland has a stable population structure with 
a relatively high incidence of certain diseases, including neurodegenerative diseases; iii) each 
patient has a unique community health index (CHI) identifier, enabling data linkage between 
community, hospital, prescribing and population health records[197].  The result is an 
integrated healthcare system, whereby patient data are uniformly collected across 14 health 
boards (Figure 3).  Prospective, longitudinal monitoring and epidemiological analyses of rare 
diseases are therefore eminently possible.  Scotland has one of the highest incidences of 
multiple sclerosis (MS) in the world and research into this disease has set precedent for other 
neurodegenerative diseases[198].  Scotland also has a history of robust epidemiological 









Figure 3 Fourteen health boards in Scotland 
 
 
The Scottish MND Register (SMNDR) 
 
The Scottish MND Register (SMNDR) is, to our knowledge, the first prospective national 
register of MND globally (the first retrospective national epidemiological study was in Israel 
1959-1974[201]).  In operation from January 1989, the register aimed to record and follow-
up all incident cases of MND in Scotland; in view of the projected number (100-120 incident 
cases per year) this was considered achievable[202].  A full time nurse specialist and an IT 
team, as well as willing neurologists and neurophysiologists throughout Scotland, supported 
the register.  Studies of the clinical characteristics and survival of the Scottish population 
were possible[203–205].  In combination with national hospital and death records from 
Information Services Division (ISD) Scotland, the register was able to achieve 98% case 
ascertainment[3].   
 
In 2011, the register was modernised into a web-based interface – the Scottish Motor 





Department of Clinical Neurosciences in Edinburgh  making it more accessible to MND 
neurologists at point-of-care (usually outpatient setting) and permitting prospective data 
entry.   
 
 
The Edinburgh Cognitive and Behavioural ALS Screen (ECAS) 
 
The recognition of the substantial prevalence and impact of cognitive abnormalities in 
pwMND, including MND with FTD, is now well established[8]. This reflects in part the advent 
of standardised cognitive tools such as the recently validated Edinburgh Cognitive and 
Behavioural ALS Screen (ECAS) pioneered by Edinburgh Clinical Neuropsychology[206–208].  
The ECAS has been incorporated into routine clinical care and MND research globally: there 
are now multiple versions and it has been translated into several different languages[209–
211].  The ECAS can also be used to measure change in cognition over time[212,213].   
 
 
The Scottish Regenerative Neurology Tissue Bank 
 
The Scottish Regenerative Neurology Tissue Bank evolved as a result of growing interest in 
genetic research into neurodegenerative diseases, particularly MND.  A study of the 
frequency of SOD1 mutations in the Scottish population paved the way for subsequent 
creation of what is essentially an anonymised research ‘DNA bank’ to give patients the 
opportunity to contribute to this emerging field[214].  The Tissue Bank is hosted by the 
University of Edinburgh and has capabilities for storage of DNA from blood or saliva, and 
cerebrospinal fluid samples, for future research.  DNA studies are overseen by the South East 
Scotland Clinical Genetics Service.   
 
 
Genetic Testing in Scotland  
 
In response to the urgent need for systematic clinical genetic testing of neurodegenerative 





2014.  This included many of the major genetic causes of MND: C9orf72, SOD1, TARDBP, FUS, 
UBQLN2, VAPB, VCP, MAPT, GRN, CHMP2B and SQSTM1 (Pal & Porteous, University of 
Edinburgh (2014) [unpublished]). The selection of these genes was informed by sporadic 
diagnostic testing in Scottish MND and cognitive clinics.   
 
Additionally, new and improved methods for detecting the C9orf72 repeat expansion have 
been pioneered in Scotland[215].  The expansion is notoriously challenging to identify and 
quantify due to its GC-rich sequence.  Indeed, blinded testing by 14 laboratories revealed 
significant discrepancies in detection results[216].  By incorporating a technique used for a 
similar repeat expansion syndrome (heat-pulse extension (HPE) used in Fragile X), the 
Edinburgh-based group developed a robust C9orf72 detection assay, involving a flanking 
assay plus bidirectional repeat-primed PCR assays[215].  These methods are able to detect 
expansions in the order >100. 
   
 





Through the SMNDR, inferences about the Scottish MND have been made.  A study of 
incident pwMND diagnosed between 1989-1990 observed a median survival from onset of 
2.5 years (95% CI 2.2-3.0)[203].  A diagnosis of PBP/bulbar symptoms was a significant poor 
prognostic marker.  A long-term follow-up study between 1989-1998 allowed for accurate 
calculation of the incidence of disease, which was stable over this 10-year period (2.40 per 
100,000 of the population (95% CI 2.22-2.58))[3].  In this population of 1226 patients, the 
male-to-female ratio was 1.19:1, 60% had spinal-onset disease and the frequency of familial 
MND was 4.8%.  Median survival was 2.1 years (interquartile range (IQR) 1.3-3.2).  The 
observation of poorer survival in the latter study prompted further analysis, which revealed 
that survival was actually declining over the years[217].  Contributors to this included bulbar-
onset disease, as previously observed (Hazard Ratio (HR) 1.25 (95% CI 1.09-1.46)) and 
increasing age.  Variables associated with better survival included longer diagnostic delay (HR 





riluzole use (HR 0.24 (95% CI 0.14-0.42))[217].  During this study period, the rate of 
intervention with gastrostomies for dietary supplementation doubled but did not confer any 
significant survival advantage[218].   
 
A related study identified that 11% of this population were age 80 years or over, of which 
50% had bulbar-onset disease[204].  Older people with MND were less likely to be prescribed 
riluzole (Odd’s Ratio (OR) 0.12 (95% CI 0.02-0.89)) or be assessed by a neurologist (OR 0.76 
(95% CI 0.67-0.86)). 
 
The SMNDR historically has aimed to be a prospective and dynamic population register and 
this is evident from a study which evaluated the diagnostic certainty of register cases[205].  
This identified that 8% of patients studied had alternative diagnoses on follow-up, making 
researchers aware of the diagnostic difficulties and the need for continuous re-





Following the discovery of SOD1 MND variants, an unselected population of 67 apparently 
sporadic and familial cases of MND in Scotland were directly sequenced for variants in the 
gene[214].  SOD1 variants were detected in 50% (5) of familial cases and 7% (4) of the 
sporadic cases.  Six of these unrelated patients had p.I114T variants.  Subsequent analysis 
showed that these individuals had a shared haplotype, leading us to believe that the variant 
is a Scottish founder mutation[219].   
 
As part of the development of the Scottish neurodegenerative disease gene panel in 2014, a 
pilot study examining for C9orf72 expansions only, observed mutations in 8.3% (8/96) 

























1 45 22 Y Limb Y Y 
2 50 9 Y Bulbar  Y Y 
3 61 4 Y Limb &bulbar N N 
4 60 2 Y Limb N N 
5 37 1 Y Limb Y Y 
6 58 4 Y Limb Y N 
7 67 3 Y Limb Y N 
8 61 4 Y Limb Y Y 
 
Table 4 Pilot data illustrating phenotypic heterogeneity amongst patients with pathogenic C9orf72 









1.5 THESIS QUESTIONS, OBJECTIVES AND HYPOTHESES 
 
In this introduction I have attempt to outline the current issues presented by phenotypic 
heterogeneity in MND, the recent explosion in knowledge of underlying genetic mutations 
and the lack of clarity in how these factors impact on survival.  The current incidence and 
phenotypic components of the Scottish MND population is unknown.  Similarly, in spite of 
accumulating DNA donations to the Scottish Regenerative Neurology Tissue Bank, gene panel 
testing of this population has not been exploited and so the incidence of gene carriers is also 
unknown.    
 
During my PhD, I aimed to answer some of these questions with specific reference to the 
Scottish population.  In order to achieve this, I helped to modernise the existing Scottish MND 
Register by creating a national electronic platform for integrative data capture of incident 
cases of MND.  This platform (methods and utility outlined in Chapter 2) underpins 
subsequent study of the MND population and allows me to explore the following research 
questions:  
    
 
Question 1: Has the incidence of MND in Scotland changed over time? 
 
Objectives: 
- To determine the incidence and prevalence of MND in Scotland 2015-2017. 
- To analyse rate of change in incidence relative to the historical Scottish MND cohort 
(1989-1998). 
- To compare incidence rates to global estimates.  
 
Hypotheses: 
- The global trajectory of MND incidence is rising due to aging populations[21].  I 
therefore expect the incidence of MND in Scotland to have risen over time.   
- I expect that the incidence and prevalence of MND in Scotland in 2015-2017 will be 






Question 2: Can deep clinical phenotyping of the Scottish MND population reveal 
predictors of survival? 
 
Objectives:  
- To optimise on the breadth of phenotypic information that can be acquired regarding 
pwMND in Scotland (including disease characteristics, and endogenous and 
exogenous environmental exposures) and to describe phenotypic classifiers. 
- To combine all phenotypic classifiers and environmental risk factors into a prognostic 
model to identify stratifiers of disease.   Due to the expected median survival of 
pwMND in Scotland (2.1 years from onset[3]), survival studies of MND in Scotland 
will be achievable within the time-frame of this PhD project. 
 
Hypotheses: 
- The use of a standard phenotype proforma will allow a detailed characterisation of 
the Scottish MND population.   
- Results will provide clarification about the impact of endogenous or exogenous 
environmental influences and which will be hypothesis generating for future studies.   
- Results will identify predictors of survival, which will help inform patients, care-
providers and future research studies, including clinical trials.  Based on previous 
Scottish data, survival will be influenced by age, diagnostic delay and riluzole 
use[217].     
 






Question 3: What is the genetic epidemiology of MND in Scotland?  In particular, are 
there mutations unique to the Scottish population and are rare/newly described 




- To test a historical research cohort of pwMND using a select panel of key MND genes 
to identify the proportion of genetic carriers. 
- To test an incident research cohort of pwMND using an expanded and up-to-date 
neurodegenerative gene panel.  To use these data to describe the genetic 
epidemiology of MND in Scotland.   
- To develop a framework for the classification of pathogenicity of MND genomes and 
apply this to our genetic results.   
 
Hypotheses: 
- As with other European populations, I expect that that the most frequent genes in 
the Scottish MND population will be the C9orf72 hexanucleotide expansion and 
SOD1.  Based on previous study in Scotland, I expect the population to be enriched 
for the SOD1 p.I114T variant.   
- Based on the literature I expect to find rare variants and oligogenic gene carriers in 
the Scottish population.   
- Results will highlight genes that are relevant, and irrelevant, to the Scottish MND 
population and will therefore inform future clinical genetic testing of pwMND and 








Question 4: Can deep clinical phenotyping and extended genotyping of an incident 
MND cohort identify genotype-phenotype correlates (with particular regard to 
C9orf72 and SOD1)? 
Question 5: Does genotype influence survival in a multivariable prognostic model of 
MND in Scotland? 
 
Objectives: 
- To use the clinical and genotypic data of incident pwMND to undertake a national 
population based genotype-phenotype correlation study.   
- To incorporate genetics into prognostic models to assess the relative influence of 
genetics on survival and thereby select the most appropriate statifiers for future 




- Analyses will identify phenotypic characteristics associated with key MND-
associated genes such as C9orf72 and SOD1.    
- Patients with the C9orf72 expansion are expected to have cognitive impairment.  
They may have younger age of onset and poorer survival.  
- Patients with a SOD1 variant are expected to have limb onset disease.   
- Numbers of pwMND with rare gene mutations will be small and are unlikely to 
identify statistically significant associations but may identify characteristics which 
can be validated in future larger studies.  
- The presence of a likely pathogenic gene mutation is expected to impact poorly on 





1.6 ETHICAL APPROVALS 
 
This study is covered by ethical approvals for the SMNDR/Clinical Audit Research and 
Evaluation of MND (CARE-MND) and the Scottish MND DNA Bank/Regenerative Neurology 
Tissue Bank.  SMNDR approvals are: MREC/98/0/56 1989-2010, 10/MRE00/78 2011-2015.  In 
2015 the ethical approvals were renewed by the Scotland A Research Ethics Committee 
15/SS/0126 for this study.  The Scottish MND DNA bank was approved by MREC/98/0/56 
1989-2010, 10/MRE00/77 2011-2013, approved by the Scotland A Research Ethics 
Committee and the Scottish Regenerative Neurology Tissue Bank (including DNA collection) 
by MREC/98/0/56 1989-2010, 10/MRE00/77 2011 to 2013, 13/ES/0126 2013-2015, 
15/ES/0094 2015-present, approved by the Chief Scientist Office Scotland.  NHS Scotland 
Caldecott Guardians approvals were granted for all 14 participating health boards in 
Scotland.  The author was granted relevant honorary contracts or local R&D approval for 
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2. CARE-MND: A POPULATION DATA PLATFORM 
 
The following content has been published in Amyotrophic Lateral Sclerosis and 
Frontotemporal Degeneration[220].  It has been re-formatted for this thesis to include 
additional data relevant to thesis methodology. 
 
Danielle Leighton, Judith Newton, Shuna Colville, Andrew Bethell, Gillian Craig, Laura 
Cunningham, Moira Flett, Dianne Fraser, Janice Hatrick, Helen Lennox, Laura Marshall, 
Dympna McAleer, Alison McEleney, Kitty Millar, Ann Silver, Laura Stephenson, Susan Stewart, 
Dorothy Storey, Gill Stott, Carol Thornton, Carolyn Webber, Harry Gordon, Giulia Melchiorre, 
Laura Sherlock, Emily Beswick, David Buchanan, Sharon Abrahams, Anthony Bateman, Jenny 
Preston, Callum Duncan, Richard Davenport, George Gorrie, Ian Morrison, Robert Swingler, 
Siddharthan Chandran & Suvankar Pal. Clinical audit research and evaluation of motor 
neuron disease (CARE-MND): a national electronic platform for prospective, longitudinal 








Scotland has a population of 5.3 million and benefits from an integrated healthcare system, 
in which patient data are uniformly collected across the 14 health boards of NHS 
Scotland[221].  Individuals are identified by the unique 10-digit CHI number, which can be 
referenced against local and national health records.  Health boards have close academic 
links to the major University centres.  Prospective, longitudinal monitoring and 
epidemiological analyses of rare diseases are therefore feasible.  The Scottish Motor Neurone 
Disease Register (SMNDR) is a prime example.  Launched in 1989, the SMNDR was the first 
prospective registry of people living with MND[222].  It gave robust estimates of regional 






In 2005, NHS Scotland commissioned a review of the care of people with neurological 
diseases, identifying that such diseases were given low priority for strategic service 
provision[223].  This led to Health Improvement Scotland (HIS) best practice standards[224].  
Further to academic grant funding from MND Scotland, a web-based audit tool was designed 
to record SMNDR data, which could be used to compare against HIS guidelines (Scottish MND 
Audit, Research and Trials (SMART) study).  This was the first national audit of MND care.  It 
highlighted that over 91% of pwMND in 2011-13 were cared for within a specialist MND 
service.  However, only 21% (3/14) of health boards had dedicated MND clinical pathways.  
HIS standards recommended contact with an MND specialist within two working days of 
diagnosis.  These data were only available for 10% of incident cases in the audit period, with 
only 48% of these meeting this target.  Indeed, a parallel Scottish study indicated that 
patients and carers felt that access to MND services was poor and that clinical specialists 
were time-pressured[225].   
 
In 2015, a formal review of the register was conducted, with the intention of improving and 
modernising this system to facilitate a national, harmonised approach to MND care and to 
enable patient-involvement in clinical research.  Patient-directed initiatives resulted in 
significant investment from the Scottish government to complement these efforts, including 
employment of a dedicated MND Nurse Consultant for Scotland and a doubling of the 
number of MND clinical specialist nurses/allied health professionals[226].   
 
Recent commentary has outlined key features of an effective register and these informed 
our redevelopment: inclusivity to appreciate scope of disease; multi-source data capture; 
standardisation of data collection with respect to other national registries; long-term 
sustainability[227].  Through this, I helped to develop Clinical Audit Research and Evaluation 
of MND (CARE-MND): a national electronic platform for prospective, longitudinal monitoring 




The CARE-MND platform is an overarching ‘umbrella’ study with the following aims: 
1) To create a patient-centred approach to care based on recognised standards. 





3) To permit regular audit of care to facilitate timely improvements in service 
delivery. 
4) To integrate existing Scottish MND biomarker research repositories: 
i. The Scottish MND Register 
ii. The Scottish Regenerative Neurology Tissue Bank 
iii. The Edinburgh Brain and Tissue Bank 
5) To improve patient participation in research studies including observational 
and clinical trials. 
 
I hypothesised that the CARE-MND would be a more efficient data platform than the 
historical SMART-MND platform.  I anticipated that a more technologically-advanced and 
accessible system would better support audit and research, and therefore have direct 







Data fields for collection were reviewed in consultation with specialist healthcare 
professionals responsible for care of pwMND across Scotland via a national steering group 
meeting.  Existing data collection proformas used in a clinical or research setting (including 
SMART data fields) were harmonised.  Major national/international clinical registries and 
research repositories were scrutinised to ensure that our selected fields were comprehensive 
and internationally comparable.  The following were selected due to their compatibility with 
the Scottish population and/or their direct collaborative links: UK MND DNA Bank, European 
Network for the Cure of ALS (ENCALS)/Project MinE, the Irish MND Register and Genomic 
Translation for ALS Care (ALS Association and Columbia University).  Details regarding key 
disease progression markers were incorporated (onset, symptoms, classification of MND, 
MND-associated landmarks including insertion of gastrostomy and initiation of non-invasive 
ventilation (NIV)).  In response to an emerging literature-base of potential environmental 





(medications, surgeries, blood transfusions[228–230]), toxin exposures (heavy metals and 
pesticides[231–233]) and other lifestyle variables (smoking and alcohol, exercise 
participation[234–237])).  To complement our biomarker research (Scottish Regenerative 
Neurology Tissue Bank and Edinburgh Brain and Tissue Bank), we allowed for the inclusion 
of extended family history, focusing on family history of MND, dementia, other neurological 
diseases and psychiatric diseases.  Validated measures of MND progress were also 
incorporated, including the Revised ALS-Functional Rating Scale (ALSFRS-R)[182] and the 
Epworth Sleepiness Scale (ESS) as a marker of respiratory muscle weakness[238].  With a 
growing evidence-base regarding pervasiveness of cognitive impairment in MND through all 
stages of disease, we recognised the need to integrate cognitive testing into routine 
assessment using the Edinburgh Cognitive and Behavioural ALS Screen 
(ECAS)[206,208,212,213].  Using these sources, elements were identified for inclusion in our 
national proforma.  Finally, meetings with patient focus groups/other key stakeholders were 
arranged to ensure data fields were sensitive and appropriate to patient needs.  With this 
knowledge, we developed a national care paper proforma for use in all 14 health boards of 
NHS Scotland (Appendix 1).   
 
 
Pilot Phase: Paper Proforma 
 
All adults living with MND spectrum disorders in Scotland are included in CARE-MND.  The 
breadth of patient inclusion allows appreciation of the heterogeneous nature of the 
disease[25].  Inclusion criteria are as follows: i) individuals diagnosed by a neurologist with 
possible, probable or definite MND according to El-Escorial revised criteria [27,28] OR an 
MND subtypes (primary lateral sclerosis (PLS), progressive bulbar palsy (PBP), progressive 
muscular atrophy (PMA)), ii) adult individuals ≥16 years at diagnosis, iii) individuals resident 
in Scotland at the time of diagnosis or receiving long-term care in Scotland.     
 
From September 2015, the national proforma was piloted in paper format across the 14 
healthboards in Scotland.  In parallel with the publication of MND National Institute for 
Clinical Excellent (NICE) Guidelines in February 2016, a final paper NICE-aligned proforma was 





Procedure documentation for proforma completion were developed and the MND nurse 
consultant provided one-to-one training.   
 
Electronic Platform: CARE-MND 
 
While electronic patient health records (EPRs) in Scotland are similar between health boards, 
regional disease-specific cross-talk is often not facilitated.  The existing SMNDR web-based 
audit tool required data entry by dedicated research personnel and did not have a user-
friendly interface for routine data entry.  A modernised online platform was therefore 
designed.  This electronic platform – CARE-MND – is hosted by the University of Edinburgh 
and uses a secure web-based password-protected interface to allow access by any authorised 
and trained MND clinical specialist in Scotland.  The platform has three main goals: i) to 
enable and record patient recruitment to research, ii) to record and store prospective patient 
data for the purposes of audit and research, and iii) to make pwMND central to the process 
by allowing self-notification of interest and providing user-friendly information (Figure 4).   
 
i) Research recruitment: The platform provides a centralised portal to enable and 
record research recruitment.  All pwMND are automatically assigned a unique 
‘research-ready’ ID code.  Typically, MND nurse specialists/allied health 
professionals introduce research projects to pwMND, including the Scottish 
MND Register, Scottish Regenerative Neurology Tissue Bank and the Edinburgh 
Brain and Tissue Bank.  Once the research team has received a consent form, 
participation is marked clearly on their CARE-MND record.  Clinical 
specialists/allied specialists can view at-a-glance other studies that the patient is 
eligible for and those to which they have already contributed. 
 
ii) Prospective patient data: In Scotland, there is a MND nurse specialist-to-
prevalent-patient ratio of 1:26.  Following an introductory meeting, the nurse 
specialist/allied health professional will document patient details using the 
structure of the national proforma.  This is updated throughout the patient’s 






iii) Patient-centred approach: The CARE-MND website (https://www.care-
mnd.org.uk/) also hosts a patient-specific portal, providing key contact details 
for specialists, patient information leaflets, video information regarding research 












The CARE-MND platform was launched in February 2017.  Clinical specialists received one-
to-one training supported by an SOP (see Appendix 2) and piloted its use June to August 
2017.  During this interim period, data entry were supported by a research and audit team.  
The platform was supported by a named IT administrator at the University of Edinburgh who 
designed an in-built feedback system to allow users to generate alerts regarding glitches or 
suggest bespoke amendments.  By Autumn 2017, all MND nurse specialists/allied health 
professionals were using a finalised model of the CARE-MND platform as their primary mode 
of recording patient details.  The platform generates data and letters which can be uploaded 
to the health board-specific EPR. 
     
 
National Health Records Linkage 
 
The CARE-MND platform collates information from multiple sources: i) patient-reported data 
directly entered by MND nurse specialists/allied health professionals, ii) data extracted from 
EPR clinical reports (notably records from neurologists, neurophysiologists, radiologists, 
gastroenterologists, respiratory physicians and palliative care physicians) and iii) data directly 
obtained or entered by allied health professionals (neuropsychologists, speech and language 
therapists, dieticians, physiotherapists, ventilation nurse specialists).  To ensure 
completeness, Scottish national government statistics from the Information Services Division 
(ISD) are sought.  These routinely-collected prospective population records are a key strength 
of the SMNDR[3].  The following data items were sourced: 
 
1. Scottish Morbidity Records (SMR01) – patients coded with International Classification 
of Diseases 10th revision (ICD-10) code G12.2 (Motor Neurone Disease) from 
inpatient and day case records from non-obstetric and non-psychiatric specialties.  
Data regarding “Ethnic Group” were also extracted from SMR01 records.   
2. National Records of Scotland (NRS) Deaths – patients where the ICD-10 code G12.2 
(Motor Neurone Disease) is listed as the primary or secondary cause of death.  Data 
regarding “Date of Death” and “Place of Death” were also extracted from NRS 
records.   
3. Prescribing Information System (PIS) – patients prescribed riluzole, a drug uniquely 





Relevant data are transcribed to the CARE-MND platform.  Corroboration with medical 
records occurs if required.  For the purposes of this study and PhD, ISD data were applied for 
on 3rd May 2017.  A summary of the final CARE-MND platform is illustrated in Figure 4. 




Ethical approvals were obtained for the SMNDR as stated in Chapter 1, Section 1.6.  In 2017, 
the 15/SS/0126 approval was amended to reflect the CARE-MND brand.  The CARE-MND 
Project Manager was granted approval for use of ISD data by the Public Benefit and Privacy 
Panel (PBPP) for Health and Social Care, Scotland, on behalf of the University of Edinburgh 
and our funders at MND Scotland and in line with National Health Care Improvement 
Standards Scotland[239].  Researchers accessing ISD data completed an approved Medical 





To assess platform efficiency and sustainability, data capture pre- and post-CARE-MND 
implementation were audited with reference to MND NICE Guidelines.  Seventeen data fields 
were identified related to MND nurse/allied health specialist contact, health demographics, 
MND outcomes and interventions (Table 5).  The fields were selected because of their 
relevance to NICE recommendations for care and management, or their importance in 
guiding MND prognostication[9].  Although CARE-MND incorporates cognitive assessment, 
in line with NICE standards, these data were not available for the 2011-14 period.   
 
The proportion of data captured using the historical SMART platform (2011-2014) was 
compared with that using CARE-MND (2015-2017).  Pre- and post-intervention data capture 









Information Services Division (ISD) National Records Linkage 
 
 
ISD data obtained via PBPP for this study period were examined and processed to extract 
relevant information for inclusion on the CARE-MND database.  The process of extraction and 
number of data entries examined at each stage are outlined in the flow chart in Figure 5.  At 
the final stage of filtering/processing, raw ISD data were entered onto the electronic CARE-
MND database (n = 1186 rows of data).  Examples of common ICD-10 data uploaded to CARE-
MND included: 
 
- J69.0 Pneumonitis due to food and vomit  
- I10 Essential (primary) hypertension 
- K59.0 Constipation 
 
Twenty one patients were identified who were not known to CARE-MND.  The reasons for 












CARE-MND Platform Evaluation 
 
All pwMND in the 2015-17 CARE-MND (n=588) and 2011-14 SMART (n=703) platforms were 
studied (total n=1291; Table 5).  Data field completion for 17 NICE-relevant data fields were 
extracted from the SMART (2011-14) and the CARE-MND databases (2015-17).  Percentage 
completed fields using the SMART platform ranged from 4-95%; median completion 50%.  
CARE-MND capture ranged from 32-98%; median 87%.  Fifteen of 17 fields were significantly 
more complete in CARE-MND (p<0.001).  “Place of death” capture remained high (95%, 97%).  
“Forced Vital Capacity (FVC)” capture remained low (34%, 32%) (Table 5).   
 
During 2011-14, only 21% (3/14) of health boards had dedicated MND clinical pathways[241].  
However, through CARE-MND 100% of health boards now have a standardised proforma, 







n = 588 
SMART 2011-2014 
n = 703 
Statistical Difference 
(Z-Test of Proportions p-
value) 
Data type Data available 
(number of 
patients) 
% completed Data available 
(number of 
patients) 
% completed  
Clinical specialist name 575 98% 370 53% <0.001 
Date of referral to Clinical Specialist 359 61% 348 50% <0.001 
Date of first contact with Clinical 
Specialist 
341 58% 190 27% <0.001 
Date of symptom onset 530 90% 524 75% <0.001 
Date diagnosis confirmed 571 97% 542 77% <0.001 
Electrophysiology 448 76% 212 30% <0.001 
Classification of MND 507 86% 514 73% <0.001 
Past medical history 509 87% 431 61% <0.001 
Family History of MND (Yes/No) 524 89% 415 59% <0.001 
Taking riluzole (Yes/No) 554 94% 434 62% <0.001 
Feeding tube inserted (Yes/No) 522 89% 329 47% <0.001 
Use of Non-invasive ventilation 
(Yes/No) 
527 90% 279 40% <0.001 
Forced Vital Capacity  189 32% 240 34% 0.4845 
Amyotrophic Lateral Sclerosis 
Functional Rating Scale 
418 71% 321 46% <0.001 
Epworth Sleepiness Scale Score 225 38% 25 4% <0.001 
Body Mass Index 413 70% 26 4% <0.001 
Place of death 305/314 97% 593/621 95% 0.2987 
 







Data access, utility and dissemination 
 
 
As part of this PhD, I helped to develop, launch and implement CARE-MND, a national 
electronic platform for prospective, long-term monitoring of MND in Scotland.  The CARE-
MND platform has been delivered as a result of significant dedicated research funding, 
supporting investment in personnel and infrastructure.  Its success, application, and 
sustainability is predicated on ongoing engagement from all MND nurse/allied health 
specialists in Scotland who have now incorporated CARE-MND into routine clinical practice.  
All recorded incident cases of pwMND in Scotland from 2015 have been phenotypically 
characterised longitudinally and offered participation in relevant research studies where 
appropriate.   
 
To monitor sustainability, data entry has been audited monthly since launch.  Median data 
capture as of November 2018 was 96%.  Implementation of the CARE-MND platform has 
resulted in more complete ascertainment of clinical parameters emphasised in NICE 
Guidelines.  This facilitates better coordinated care and continuous assessment of patients’ 
needs together with prompt appropriate referral to relevant multidisciplinary team 
members[9].  Assessment of forced vital capacity (FVC), a measure of respiratory muscle 
weakness, is an exception.  The low data-capture rate of 32% may reflect a general recent 
trend towards other methods of assessing respiratory function such as transcutaneous CO2 
monitoring.  Anecdotal evidence from Scottish respiratory care-providers suggests that FVC 
assessment is dependent on accurate technique and results can be inaccurate.  A need to 
transcribe respiratory measures from the local respiratory EPR to the CARE-MND platform 
by the clinical nurse/allied health specialist may also be a barrier, and partly explain the low 
capture rates of both FVC and the Epworth Sleepiness Scale Scores (38% capture).   
 
All pwMND in Scotland who require respiratory input have access to appropriate referral 
pathways whereby they are reviewed at their local clinic or in the community.  As a result of 





CARE-MND directly.  Respiratory monitoring of MND in Scotland is also currently being 
audited to investigate regional variations (Table 6).   
 
We also acknowledge that capture of other data fields, in particular dates (e.g. Date of 
referral to Clinical Specialist and Date of first contact with Clinical Specialist) is below average 
(61% and 58% respectively).  On liaising with our clinical teams, our understanding is that 
these fields were given low priority in favour of seemingly more pertinent measures.  
However, the publication of NICE Guidelines and our parallel efforts to audit care have 
highlighted the importance of these fields and we anticipate that future completion will be 
much improved.   
 
Due to the relative completeness of the CARE-MND dataset, national audits of MND care in 
Scotland have been possible (Table 6).  Through CARE-MND, patient recruitment to the 
SMNDR, Scottish Neurology Tissue Bank and Edinburgh Brain and Tissue Bank can be 
recorded and appropriate patients approached for ongoing study.  Local and collaborative 
teams can also apply for access to anonymised data from consenting patients for research.  
Scottish research projects have included the study of the epidemiology of MND in 
Scotland[242], genotype-phenotype correlations[243] (both of which are described in this 
thesis), cognitive profiles[212,213,244], neuropsychiatric phenotypes, and clinico-
pathological studies[245].  CARE-MND has also provided data for collaborative work with 
international partners, including oropharyngeal secretion management[246] and 
genetics[247,248].  We have also been able to provide information for third sector and 







National Audits of MND Care in 
Scotland 
Key Outcomes and Actions 
 
Key Actions 
Cognitive assessment Neuropsychologists are completing 
assessments but sometimes these are 
not reflected on CARE-MND.   
Neuropsychologists have been given 
access to CARE-MND for 
documentation of assessment. 
Gastrostomy insertion and 
survival[250]  
Incidence of gastrostomy insertion has 
increased over time.  There is a lower 
30-day mortality in 2015-16 than in 
1989-1998.  Use of riluzole alongside 
gastrostomy has survival benefits.  
Measurement of quality of life was not 
included in this study and should be 
assessed subsequently.  
Reasons for unexplained hospital 
admissions  
Main reason for admission is falls.   A series of educational videos were 
created aiming to prevent falls in the 
community. 
Riluzole prescription  Only 40% of people with MND in 
Scotland are taking riluzole. 
Neurologists have been encouraged to 
document discussions regarding 
riluzole including reasons for not 
prescribing.  
Augmentative and alternative 
communication (AAC) provision[251] 
All health boards offer AAC in a timely 
manner.  A third of patients use AAC. 
A guide for allied health professionals 
detailing patient thresholds for AAC 
requirements is in development. 
Respiratory monitoring  Patients would like to learn more about 
non-invasive ventilation through videos 
and leaflets.   
Ongoing. 
   






Challenges and Future Development 
 
We have developed an electronic platform that is fit for purpose as a contemporary audit 
and research tool.  As the platform operates via a secure website, it is currently not possible 
for MND specialists/allied health specialists to access the website off-site (e.g. via tablet) 
unless they have in-built internet data on their device.  As such, paper notes are required for 
some specialists visiting patients at home.  These paper records, however, can be transcribed 
to CARE-MND on return to their work base.  We have strived to ensure that the platform 
complies with local NHS health board governance requirements.  This is coordinated and 
monitored by the MND nurse consultant for Scotland.  Currently the platform does not 
integrate with existing NHS EPR portals but we are exploring this for the future.  As a 
temporary solution, structured clinical letters can be automatically generated from CARE-
MND content which can be printed and uploaded to local electronic records.  The evolving 
nature of technology and the growing evidence-base in MND will inevitably necessitate 






In a condition for which systematic data collection is challenging and for which treatments 
are currently limited, we have evolved a sustainable platform in which patients throughout 
Scotland can be included prospectively and longitudinally in routine audit of care and 
research.  All health boards in Scotland now have dedicated care pathways for MND and, 
through national monitoring, we have demonstrated an improvement in equity of care and 
service provision, as well as stratification of the population for research, including future 
clinical trials.  In a technologically advancing climate, we aim to optimise available resources 








3. EPIDEMIOLOGY OF MND IN SCOTLAND 2015-2017 
 
The following content has been published in Journal of Neurology[242] and re-formatted 
for this thesis: 
 
Danielle J Leighton, Judith Newton, Laura J Stephenson, Shuna Colville, Richard Davenport, 
George Gorrie, Ian Morrison, Robert Swingler,  Siddharthan Chandran, Suvankar Pal on behalf 
of the CARE-MND Consortium.  Changing epidemiology of motor neurone disease in 









Recent discoveries in the genetics of MND have provided important clues for 
aetiopathogenesis and support a multifactorial pathophysiological process with genetic 
and/or environmental risk factors[143,160].  Regional variation in disease incidence could 
therefore be expected, corresponding with differing population ancestral origin and 
environmental exposures[252].  However, a recent meta-analysis of global registry data of 
MND (ALS and MND-subtypes) observed epidemiological homogeneity amongst populations 
of predominantly European origin[253].   
 
Scotland benefits from a culture of longstanding MND data capture[199,200].  Annual 
incidence of MND in Scotland was 2.40 per 100,000 population (95% confidence interval (CI) 
2.22-2.58) between 1989-1998, standardised to 1994 mid-year Scottish population 
estimates[3].  Multiple sources were used for case ascertainment including direct notification 
from MND clinical nurse/allied health specialists, neurologists and neurophysiologists and 
national hospital discharge records from Information Services Division (ISD) Scotland.  A two 






SMNDR coverage declined between 1999 and 2014[227].  However, in 2015, the CARE-MND 
platform permitted more thorough data capture.  This coincided with public awareness 
initiatives and government-led doubling of the number of MND clinical nurse specialists in 





I aimed to use CARE-MND to describe the epidemiological characterisation of MND in 
Scotland in 2015-2017, in comparison to the 1989-1998 study period.  Phenotypic 








All adults living with MND in Scotland are eligible for inclusion in CARE-MND.  Inclusion 
criteria for this study were: i) diagnosed by a neurologist with suspected ALS, possible, 
probable or definite ALS according to El-Escorial revised criteria OR an MND subtypes 
(primary lateral sclerosis (PLS), progressive bulbar palsy (PBP), progressive muscular atrophy 
(PMA)) [27], ii) diagnosed between 1st January 2015 and 31st December 2017, iii) ≥16 years 
at diagnosis, iv) resident in Scotland at time of diagnosis or receiving care in Scotland during 





CARE-MND retrieves population data from five sources: two CARE-MND clinical sources, 





system draws on the strengths of an integrated healthcare system in Scotland, whereby 
individuals are identified by a unique Community Health Index (CHI) number, which can be 
referenced against local and national health records.  ISD data were sourced for incident 
patients in 2015 and 2016.  Medical records for all pwMND unique to ISD were examined to 




Figure 6 Multiple source algorithm for accurate ascertainment of MND cases: i) CARE-MND platform, 
ii) Information Services Division data 
 
 
i) CARE-MND Database 
 
MND nurse/allied health specialist notification: The CARE-MND platform is a prospective 
clinical tool and all cases are monitored by neurologists and nurse/allied health specialists.  
If a diagnosis is revised or revoked, the patient is removed from the database.  CARE-MND 
notifications are therefore considered ‘gold-standard’.  Patients are referred to a local MND 
nurse/allied health specialist, who coordinates care.  The CARE-MND electronic platform 
operates via a secure website hosted on an academic server.  MND specialists enter 
information about incident patients following referral and until death.  If a patient is 
diagnosed with MND shortly before, or after, death the relevant care provider can refer for 






Patient self-notification:  PwMND are invited to participate in the CARE-MND platform and 
can self-notify online.  A member of the CARE-MND team contacts the patient’s neurology 
consultant/clinical specialist to confirm diagnosis before entry onto the database.     
 
ii) ISD Data 
Information Services Division (ISD) Scotland data were extracted (see details Chapter 2.2 
National Health Records Linkage).  Patients were sourced if they were assigned International 
Statistical Classification of Diseases v10 (2016) (ICD-10) codes for Motor Neurone Disease 
(G12.2) or Frontotemporal Dementia (G31.0 and/or F02.0) on hospital records or as primary 
or secondary cause of death during 2015 and 2016.  Patients prescribed riluzole, a drug 
uniquely used for MND, were also included.   
 
 
Data Extraction and Statistical Analysis 
 
CARE-MND clinical specialist and patient notifications are related sources and were collapsed 
into one measurement.  ISD information sources were also combined.  The result was two 
independent sources for capture-recapture analysis.  Maximum likelihood estimates were 
used to determine total incidence rates and CARE-MND database coverage[3].     
 
Incidence data were analysed by age and sex.  Prevalence data were extracted directly from 
CARE-MND.  Incidence and prevalence rates were calculated in reference to NRS mid-
population estimates[221]. Incidence rates were standardised using the direct method to the 
US 2010 Census population to facilitate international comparison[254,255].  The US 
population has historically been used for Scottish cohort and other population 
standardisation[3,253].  The 2010 population was chosen to allow direct comparison with 
recent pooled incidence data[253].  Confidence intervals were calculated assuming a Poisson 
distribution[256].   
 
The CARE-MND platform provides a standardised national proforma.  The following fields 
were extracted: i) age of onset, ii) age of diagnosis, iii) sex, iv) site of onset, v) family history 
of MND (first, second or third degree relative), iv) family history of dementia (first, second or 





insertion, xi) non-invasive ventilation (NIV) use.  T-tests and Chi-square tests (parametric 
data) and Wilcoxon rank-sum test (nonparametric data) were used for univariate analyses of 
sex differences.  Proportions were compared using Z-test of proportions.  Individuals 
diagnosed in 2015-16 were followed up for at least one year (censorship 31st December 
2017); 6-month and 12-month survival from onset and diagnosis were examined.   
 
Patients were mapped to their corresponding Scottish Index of Multiple Deprivation (SIMD) 
2016 data zone.  The SIMD is a Scottish Government tool that ranks 6976 small data zones 
(760 people per zone) according to level of deprivation.  Seven domains are used: 
employment, income, crime, housing, health, education and access (to medical care, public 
transport).  SIMD rank was sourced for each patient and the corresponding SIMD quintiles (1 
most deprived, 5 least deprived) analysed using Dunn’s test of multiple comparisons using 
rank sums.   
 
R version 3.4.3 was used for all statistical analyses (packages “epitools”, “epiR”, “DescTools” 





As described previously, ethical approvals were obtained for the SMNDR/CARE-MND 
(MREC/98/0/56 1989-2010, 10/MRE00/78 2011-2015, Scotland A Research Ethics 
Committee (15/SS/0216) 2015-present).  Access to ISD data was approved by the Public 














Year Source Number of 
pwMND 
2015 CARE-MND Clinical Nurse/Allied Health Specialist Notifications 221 
    Total 221 
  ISD SMR01 179 
  
 






Total Unique 211 




  ISD SMR01 107 
  
 






Total Unique 152 
2017 CARE-MND Clinical Nurse/Allied Health Specialist Notifications 189 
  
 
Patient Notifications 5 
  
 
Total  192 
  ISD SMR01 Na 
  
 






Total Unique Na 
 
Table 7 Sources of incident cases of MND 2015-2017 
 
 
All CARE-MND patients were diagnosed by a consultant neurologist and were aware of their 
diagnosis.  If a diagnosis is revised or revoked, the patient is removed from the database.  
CARE-MND notifications can therefore be classed as a ‘gold-standard’.  The CARE-MND 
database alone identified 406 true MND cases diagnosed in 2015-16 (Table 8).  There were 
596 prevalent patients in 2015-2016 coded with the G12.2 code in ISD datasets.  Of these, 
342 were ‘true’ incident cases (also present in CARE-MND 2015-16).  A further 262 patients 
were coded with G12.2: 21 were incident MND cases unique to ISD and were included in our 
analyses (Table 7, Table 8); eight had MND but were diagnosed before 2015 and were not 
included.  Case-notes of the remaining 233 patients were reviewed; none had MND.  In 
summary, we identified 21/596 (3.5%) people with MND unique to ISD and 233/596 (39.1%) 
patients from ISD records who were coded with an ICD-10 MND code inaccurately.  Forty two 





diagnoses included pseudobulbar palsy secondary to cerebrovascular disease or dementia.  
Sensitivity of ISD code G12.2 for incident patients 2015-16 was therefore 0.89 (95% CI 0.86-
0.92) with a positive predictive value (PPV) of 0.61 (95% CI 0.57-0.65).  The specificity and 
negative predictive value were 100% and 1 respectively, as MND is rare in the general 
population.  Sensitivity and PPV for hospital records were 0.74 (95% CI 0.69-0.78) and 0.66 
(95% CI 0.62-0.71) respectively; for death records 0.42 (95% CI 0.37-0.47) and 0.55 (95% CI 
0.49-0.61); for PIS records 0.40 (95% CI 0.35-0.45) and 0.96 (95% CI 0.92-0.98).   
 
Average case ascertainment/coverage of the CARE-MND database was 98.9% (Table 8). 
 
 
Year 2015 2016 
CARE-MND notifications 221 185 
Notifications unique to CARE-MND 19 45 
Notifications unique to ISD 9 12 
Notifications common to CARE-MND and ISD 202 140 
Total notifications 230 197 
Maximum Likelihood Estimate 0.8465 3.8671 
CARE-MND coverage (%) 99.6 98.1 
Mid-year population estimate 5373000 5404700 
Crude incidence (per 100,000 population) 4.28 3.64 
 
Table 8 Coverage of CARE-MND Platform and Crude Incidence Rates 2015-16 
 
 
Case-notes of the 21 patients identified through ISD alone were examined.  Sixteen (76.2%) 
patients were diagnosed shortly before death (median 3.5 days (interquartile range (IQR) 1.8-
9.5)), in which case contact with a MND specialist might not have been made or pursued.  
Site of onset for these patients varied: bulbar (n=6, 37.5%), limb (n=6, 37.5%), respiratory 
(n=3, 18.8%), weight loss (n=1 (6.3%).  Two patients were diagnosed posthumously: one from 
electromyography, one on post-mortem.  The remaining three patients were: a nursing home 
resident, unknown to specialist teams; a patient with FTD-predominant disease receiving 






Due to the excellent coverage of CARE-MND, incidence for 2017 was estimated using CARE-
MND values alone: 192 new diagnoses, giving a crude incidence of 3.55/100,000 (3.07-4.09) 
(using 2016 mid-year population estimate as 2017 not yet available).  Crude incidence over 
the three-year period was 3.83/100,000 person-years (3.53-4.14).  On 31st December 2015, 
409 people were living with MND in Scotland according to CARE-MND/ISD figures (crude 
prevalence 7.61 per 100,000 (6.89-8.39)).  Similarly, prevalence rates in 2016 and 2017 were 





Incidence rates for 2015 and 2016 were age and sex standardised to the US Census 
Population 2010 using the direct method (Table 9).  This allows direct comparison with other 






    1989-98 2015 2016 






























Male 0-4 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 
Female 0-4 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 
Male 5-9 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 
Female 5-9 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 
Male 10-14 1 0.06 6.35 0 0.00 0.00 0 0.00 0.00 
Female 10-14 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 
Male 15-19 1 0.06 6.78 0 0.00 0.00 0 0.00 0.00 
Female 15-19 1 0.07 7.52 0 0.00 0.00 0 0.00 0.00 
Male 20-24 1 0.05 5.51 0 0.00 0.00 0 0.00 0.00 
Female 20-24 1 0.05 5.29 0 0.00 0.00 0 0.00 0.00 
Male 25-29 4 0.19 20.21 0 0.00 0.00 0 0.00 0.00 
Female 25-29 3 0.15 15.70 0 0.00 0.00 0 0.00 0.00 
Male 30-34 4 0.19 18.99 1 0.59 58.80 1 5.80 58.02 
Female 30-34 1 0.05 4.98 0 0.00 0.00 1 5.57 55.49 
Male 35-39 9 0.49 49.21 2 1.27 127.55 2 12.40 124.54 
Female 35-39 5 0.27 27.37 0 0.00 0.00 1 6.01 60.89 
Male 40-44 20 1.20 124.73 1 0.59 61.08 4 24.25 252.08 
Female 40-44 5 0.30 31.49 1 0.56 58.43 2 11.58 121.56 
Male 45-49 37 2.18 244.36 9 4.70 526.62 6 31.68 355.05 
Female 45-49 15 0.87 100.05 2 0.98 112.60 1 4.93 56.70 
Male 50-54 43 3.07 335.65 11 5.58 609.80 2 10.13 110.76 





Male 55-59 79 6.00 571.42 20 11.29 1075.69 8 44.26 421.55 
Female 55-59 55 3.87 392.46 6 3.23 327.58 5 26.30 266.75 
Male 60-64 86 7.05 569.46 20 12.97 1047.35 21 134.27 1084.53 
Female 60-64 69 5.01 437.90 13 7.99 698.16 12 72.66 635.11 
Male 65-69 123 11.31 661.92 31 20.46 1197.65 31 202.00 1182.20 
Female 65-69 110 8.39 552.29 17 10.53 693.05 11 67.05 441.37 
Male 70-74 120 13.16 558.51 18 16.68 707.84 16 143.02 606.99 
Female 70-74 110 8.82 444.02 14 11.25 566.53 15 117.97 593.89 
Male 75-79 80 15.47 492.32 18 21.76 692.63 12 145.43 462.81 
Female 75-79 76 8.83 365.16 20 19.07 788.70 11 105.43 436.01 
Male 80-84 48 13.90 318.92 6 10.91 250.20 10 177.93 408.24 
Female 80-84 56 7.93 273.50 10 12.61 434.81 11 137.13 472.95 
Male 85-89 8 5.79 73.76 1 3.69 46.96 4 141.41 180.13 
Female 85-89 18 4.54 106.54 3 6.14 144.00 3 60.37 141.67 
Male 90+ 2 5.00 25.79 0 0.00 0.00 2 166.43 85.85 
Female 90+ 3 1.72 23.34 1 3.52 47.83 0 0.00 0.00 
 





Age-standardised incidence for 2015 in Scotland was 3.42/100,000 of the population (95% CI 
2.99-3.91) (males and females).  Age-standardised incidence for males was 2.00/100,000 
(95% CI 1.68-2.39) and for females 2.64/100,000 (95% CI 2.12-3.27); age-adjusted male-to-
female relative risk (RR) 0.76:1.  Age-standardised incidence for 2016 was 2.89/100,000 (95% 
CI 2.50-3.34) overall; for males, 3.51/100,000 (95% CI 2.90-4.24), and for females, 
2.26/100,000 (95% CI 1.78-2.86) with an age-adjusted male-to-female RR of 1.55:1.  In both 
years, peak age-group incidence for males was 65-69 years.  For females, peak incidence 
occurred later in the 75-79 age group.  In 2016, however, it occurred earlier in the 60-64 age 
group (Figure 7).   
 
 






Incidence rates for 1989-98 were also age-standardised to allow time period comparison 
(Figure 8).  Overall, age-standardised incidence for the 1989-98 period was 2.32/100,000 
(95% CI 2.26-2.37).  In 2015-16, incidence was greater than 1989-98 across most age groups, 




Figure 8 Time period comparison of incidence rates for i) 1989-98, ii) 2015 and iii) 2016 direct age 
standardised to the 2010 US Census population 
 
 
Finally, age and sex time period comparison was plotted (Figure 9).  This highlights that the 
clearest change is among males age 60-69.  In particular, there was a 79-81% increase in 







Figure 9 Time period comparison of incidence rates for i) 1989-98, ii) 2015 and iii) 2016 direct age and 
sex standardised to the US Census population 2010 (a) Males, b) Females) 
 
 
Patient Characteristics  
 
Phenotypic characteristics were evaluated from the 2015 and 2016 cohorts (Table 10).  
Statistical comparisons were made between males and females with Bonferroni correction 
for multiple testing.  Females were significantly older at onset of symptoms and point of 
diagnosis (p=0.00086 and 0.00099 respectively).  Proportionally, more female pwMND than 





(p=0.0024).  However, there were significantly fewer females than males with onset of 
disease in the upper limbs (p=0.00072).  Although there was no sex difference for respiratory-
onset disease, significantly fewer females received NIV (p=3.27x10-5).  Six-month survival 
from onset was significantly worse in females than males (p=0.00039); however, this did not 
















Significance Test p-value 
Male-to-Female Relative Risk  100 1.53:1         
Mean Age of Onset (SD), years 97.7 65.3 (11.6) 63.7 (11.3) 67.6 (11.7) t-test 0.00086* 
Mean Age of Diagnosis (SD), years 100 66.8 (11.2) 65.4 (11.0) 69.0 (11.1) t-test 0.00099* 
Median Time to Diagnosis (IQR), months 97.7 
11.0 (7.0-
21.0) 
11.0 (7.0-20.0) 11.0 (7.0-23.0) 




   Chi square 0.039 
-          ALS 79.4 80.6 77.5 Z-test proportion 0.51 
-          MND-FTD 6.8 6.2 7.7 Z-test proportion 0.69 
-          PBP 4.9 2.7 8.2 Z-test proportion 0.018 
-          PMA 4.0 4.3 3.6 Z-test proportion 0.91 
-          PLS 3.3 3.5 3.0 Z-test proportion 0.98 
-          Other (bibrachial/flail limb) 1.6 2.7 0.0 Z-test proportion 0.077 
Site of Onset 
98.8 
      Chi square 0.0048 
-          Bulbar 28.2 22.7 36.7 Z-test proportion 0.0024 
-          Lower limb 28.4 28.1 28.9 Z-test proportion 0.16 
-          Upper limb 20.6 26.2 12.0 Z-test proportion 0.00072* 
-          Mixed (upper limb, lower limb, bulbar) 17.1 16.0 18.7 Z-test proportion 0.56 
-          Cognitive change 2.1 3.1 0.6 Z-test proportion 0.16 
-          Respiratory 1.7 1.6 1.8 Z-test proportion 1 
-          Other (weight loss, camptocormia) 1.9 2.3 1.2 Z-test proportion 0.64 
Ethnicity (%) 
90.6 
   Chi square 0.71 
-          White Scottish 75.2 75.1 75.3 Z-test proportion 1 
-          White British/Irish/Not Specified 23.3 23.2 23.3 Z-test proportion 1 
-          Ethnic Minority 1.3 0.9 1.3 Z-test proportion 1 






-          MND 96 8.5 5.6 12.8 Chi square 0.013 
-          Dementia 80 27.7 26.5 29.7 Chi square 0.22 
Riluzole Medication Prescription (%) 98.1 37.9 37.6 38.4 Chi square 0.4 
Gastrostomy Insertion (%) 99.5 31.5 32.0 30.8 Chi square 0.71 
Non-invasive Ventilation (%) 95.3 33.9 41.6 21.7 Chi square 3.27x10-5* 
6-Month Survival (%)       
 
-          From Onset 97.6 94.2 95.3 92.1 Z-test proportion 0.00039* 
-          From Diagnosis 100 70.0 74.4 62.7 Z-test proportion 0.092 
12-Month Survival (%)       
 
-          From Onset 97.6 70.0 85.0 80.0 Z-test proportion 0.0033 
-          From Diagnosis  100 51.3 55.8 44.4 Z-test proportion 0.0032 
 





Scottish Index of Multiple Deprivation (SIMD) Mapping 
 
PwMND for whom postcodes were recorded on the database (n=382) were assigned their 
corresponding SIMD social deprivation small area rank.  Ranks ranged from 24 (most 
deprived) to 6953 (least deprived) (median 3512, IQR 1964-5210).  There was an equal spread 
across deprivation quintiles (Figure 10).  Dunn’s test of multiple comparisons using rank sums 




Figure 10 Scottish Index of Multiple Deprivation (SIMD) Scores for incident 2015-16 patients by 
quintiles from 1 (most deprived) to 5 (least deprived): 1) 1-1395, 2) 1396-2790, 3) 2791-4185, 4) 













Through this work, I can report an up-to-date and standardised epidemiological analysis of 
the Scottish MND population.  Case ascertainment methods were similar to those employed 
in the 1989-98 Scottish MND Register analysis and capture-recapture coverage is improved 
(98% in 1989-98, 99% in 2015-16)[204].  Some population registries report relatively low 
percentage coverage (81.1-89.5%) but our ascertainment is comparable with other small 
country/regional epidemiological MND studies[257–259].  We identified 21 pwMND not 
captured by CARE-MND: the reasons for their exclusion will inform future nursing care, 
ensuring that, for example, patients in nursing homes and those with FTD are offered access 
to adequate care support.         
 
 
Validation of ISD Coding 
 
With reference to the CARE-MND database, ISD records had relatively low PPVs for MND.  
Death records were likely under-representative due to the relatively short follow-up time for 
this incident cohort (median six months, maximum 18 months).  The high predictive power 
of prescribing records is expected as riluzole is unique to the disease.  One of the main 
problems with coding was inaccurate coding of patients with PSP.  While individuals with this 
condition can develop a bulbar palsy similar to that seen in MND, their disease course and 
pathology is distinct.  This error has been observed previously and has implications for both 
national MND and PSP statistics[260–262]. 
 
 
Incidence and Prevalence 
 
Prevalence in 2015-17 ranged from 7.61-7.81/100,000 population.  This is comparable with 
recently published cohorts in Italy, Cyprus and the Faroe Islands[5,263,264].  However, it is 





100,000 of the population)[257,265,266], perhaps suggesting poorer survival in Scotland.  
Future work comparing survival in the Scottish population with other European populations 
may guide management direction.  
 
Direct standardised incidence in 2015-16 (average 3.16/100,000) has increased by 36.0% 
compared with the 1989-98 period.  Although this contrasts with other historical 10 year 
studies[3,267,268], it mirrors longer and more recent analyses[21,22].  The age-standardised 
incidences of MND in Scotland for both 2015 and 2016 are the highest reported in the 
literature.  Combined incidence for 2015-16 is 66.9% higher than pooled Northern European 
standardised rates[253].   
 
Possible hypotheses for these observations can be categorised as follows: i) ascertainment, 





Ascertainment is the strongest argument for our relatively high incidence rates.  The data 
suggest that no particular age groups are overlooked; older age groups are well-represented 
(11.9% of cohort ≥80 years at diagnosis).  This challenges recent discourse suggesting that 
MND is underdiagnosed in older populations[269].  However, this does not explain the 
increase over time.  Awareness of MND amongst health professionals and the public has 
heightened in recent years.  In 2015, Scottish MND funding and care services were boosted 
through substantial government investment.  This may, in part, explain the peak in incidence 
in 2015.  2016 marked a doubling of MND clinical nurse/allied health specialists in Scotland, 
with a specialist-to-prevalent-patient ratio of 1:26.  Each nurse acquires approximately 12 
new pwMND annually, compared with 31 new pwMND annually between 1989 and 1998.  
Similarly, in 1989 there was one neurologist for approximately every 231,500 people in 
Scotland but the ratio in 2016 was approximately 1:63,500.  New patient referrals to 
neurology in Scotland rose by 50% from 2007 to 2016, suggesting better access to and more 
timely referral for tertiary review[270].  Indeed, median diagnostic delay in this study was 





Concomitant with an increase in neurology service provision is better awareness of the 
extended phenotype of MND.  In comparison to 1989-98, MND-FTD is a new addition (6.8% 
of 2015-16 cohort).  Such patients were previously classified as having a “MND plus” 
disorder[205,227,259].  Better recognition of the cognitive phenotype, using tools such as 
the Edinburgh Cognitive and Behaviour ALS Screen, may explain some of the change in 





The rise in incidence is dominated by males age 65-69, contradicting studies suggesting older 
women drive increased incidence in aging populations[227,257,271].  In a Scottish analysis 
of pwMND >80 years, standardised incidence was greater in men suggesting a possible 
localised geographical effect[204].  We found no association between MND incidence and 
social deprivation (SIMD).  This agrees with recent findings in MND (including a historical 
Scottish case-control study) and a Scottish Parkinson’s Disease cohort[272–275].  SIMD is a 
marker of residence, rather than individual environmental and lifestyle factors; the latter 
requires separate evaluation.  
 
The change in incidence might be consequent on improved survival from competitive 
diseases (such as cardiovascular disease), allowing for increased manifestation of MND (a 
Gompertzian model)[271].  Age and sex adjusted mortality from heart disease has decreased 
by 35.5% in Scotland over the last 10 years, with noted decline across all health boards and 
SIMD quintiles[276].  Indeed previous studies observing rising incidences suggest that better 
care and treatment of people over the age of 60 may be contributory, especially in the 
context of MND for which there is no disease-modifying treatment[201].                     
 
Similarly high standardised incidence rates have been observed in Canterbury, New Zealand 
(where capture rates and population size are comparable[22]), the Faroe Islands and Finland 
which raises the possibility of latitudinal influence, similar to that found in multiple sclerosis 










Since the identification of ‘genetic’ MND, in particular, SOD1 mutations and the C9orf72 
hexanucletoide repeat expansion, patients are increasingly undergoing genetic testing as 
part of the diagnostic work-up of MND.  Clinicians are more aware of the phenotypic 
spectrum of disease of these mutations; for example, C9orf72 carriers can present with a 
pure FTD phenotype but have subsequent sequential motor involvement[75].  The C9orf72 
expansion was first associated with MND in 2011 and so it is possible that these patients 
were missed from historical epidemiological cohorts[73].   
 
A previously published SOD1 genetic variant (p.I114T) is thought to be a founder mutation in 
the Scottish population[219].  While we do not anticipate that the frequency of this mutation 
has changed over time, it may suggest presence of other Scottish haplotypes which are 
driving disease.  The relative ethnic homogeneity of Scotland may support this hypothesis.  
The ethnicity of this cohort is comparable with that of the general population in Scotland, 
2015[277].  People who identify as white have been found to have a higher incidence of MND 
than ethnic minorities in more diverse populations, irrespective of socioeconomic 
status[273].  The relative ethnic homogeneity of Scotland does not allow us to come to such 
conclusions but does lend evidence to a possible genetic influence in Scotland.  Genetic 
admixture seen in African American populations is thought to be protective against disease, 
whereas people of European origin are more likely to harbour homozygous and “probably 
damaging” genetic alleles[278].  Genetic data were not available at the time of publication 





In this cohort, the male-to-female ratio and mean ages of onset/diagnosis are 
typical[3,5,199,243].  The majority of patients (79.4%) had an ALS form of MND, the 
remainder MND subtypes including MND-FTD (6.8%, a rate very similar to that observed in 





reach statistical significance.  As in the previous Scottish cohort, limb-onset MND dominated 
(49.0% of cases).  Pooled Northern European estimates for proportion of bulbar-onset 
patients is 45.4%[252].  We include a cohort of pwMND presenting with mixed signs and 
symptoms; historically these have been considered bulbar-onset for the purposes of 
dichotomisation.  When combined with our proportions of bulbar patients the figures are 
indeed comparable[204].   
 
Rates of gastrostomy insertion are similar to the LIGALS population, although NIV use is lower 
(33.9 vs 55.7%)[5], perhaps reflective of the relatively short follow-up period.   
 
Examining between-sex differences, we observe significantly higher ages of onset and 
diagnosis in females, with significantly poorer survival of females at six months after onset.  
More females than males have bulbar-onset disease (although this did not reach statistical 
significance) which might explain the drop in survival shortly after onset.  Interestingly, 
significantly fewer females than males made use of NIV; the reasons for this, and the impact 





While data capture methods are similar between the 1989-98 and 2015-17 cohorts, there 
were key differences in diagnostic inclusion criteria: the historical dataset was obtained 
before publication of revised El Escorial criteria, instead relying on modified World 
Federation of Neurology diagnostic criteria for half of the cohort, and original El Escorial 
criteria for the remainder[28,202].  Unfortunately, this is a limitation for many longitudinal 
MND population studies.    
 
Data collection was less comprehensive between 1999 and 2014 and our study does not 
allow for age-period-cohort (APC) analysis.  Nevertheless, it gives an accurate representation 
of the current climate of MND in Scotland.  APC analysis highlights historical rather than 
existing potential environmental aetiology only.  Recent APC analysis from Ireland, a 








This epidemiological study fulfils criteria for a population-based study in MND[227,271] and 
shows an increasing incidence of MND in Scotland, with the highest and most up-to-date 
standardised incidence rates reported in the literature.  We have re-established the Scottish 
MND Register (now CARE-MND platform) and can achieve 99% capture of patients in 
Scotland.  The high ascertainment rates obtained from a national prospective, multi-source 
register imply that findings can be generalised to other Northern European populations.  This 
work and future CARE-MND analyses will help model demand for clinical MND services in 







4. PHENOTYPING AND PROGNOSTIC MODELLING 
 




As discussed, MND populations are heterogeneous in presentation and prognosis.  
Characterisation of a population using a national register can therefore help to prioritise 
service needs and allocate care appropriately, as well as helping to increase the knowledge 
base for patients, funders and researchers.  A national register is indiscriminate, capturing 
people at all stages of disease, in contrast to clinical trials, which may be biased towards 
patients who have access – either through service provision or because of physical ability – 
to specialised trial sites.  The Joint Programming Initiative on Neurodegenerative Disease 
Research (JPND) – an international network geared toward the acceleration of discovery and 
treatment in neurodegenerative disease – recently highlighted the importance of 
longitudinal population data collection[280].    
 
As introduced in Chapter 1.1, environmental risk factors are thought to contribute to the 
accumulation of burden of risk required for MND to manifest (the multistep and “Gene Time 
Environment” hypotheses)[143,160].  Additionally environmental influences may contribute 
to survival and speed of decline.  Such factors can be categorised as endogenous or 
exogenous, though, of course, there can be interaction between the two.   
 
 
i) Endogenous Factors 
 
Endogenous variables include an individual’s past medical history and family history of 
disease.  Past history of autoimmune disease is thought to be linked with MND, with an 
increased frequency compared to controls[281].  Carriers of C9orf72 expansions are also 
thought to have an increased prevalence of nonthyroid autoimmune diseases suggesting a 
shared inflammatory pathophysiology[282].  Epidemiological studies of ALS in cancer 
survivors have been undertaken and have not found an association between cancer and risk 





a diagnosis of ALS[283].  However, this may be related to exogenous factors such as specific 
cancer treatments, rather than the malignant process itself.  MND has been found to be 
associated with previous cerebrovascular disease, suggesting a pathogenic continuum 
between tissue damage, triggering TDP-43 mislocalisation and aggregation, and subsequent 
MND[285].   
 
 
ii) Exogenous Risk Factors 
 
Brain vulnerability is also a factor in the consideration of exogenous triggers of disease.  One 
example, which is debated, is the influence of head injuries on MND risk.  Case-control 
studies and meta-analyses suggest a modest association, with increasing risk with 
accumulation of injuries[286].  The mechanistic link is plausible considering that TDP-43 
accumulation is a common marker in patients with chronic traumatic encephalopathy (CTE) 
secondary to repeated head injury, and MND[287,288].  Recall bias in head injury is a 
concern; a study looking only at hospital records of serious head injury requiring admission 
suggested no association with MND[289].  Head injury may in fact be a prodromal sign of 
MND, for example in association with falls, and so it is important to clarify temporal 
relationship[289,290].  Indeed a Swedish register study showed increased risk of head injury 
in the one year preceding ALS diagnosis but not at three years prior to diagnosis[291].  
Another related potential exogenous influence is physical exercise.  Most recent studies 
suggest that physical activity itself does not pose a risk to development of 
MND[237,292,293].  One study found that strenuous activity >3 days per week shortened 
survival in postmenopausal women with ALS; however, the study did not adjust for site of 
onset or interventions[294]. 
 
Other exogenous elements that have been explored in MND include occupational exposure 
to chemicals and agricultural pesticides[295–297] and heavy metals such as lead and 
mercury[295,298,299].  So far, there is no firm evidence to suggest that these exposures 
contribute to MND risk or survival.  A genotype-environmental link was proposed in the 
context of agricultural pesticides, specifically organophosphates: the paraoxonase gene 
(PON1) detoxicates paraoxon, the active ingredient in organophosphates.  Mutations in the 





not been proven[300,301].  In the case of lead, which is thought to be neurotoxic, increased 
exposure may even prolong survival in MND[298].  Other occupational considerations have 
been studied and jobs which involve direct contact with the general public have been 
implicated, perhaps due to exposure to infections[302].  A large retrospective study in 
Scotland revealed that military veterans were more likely to develop MND than non-
veterans; however, the relative risk was very small (adjusted HR 1.49, 95% CI 1.01-2.21, 
p=0.046) and the study was not adjusted for other measures such as smoking[303].   
 
Exposure to certain drugs, particularly statins, has also been explored[229,304–306].  Again, 
these studies have conflicting messages that do not allow us to come to conclusions 
regarding risk.    
 
As discussed, there is thought that MND may be a prion-like disease due to its contiguous 
spread[63,64].  As such, the impact of blood transfusion from patients with 
neurodegenerative disease might influence disease onset.  However, a large retrospective 
cohort study did not find association in neurodegenerative disease[228].  In terms of more 
conventional exogenous exposures, smoking is generally considered a risk factor for MND.  
However, studies are again conflicting with some suggesting an unequivocal relationship and 
a dose response[236,307,308] and others describing a trend towards association in women 
only[235].    
 
The fact that all the above factors have been questioned in the development or progression 
of MND in recent years suggests that the environmental contribution is still very much open 
for debate.  As such, an extensive longitudinal register such as CARE-MND has the potential 
to test and generate hypotheses about these factors in the Scottish population. 
 
As discussion in Chapter 1.2, predicting outcomes in MND is fraught with difficulty as the 
population is heterogeneous in presentation and prognosis.  Factors which are thought to be 
poor prognostic markers include older age at onset, bulbar or respiratory onset disease, ALS 
(over other forms of MND), cognitive impairment, early progression of ALSFRS-R 
score[58,185].  However, while there are supportive studies for these, there are also 
contradictory ones[58].  It is also unclear if cognition is an independent prognosticator or if 





use patients recruited to trials are subject to selection bias and by default model only MND-
specific variables[58].  Most studies involving patient data from electronic records have 
missing values[191,194].  Exclusion of these variables/individuals can further introduce bias.  
The best approach is considered to be population-wide recruitment using multiple sources 





Clinical Audit Research and Evaluation of MND (CARE-MND) is a newly relaunched national 
platform for prospective data collection of demographics and health-related variables, 
including past medical and drug histories, of people with pwMND in Scotland.  I aimed to 
characterise phenotypically the population in the first few years of inception (2015-2017), 
with the following intentions: 
 
i) To describe a national cohort in terms of demographics, clinical phenotypes and 
environmental exposures.  
ii) To undertake a survival analysis using selected features described in the literature to 









All available data stored on the CARE-MND database were sourced for this component of the 
study.  Only patients who had provided written informed consent to share their data were 
included.  Patients who lacked capacity at diagnosis were therefore not included in this part 
of the analysis.  Patients consented to examination of medical notes, processing of this 
information and storing of the data securely, via the CARE-MND database (see MND Register 





processors who are based at the University of Edinburgh.  Application for data requires 
submission of a form detailing requirements and project specifications including ethical 
approvals and funding.  This is subsequently reviewed by the CARE-MND Research Project 
Manager who has the power to grant release of data.  From 25th May 2018 all data handling 
adhered to General Data Protection Regulation guidelines.    
 
 
Variables and Pre-processing 
 
Data are anonymised using a unique patient code. Released data are ‘raw’ ie. As entered 
prospectively onto the CARE-MND platform.  Pre-processing is therefore required to ‘clean’ 
the data and make it more interpretable[309].  Pre-processing is a key component of data 
mining in medical datasets and involves various steps including i) data cleaning, ii) missing 
data imputation and iii) feature selection[309].   
 
During platform development, we aimed to include mainly binary/drop-down options to 
facilitate easy data interpretation.  However, by its nature, CARE-MND is a prospective source 
for MND clinical/allied health specialists and ‘free text’ boxes are required for elaboration 
and explanation of factors relevant to patient care.  Data cleaning is therefore essential for 
raw medical data stored on CARE-MND.  The variables included and specifics regarding pre-
processing are outlined below.  All environmental and past medical history data refers to pre-
morbid state prior to recorded date of MND onset. 
 
 
i) Demographic Variables 
 
Demographic variables related to patient sex and ethnicity.  Ethnicity was coded as per ISD 
guidelines[310]; indeed some of this information was extracted from ISD records (see 
Chapter 2.3).  Due to the low variance in ethnicity in the population studied (infrequency of 
ethnic minorities), this variable was reclassified into the following: i) Group A – White, 1A 
White Scottish, ii) Group A – White, 1B Other British, iii) Group A – White Other (including 1C 





Scottish or Asian British, v) Group G – Refused/Not provided by patient and Group H - 
Unknown.  Group G was classed as missing data.   
 
 
ii) Environmental Variables 
 
Environmental variables included those related to social circumstances (co-habitation, 
occupation, military service, exercise participation) and exogenous exposures (smoking, 
alcohol, recreational drugs, heavy metal and pesticide exposure).  Co-habitation was 
dichotomised into a Yes (Married/Living with partner) or No (Single/Divorced/Separated) 
variable with reference to a recent retrospective analysis[311].  Occupational histories were 
recorded as free text.  The patient’s primary occupation was analysed; where this was unclear 
the highest skilled occupation was selected.  Rather than make artificial assumptions about 
occupation type, each individual’s occupation was coded as per the UK Office for National 
Statistics using the Standard Occupational Classification coding index 2010[312].  This system 
ranks occupations into nine major groups (level from 9, low skill, to level 1 high skill).  Military 
service was dichotomised into Yes/No variables and required patients to have partaken in 
active service.  Exercise participation was crudely screened using 
None/Light/Moderate/Heavy levels.  Examples of “Light” exercise included dog-walking and 
“Heavy” exercise was considered as strenuous physical activity more than five times per 
week or professional/semi-professional sportsmanship.   
 
Smoking was recorded as Yes/Ex-smoker/Never smoked and then dichotomised into Ever 
Smoked/Never Smoked variables.  Alcohol use was examined from the perspective of 
hazardous drinking (>14 units per week for men and women) and harmful drinking (>35 units 
per week for women, >50 units per week for men) as per NICE Guidelines for Alcohol-use 
disorder[313].  Recreational drug misuse, heavy metal exposure and pesticide exposure were 










iii) Past Medical History 
 
Based on a review of the literature, past medical history data were interrogated for the 
following: surgical intervention within one year preceding symptom onset (Yes/No); past 
medical history of malignancy (Yes/No), cardiovascular disease (Yes/No), autoimmune 
disease (Yes/No), central nervous system surgery (Yes/No), psychiatric illness (Yes/No), 
nervous system infection (Yes/No), significant pre-morbid head injury (Yes/No) and pre-
morbid receipt of blood products by transfusion (Yes/No); number of pre-morbid co-
morbidities; number of pre-morbid surgical interventions.  Co-morbidities were defined as 
chronic conditions requiring medical input (excluding acute infections or injuries).  Accurate 
past medical and surgical histories including dates were obtained from patient self-report, 
GP records and ISD data (see Chapter 2.3).     
 
Medication history was sourced but for the purposes of analysis, only pre-morbid statin use 
(Yes/No) was examined.  Accurate medication history was obtained from patient self-report, 
GP records and Emergency Care Summary (ECS) records on EPRs.       
 
 
iv) Family history 
 
Family history was obtained from patients, with corroboration from a family member where 
possible.  History was explored across four generations (patient’s grandparents to children), 
though documentation of this was sometimes limited by patient recall or family 
estrangement.  Patients were questioned specifically about family history of MND 
(considered positive (Yes/No) if there was any family member with MND), other neurological 
diseases (Yes/No) with a separate analysis for neurodegenerative diseases (multiple sclerosis 
(Yes/No) and Parkinson’s disease (Yes/No)), dementia (Yes/No) with a separate analysis for 










v) Characterisation of Disease  
 
Variables related to disease onset and trajectory included those from diagnosis (mean age of 
onset, mean age of diagnosis) to initial assessment (site of onset, El Escorial classification of 
disease[27], baseline ALSFRS-R score[182], presence of cognitive impairment and ECAS ALS-
specific and ALS-non-specific scores[206,208].  Site of symptom onset was classified as: 
bulbar; upper limb; lower limb; mixed; cognition; respiratory; other.  ‘Mixed’ onset refers to 
pwMND for whom it was not possible to identify an initial one symptom.  ‘Other’ refers to a 
small proportion of patients for whom symptom onset could not be classified into other 
categories.   
 
Additionally, rate of ALSFRS-R decline was calculated using the concept of the ‘preslope’ or 
ALSFRS-R-based linear estimate of rare of disease progression ie. The rate of decline in 
function between the day before symptom onset (date of onset minus one) and the date of 
the first ALSFRS-R after diagnosis (providing this is within six months of diagnosis) (see Figure 
11).  The ‘preslope’ is a recognised phenomenon and has been used for prediction modelling 














vi) Markers of Care 
 
Through CARE-MND, we can also assess quality of care delivery and align these to NICE 
standards.  Data regarding the following were collected: time to neurology clinic review; time 
to MND specialist clinic review; referral to a neuropsychologist (Yes/No); referral to a 
dietician (Yes/No); discussions undertaken regarding feeding tubes (Yes/No); referral to a 
speech and language therapist (Yes/No).  Place of death was also recorded as a surrogate 





Again, in line with NICE recommendations, proportion of patients undergoing interventions 
relevant to quality of life or survival was examined.  This included: proportion of patients 
undergoing ECAS assessment (Yes/No); patient decision regarding riluzole treatment 
(Yes/No/Undecided at time of censorship); proportion of patients taking riluzole at 
censorship (excluding patients who had taken riluzole at any point and had subsequently 
discontinued treatment); proportion of patients who had taken taken riluzole but 
subsequently discontinued treatment; patient decision regarding feeding tube placement 
(Yes/No/Undecided); proportion of patients undergoing feeding tube insertion by time of 
censorship; patient decision regarding non-invasive ventilation (NIV) (Yes/No/Undecided); 





Finally, summary survival data were sourced to assess the data in advance of further survival 
analysis.  The following were summarised: proportion of deaths and proportion of patients 
alive at censorship; median survival in days and months; proportion of patients who had died 










From study of the CARE-MND database (Chapter 2), missing data were anticipated.  While 
the analysis of CARE-MND compared with MND-SMART revealed a significant improvement 
in ascertainment across almost all domains (Chapter 2.3), some of the variables on the CARE-
MND proforma were new to both MND clinical nurse specialists/allied health professionals 
and patients.  It is well-recognised that new population registers take time to achieve 
adequate data capture[227] and we suspected that capture of new variables might be low in 
the 2015-2017 time period.  Real-world, routinely-collected data is rarely complete but 
ignoring variables with missingness can be misleading and can introduce bias[191,309].  In a 
recent review of missing data in prediction studies for diabetes, 62.5% of studies did not 
acknowledge missing data; of the studies that did acknowledge missing data, 43.8% excluded 
all individuals with missing data[192].   
 
Potential reasons for missingness in our dataset include: 
- Incomplete CARE-MND proformas due to patients not being asked relevant 
questions by clinical specialists due to: 
 Time constraints 
 Prioritisation of other variables in a patient who is struggling to 
communicate 
- Patient declining to answer certain questions 
- Data not available at time of censorship due to proforma being in progress 
 
Following pre-processing, descriptive statistics and percentage missingness were calculated 
for each variable.   
 
 
Statistical Modelling of Data 
 
 
Subsequent to descriptive analysis, variables were incorporated into models to identify 
predictors of survival.  Based on review of the literature, only selected clinically-relevant 





undertaken to select appropriate features.  Variables with zero variance were excluded.  A 
correlation matrix was generated to identify highly correlated variables using Pearson’s 
correlation coefficients; coefficients >0.5 were considered significant[315].  A maximum 
variable limit was set to ensure that the models did not exceed the ‘one in ten’ rule[195,316].  
Values were standardised (centred and scaled) for model analysis.  Categorical variables were 
dummy coded into dichotomous variables.   
 
In order to analyse data in the context of missingness, imputation was required to replace 
data values with statistically plausible estimates (required when >15% missing 
data)[191,192,194].  Our missing values were assumed to be missing at random (MAR); while 
missingness was not biased towards any particular patient groups, there was a trend toward 
missingness for variables new to CARE-MND (eg. Exposure to heavy metals and pesticides, 
cognitive screening).  
 
Multiple imputation is considered best practice and a recognised method is Multiple 
Imputation by Chained Equations (MICE)[191,193,194].  Standard MICE software 
incorporates predictive mean matching (PMM) which is a parametric and non-parametric 
approach; it has been shown to be a good option for Cox regression models where 
missingness ranges between 10-50%[317].  M=10 imputations were used and results pooled 
using Rubin’s rules[318].  Sensitivity analyses were performed whereby models were 
imputed and tested using all variables with i) ≤25% missing data, ii) variables with ≤50% 
missing data and iii) all variables.  Cox regression modelling was used to assess 
simultaneously the effect of multiple variables, both quantitative and categorical, on survival.  
Due to the conflicting evidence in the literature regarding risk factors for MND, a data-led 
hypothesis-free approach was taken whereby as many variables as possible were included in 
the model.  This approach also provides more information for multiple imputation[194].   
 
Model development was outlined with reference to TRIPOD guidelines[195,196].  R v3.4.3 
was used for all statistical analyses (in particular, packages “caret”, “mice”, “DescTools”, 













Of the 619 pwMND diagnosed in Scotland in 2015-2017, 437 (70.6%) consented to share their 
medical record data.  The dataset was split into two cohorts for censorship.  2015-16 data 
were censored on 16th April 2018.  To maximise follow-up, 2017 patients were censored on 
20th July 2018.  The mean follow-up time was 23.0 months (SD 9.2, range 6.0 – 39.0 months).  
Descriptive statistics by phenotypic category are presented in Table 11.  Values and 
percentages relate to completed fields, excluding missing data.  
 
Ethnic minorities included people of Pakistani origin (n=3), Chinese origin (n=1), Indian origin 
(n=1) and Other Asian (non-Chinese) origin (n=1).  For the individuals in whom Site of Onset 
was defined as “Other” (n=4), sites included: weight loss (n=2), truncal 
weakness/camptocormia and generalised fasciculations.  Of the 41 patients who had 
“Mixed” onset disease, 21 (51.2%) had bulbar symptoms at onset.  Therefore 144 (33.3%) of 
pwMND had bulbar symptoms at onset.   
 
Premorbid surgeries were defined as major or minor surgical procedures performed prior to 
disease onset.  While the median number of surgeries is zero, the maximum number was 13. 
   
Twenty one pwMND were referred for genetic counselling; if this field was blank it was 















- Males (%) 





- White All (Group 1A, 1B and 1 Other) (%) 
- White Scottish Group 1A (%) 
- White British Group 1B (%) 








Cohabiting, Yes (%) 6.9 307 (75.4) 
Highest Occupational Classification  
- 1 (%) 
- 2 (%) 
- 3 (%) 
- 4 (%) 
- 5 (%) 
- 6 (%) 
- 7 (%) 
- 8 (%) 
- 9 (%) 












History of Active Military Service, Yes (%) 42.1 32 (12.6) 
Ever Smoked, Yes (%) 10.3 209 (53.3) 
History of Alcohol Intake Exceeding 14 units/week, Yes (%) 31.8 79 (26.5) 
History of Harmful Alcohol Intake Exceeding 35 units/week for 
women, 50 for men, Yes (%) 
31.8 36 (12.1) 
Recreational Drug Use, Yes (%) 47.4 24 (10.4) 
Premorbid Exercise Participation 
- Grade 4: Heavy (%) 
- Grade 3: Moderate (%) 
- Grade 2: Light (%) 






History of Heavy Metal Exposure, Yes (%) 32.0 46 (15.5) 
History of Pesticide Exposure, Yes (%) 33.2 35 (12.0) 
 
Past Medical History (PMH) 
Median number of co-morbidities (IQR) 0 3.0 (1.0-5.0) 
PMH Cardiovascular Disease, Yes (%) 0 206 (47.1) 
PMH Autoimmune Disease, Yes (%) 0 66 (15.1) 
PMH Malignancy, Yes (%) 0 37 (8.5) 
PMH Psychiatric Condition, Yes (%) 0 88 (20.1) 
PMH Nervous System Infection, Yes (%) 0 15 (3.4) 
Premorbid Statin Use, Yes (%) 0 54 (12.4) 





Premorbid Surgery, Yes (%) 0 202 (46.2) 
Surgery <1 year before Disease Onset, Yes (%) 0 13 (3.0) 
PMH of Central Nervous System Surgery, Yes (%) 0 8 (1.8) 
PMH of Significant Premorbid Head Injury, Yes (%) 30.9 78 (25.8) 
PMH of Blood Transfusion, Yes (%) 34.6 28 (9.8) 
 
Family History 
Family History of MND, Yes (%) 2.7 39 (9.2) 
Referred for Genetic Counselling, Yes (%) 0 21 (4.8) 
Family History of Dementia, Yes (%) 





Family History of Neurological Conditions, Yes (%) 
- Family History of Parkinson’s Disease, Yes (%) 






Family History of Psychiatric Conditions, Yes (%) 16.9 54 (14.9) 
 
Characterisation of Disease 
Mean age of Onset, years (SD) 1.6 63.9 (10.9) 
Mean age of Diagnosis, years (SD) 0 65.5 (10.7) 
Median Time to Diagnosis, months (IQR) 1.6 12.0 (8.0-23.0) 
Site of Onset 
- Bulbar (%) 
- Upper limb (%) 
- Lower limb (%) 
- Mixed (%) 
- Cognition (%) 
- Respiratory (%) 









Mean Baseline ALSFRS-R (SD) 24.0 37.4 (7.2) 
Mean Time from Diagnosis to Baseline ALSFRS-R, months (SD) 24.0 0.9 (1.5) 
Median Rate of Decline in ALSFRS-R from Onset to First 
Assessment (IQR) 
24.0 0.6 (0.3-1.1) 
MND Classification 
- ALS El Escorial Definite (%) 
- ALS El Escorial Probable (%) 
- ALS El Escorial Possible (%) 
- ALS Clinician Diagnosis (%) 
- MND-FTD (%) 
- PBP (%) 
- PLS (%) 
- PMA (%) 











Cognitive Impairment, Yes (%) 42.3 99 (39.3) 
Median ECAS Total Score (IQR) 
- Median ALS-Specific Score (IQR) 








Markers of Care 
Median Time from Disease Onset to Neurology Clinic Review, 
months (IQR) 
36.4 8.0 (5.0-16.0) 
Median Time from Disease Onset to MND Specialist Clinic 
Review, months (IQR) 
36.2 13.0 (8.0-26.0) 





Referral to Dietician, Yes (%) 9.2 298 (75.1) 
Feeding Tube Discussed, Yes (%) 7.6 282 (69.8) 
Referral to Speech & Language Therapist, Yes (%) 6.9 315 (77.4) 
Place of Death (n=242) 
- Home (%) 
- Hospital (%) 
- Hospice (%) 






Management   
ECAS Assessment, Yes (%) 1.6 244 (56.7) 
Patient Decision Regarding Riluzole 
- Yes (%) 
- No (%) 





Taking Riluzole at Censorship, Yes (%) 0.9 173 (40.0) 
Riluzole Discontinued Ever, Yes (%) 0 42 (9.6) 
Patient Decision Regarding Feeding Tube 
- Yes (%) 
- No (%) 





Feeding Tube Inserted by Censorship, Yes (%) 0.7 136 (31.3) 
Patient Decision Regarding NIV 
- Yes (%) 
- No (%) 









Death During Follow-up 
- Death (%) 




Median Survival from Onset All 
- Days (IQR) 
 





Median Survival from Onset Death Only 
- Days (IQR) 
 





<2 year Survival from Onset Death Only, Yes (%) 1.2 117 (49.0) 
 











Variables relevant to survival were selected for modelling and are summarised in Table 12.  
As described in the table, variables were simplified for ease of modelling and interpretation.  
In particular, levels of classification of “Site of Onset” and “Classification” were simplified to 
test hypotheses relevant to survival (as described in review of the literature in Chapter 1.1).  
For example, bulbar-onset disease is considered to have poorer survival than limb-onset 
disease, but the impact of ‘other’ sites of onset (respiratory, weight loss) is unclear.  Further, 
more atypical forms of MND (PLS, PMA, PBP) and thought to confer a longer survival benefit 
than typical ALS presentations but people with MND-FTD are considered to have poor 
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Age of onset 
Site of Onset 




     ALS, MND-FTD, 
Other 
ALSFRS-R Preslope 




Time to Neurology 
Clinic 












After removing variables with near-zero variance, there remained 27 variables with a total of 
28 predictors taking into account variables with multiple levels.  Correlated variables were 
then reviewed using a correlation matrix (Figure 12).  Of each correlated pair, the most 
clinically applicable variable was preserved.  As such, the following variables were excluded 
based on a correlation coefficient cut-off of 0.5: Time from Onset to Neurology Clinic, Time 
from Onset to MND Clinic, and ALS Non-Specific Score. Number of comorbidities was also 
excluded as this was closely correlated with past medical history of cardiovascular disease 










The Cox regression model was first tested using ≤25% missing data.  Twenty predictors were 
featured in this model (p = 20) (Figure 13 (i)).  The following were significant predictors of 
death: increasing Age of Onset (p=0.0013), Family History of MND (p=0.0026) and steeper 
ALSFRS-R Preslope (p=0.0025).  In contrast, a longer Time to Diagnosis (p<0.00001), 
Classification: Other (which included PLS, PMA and PBP) (p=0.0044), Past Medical History of 
Autoimmune Disease (p=0.043) and a history of Ever Smoked (p=0.0081) were associated 
with better prognosis.  The pseudo-R2 for the Cox model was 0.511 (95% CI 0.506-0.517), 
suggesting that 51% of the variance in survival could be explained by these predictors. 
 
Using variables with ≤50% missing data (p =23), again increasing Age of Onset (p=0.0013), 
Family History of MND (p=0.00077) and ALSFRS-R Preslope (p=0.0028) predicted death and 
increasing Time to Diagnosis (p<0.00001), Classification: Other (p=0.0031), Past Medical 
History of Autoimmune Disease (p=0.029) and a history of Ever Smoked (p=0.0077) predicted 
survival.  The pseudo-R2 for this model was 0.521 (95% CI 0.514-0.527) (Figure 13 (ii)).  
 
Finally, by including and imputing all predictors (p=24), predictors of outcome remained 
relatively stable with increasing Age of Onset (p=0.012), Family History of MND (p=0.0023) 
and ALSFRS-R Preslope (p=0.0010) predicting death and increasing Time to Diagnosis 
(p<0.00001), Classification: Other (p=0.0020) and a history of Ever Smoked (p=0.0013) 
predicting survival (Figure 13 (iii)).  In this final model, a Past Medical History of Autoimmune 
Disease no longer predicted survival (p=0.058) but exposure to Heavy Metals or Pesticides 
was associated with poorer survival (p=0.042).  The pseudo-R2 for this model was 0.538 (95% 
CI 0.531-0.545).  This model was considered the best in view of the higher pseudo-R2 value.  
Hazards ratios and confidence intervals for this model are summarised in Table 13, ranked 
by hazard ratio from most significant predictor of death to most significant predictor of 

















Figure 13 Cox Regression Model predicting survival i) With <= 25% missing data, ii) With <=50% 











ALSFRS-R Preslope 1.29 1.11-1.50 
Age of Onset 1.28 1.06-1.56 
Family History of MND 1.24 1.08-1.43 
Heavy Metal or Pesticide 
Exposure 
1.20 1.01-1.43 
Family History of Psychiatric 
Disorders 
1.12 0.96-1.30 
PMH Cardiovascular Disease 1.06 0.91-1.24 
Family History of Dementia 1.06 0.91-1.24 
Classification: MND-FTD 1.03 0.86-1.23 
PMH Psychiatric Disease 1.03 0.89-1.19 
Blood Transfusion 1 0.83-1.20 
Feeding Tube Insertion 0.99 0.84-1.16 
Non-Invasive Ventilation 0.97 0.84-1.12 
Head Injury 0.96 0.81-1.14 
Exercise Participation 0.96 0.80-1.14 
Riluzole 0.95 0.82-1.10 
Sex (Male) 0.92 0.78-1.09 
Site of Onset: Limb 0.92 0.79-1.09 
Family History of Other 
Neurological Disorders 
0.90 0.77-1.04 
PMH Malignancy 0.87 0.75-1.01 
PMH Autoimmune Disease 0.86 0.74-1.00 
ECAS: ALS Specific Score 0.82 0.59-1.13 
Ever Smoked 0.79 0.68-0.91 
Classification: Other 0.76 0.65-0.91 
Time to Diagnosis 0.062 0.034-0.11 
   
 












The male-to-female ratio in this research cohort of pwMND was 1.70:1; this is higher than 
that seen in the unselected incident cohort described in Chapter 3 (1.53:1) suggesting that 
more males than females were willing to, or able to, consent to research.  To our knowledge, 
this is not a recognised observation and may be unique to this particular research cohort.  
Similarly, research participants were slighter younger than the overall incident cohort (age of 
onset and diagnosis 63.9 and 65.5 years versus 65.3 and 66.8 years respectively), as has been 
observed in other studies[178].  However, the figures remains fairly typical compared with 
other population cohorts[3,5,199,243].  There were comparable proportions of patients with 
bulbar onset MND and MND-FTD between the two cohorts (28.5% and 5.7% in the research 
cohort versus 28.2% and 6.8% in the incident cohort) showing that these factors were not 
barriers to research recruitment.  The ethnic homogeneity of the research cohort was 
comparable with the incident cohort and with Scottish government data[277].   
 
This study does not benefit from a matched control population to which phenotypic 
characteristics can be directly compared; as such the influence of environmental factors on 
MND onset cannot be assessed.  However, Scottish government statistics are available for 
some of the features to allow us to contextualise the cohort.  Government statistics are 
broken down by age and sex; considering our population, males age 65-74 are likely the most 
directly comparable.       
 
Seventy five percent of the Scottish MND cohort were cohabiting; this is higher than Scottish 
census statistics for 2011 (50.4%)[319].  This may reflect the level of disability and 
dependence of some pwMND.  In accordance with our analysis of social deprivation in the 
Scottish MND population (Chapter 3), there also seemed to be an even distribution across 
occupational classifications in the cohort.  A small proportion of patients (12.6%) had 
participated in previous military service but there was a high proportion of missing data 
(42.1%) and insufficient details regarding type and duration of service making further 






In the 2017 Scottish Health Survey, 32% of men aged 65-74 reported having had any form of 
cardiovascular disease[320].  In comparison, 47.1% of our MND cohort had had some form 
of cardiovascular disease.  The higher proportion in our study may reflect sources of 
information: ISD and GP records were sourced for the MND cohort whereas the Scottish 
Health Survey is self-reported only.  However, as discussed, vascular disease may be a risk 
factor for MND[285].  In the same survey, 17% of all adults had self-reported psychiatric 
symptoms as studied using the Global Health Questionnaire (GHQ); however, this proportion 
was lower in adults >65 years (12-13%)[320].  In our MND population, 20.1% had a 
documented or reported psychiatric illness.  Recent data from CARE-MND and other studies 
suggest that neuropsychiatric disease may be a prodrome for both neurodegeneration 
associated with MND and with specific cognitive and/or behavioural changes and this may 
explain the relatively high proportion of premorbid psychiatric disease in the MND 
cohort[321,322].  In 2017, 44% of all adults were current or ex-smokers compared with 53% 
of the MND cohort[320].  However, 57% of males age 65-74 were current or ex-smokers 
which is more comparable.  Our cohort figures, however, are higher than in other European 






Through this study, I aimed to identify a model which would optimise on the breadth of CARE-
MND data.  Using a hypothesis-free data-driven approach, a Cox regression survival model 
(measuring survival in days) was tested.  Sensitivity analysis revealed that inclusion of all 
variables in the imputation process provided more information than excluding variables with 
different missingness thresholds.  This highlights the statistical power of multiple imputation.  
By excluding variables with missing data the dataset is subject to increased variance due to 
chance without correcting for bias[194].   
 
The most informative model is model (iii) (Figure 13).  By defaulting to this model, it is 
possible to conclude that ALSFRS-R score can predict survival, with a steeper decline from 
baseline to first assessment (within six months of diagnosis) predicting an earlier death (HR 
1.29, 95% CI 1.11-1.50).  Similarly, longer time to diagnosis (with each increasing month) 





decline.  El Escorial Classification: Other might also be considered to be related to these 
predictors: a more slowly progressive, atypical form of MND (PLS, PMA or PBP) is associated 
with longer survival (HR 0.76, 95% CI 0.65-0.91).  Collectively, these observations suggest that 
early widespread manifestation of combined upper and lower motor neurone degeneration 
will result in a faster time to death.  Whilst this is not surprising - and indeed has been 
observed in other survival studies[7,184,187,324] -  it is important to know that these factors 
predict survival independent of all other medical and environmental influences.  Such 
patients can be identified at point of recruitment into clinical trials, and their progress studied 
separately to measure impact of the intervention on their survival.  Patients with a family 
history of MND have significantly poorer prognosis (HR 1.24, 95% CI 1.08-1.43); inclusion of 
genetic data in the model may provide further clarification on this observation (discussed in 
Chapter 7).  Being older at onset of disease is also associated with poorer outcomes (HR 1.28, 
95% CI 1.06-1.56, with each increasing year of age).  This has been observed in the Scottish 
population previously[3].  However, on this occasion, we observe its influence independent 
of other comorbidities such as cardiovascular disease and history of malignancy, perhaps 
supporting prior theories that older people with MND are more vulnerable due to aging or 
depleted motor neurones[178,204].   
 
Interestingly, two environmental features had prognostic influence.  A history of ever 
smoking was associated with better prognosis (HR 0.77, 95% CI 0.64-0.92).  This feature was 
stable across all three Cox regression models.  Our findings mirror observations in another 
neurodegenerative disease – Parkinson’s disease – where smoking is found to be protective 
in a dose-dependent fashion[325].  A possible biological explanation for this relates to 
changes in the gut microbiome: cigarette smoking is thought to reduce gut inflammation (as 
seen in ulcerative colitis) and by extension decreases protein misfolding and propagation of 
misfolded alpha-synuclein through the CNS[325,326].  As discussed in Chapter 1, the role of 
misfolded TDP-43 and the apparent contiguous spread of ALS could represent a parallel 
model of disease.  While there has been a recent surge in interest in the microbiome in 
neurodegenerative diseases, including MND, the biological interactions are as yet 
unclear[327–329].  The fact that a Past Medical History of Autoimmune Disease was a 
potential protective marker (significant in models (i) and (ii) though not significant in the final 
model; HR 0.86, 95% CI 0.74-1.00) may also hint at a potential link between MND and 





CSF inflammatory biomarkers is a current topic of debate[330].  Nevertheless, the findings in 
relation to smoking contradict previously published populations studies[307,308,323], 
although these studies did not control for other endogenous and exogenous influences and 
potential modifiers of MND progression and survival.  Most recently, a large case-control 
study examined pack-year history and time from stopping smoking from three pooled 
European population cohorts, controlling for sex, age, site, alcohol intake and educational 
level[331].  Results from this work suggest that there is an increased risk of developing ALS 
with smoking and that this risk diminishes with time after stopping smoking.  However, the 
effect of smoking on survival was not studied.  This study used detailed questionnaires to 
capture smoking history; the authors acknowledge that this may limit patient inclusion (by 
excluding, for example, fast progressors and those unable to complete questionnaires).  In 
contrast, data collection in Scotland was via a simple screening question (Smoking: 
Yes/Ex/Never; Provide Details).  Future work in Scotland to explore the smoking hypothesis 
could learn from the more structured approach to this variable.   
 
Exposure to Heavy Metals or Pesticides reached statistical significance in the final imputed 
model (HR 1.20, 95% CI 1.01-1.43).  As this variable was an amalgamation of two different 
observations of toxin exposure, and as it was unstable (being absent from other models), it 
is not possible to draw firm conclusions about its impact on survival.  However, it warrants 
further study using case-control methods using the CARE-MND population.  Interestingly, a 
historical case-control Scottish survey of environmental exposures found a significant 
increase in exposure to heavy metals and pesticides in MND cases versus controls (OR 3.2 
(95% CI 1.5-7.3)[275].  However, again, these data were subject to recall bias.  It may be that 
patients with MND are more hyper-vigilant to potential causative agents and might scrutinise 
their past history more carefully.  A case-control study using occupational records and with 
an attempt to quantify exposures would be more beneficial.   
 
 Other exogenous factors including exercise participation and history of blood transfusion did 
not influence survival.  This is unsurprising considering the conflicting evidence regarding 
their impact in MND.  However, these factors were self-reported, relying on patient 
recollection and awareness of exposures, and so may not be wholly reliable as anything more 






Site of onset was not a significant predictor of outcome.  Our results therefore agree with 
previous dialogue, which proposes that conventional stratification of pwMND for clinical 
trials by region of onset (eg. Bulbar or spinal onset) is artificial and inadequate[58].  This may 
relate to poor recall of first symptoms – indeed in the Scottish cohort many patients report 
a ‘mixed’ presentation at onset.  However, from our other observations, it appears that 
burden of motor neurone degeneration, rather than the origin of symptoms is of greater 
importance.  It is possible that individuals with fast and global expression of disease have a 
stronger underlying predisposition (such as a genetic cause) or other biological or 
environmental factors, which make their CNS more vulnerable to a cascade of decay.   
 
Further, initiation of riluzole, gastrostomy feeding or NIV did not confer any survival benefit 
in this analysis.  Although the follow-up times may be too short to comment conclusively, it 
appears that predetermined markers of disease, which are present at diagnosis, overpower 
any survival benefit of current available interventions.  Previous studies have excluded NIV 
and gastrostomy from survival models because of assumptions that they are markers of 
advanced disease and would confound results[178].  However, the proportions of 
gastrostomy (31.3%) and NIV (27.2%) by censorship time (mean follow-up 23.0 months) in 







Using a hypothesis-free, data-driven approach and the wealth of clinical phenotypic 
information collected via CARE-MND, I have been able to stratify patients in Scotland to 
identify outcomes that independently predict survival.  These variables should be used to 
stratify patients for Scottish clinical trial study groups, rather than more conventional but 
arbitrary group categorisation.  Future models should build on this approach but also include 
weight/BMI at diagnosis, electrophysiological markers and, with emerging research, imaging 
biomarkers such as iron deposition quantification[332,333].  Further study into gut 
microbiota in pwMND may clarify our findings that smoking is protective.  Finally, the 
contribution of genetic information to these survival models should be explored and will be 






5. GENOTYPE-PHENOTYPE PILOT STUDY OF HISTORICAL 
COHORT (1989-2014) 
 
The following content has been published in Neurobiology of Aging and re-formatted for this 
thesis: 
 
Holly A Black*, Danielle J Leighton* (*Joint First Authors), Elaine M Cleary, Elaine Rose, Laura 
Stephenson, Shuna Colville, David Ross, Jon Warner, Mary Porteous, George H Gorrie, Robert 
Swingler, David Goldstein, Matthew B Harms, Peter Connick, Suvankar Pal, Timothy J Aitman, 
Siddharthan Chandran. Genetic epidemiology of motor neuron disease-associated variants 
in the Scottish population. Neurobiol Aging. 2017 Mar;51:178.e11-178.e20.  
 
Genotyping (sequencing, filtering and variant calling) was led by Dr Holly Black at the Institute 
of Genetics and Molecular Medicine, Edinburgh University.  Phenotyping was undertaken by 
the author (Dr Danielle Leighton).   
 
 




The major genetic contributors of monogenic MND in the UK population and European 
populations are expansions of an intronic hexanucleotide repeat in C9orf72, and missense 
variants in SOD1 and TARDBP[102,334,335].  In Scotland, the SOD1 p.I114T variant has been 
described as a founder mutation[144,214,219,336] and, more recently, C9orf72 expansions 
were found in 11% of Scottish cases[215].  The incidence of MND-associated variants 











To investigate this knowledge gap further, we investigated a historical cohort of individuals 
with MND in Scotland diagnosed between 1989 and 2014, in collaboration with researchers 
at the Institute of Genomic and Molecular Medicine, University of Edinburgh.  This work 
acted as a pilot study of a limited panel of MND-associated genes before embarking on a 
more detailed study using an incident cohort of patients (Chapter 6).  We aimed to determine 
the contribution of variants in a selected group of genes commonly associated with MND to 
the burden of cases, and their association with disease phenotype.  This included studying 
two genes that were found to be associated with MND after the inception of this PhD project 





MND cases were recruited through the SMNDR.  Recruited cases included individuals aged 
≥16 with possible, probable or definite amyotrophic lateral sclerosis and individuals with 
MND subtypes (PBP, PMA and PLS).  Individuals provided written consent for DNA extraction 
and genetic studies.   
Four hundred forty-one samples, obtained from cases diagnosed with MND in Scotland in 
the years 1989–2014, were included in this study, which included three pairs of related 
individuals (two brothers, two first cousins, and two first cousins once removed).  Case 
records were examined for seven phenotypic characteristics: sex, age at onset, age at 
diagnosis, time to diagnosis, duration of disease (until death or final data review [20th April 
2016]), site of onset (bulbar or spinal), and family history of MND.  Individuals were classified 
as having a family history of MND if a first, second, or third degree relative had been known 
to have MND.  The study did not include the presence of frontotemporal dementia (FTD) 
alone as a criterion for positive family history.  Five individuals were lost to follow-up due to 
relocation from Scotland, and survival dates were censored to date of last contact.  The 
cohort was screened for expansions of the C9orf72 intronic hexanucleotide repeat, as 
described by Cleary et al.[215].  A subset of the cohort had been screened for variants 





Five MND cases, each with a variant in one of the five genes sequenced, were included as 
positive controls; these were taken from the cohort described by Cirulli et al.[86]. Four 
hundred ethnicity and sex-matched healthy controls were selected from the Generation 
Scotland Donor DNA databank[337].  The selected controls were aged ≥56 at the time of 
collection (20% aged 50–56, 66% aged 60–65, 14% aged 66+); an older cohort was chosen to 




Five genes were sequenced: SOD1, TARDBP, OPTN, TBK1, and NEK1; these will be referred to 
hereafter as the MND gene panel. The panel includes the recently associated TBK1 and NEK1, 
alongside genes that are among the largest contributors to cases in UK and European 
populations (SOD1, TARDBP, and OPTN), after C9orf72[102,334,335].  All samples were also 
screened for C9orf72 hexanucleotide expansions using repeat-prime PCR methods published 
by Cleary et al[215].  Expansions >30 repeats were considered pathogenic.    
Genotyping, variant calling and variant classification were undertaken by a team at the 
Institute of Genomic and Molecular Medicine, University of Edinburgh, led by Dr Holly Black.  
The following methods were outlined by Dr Holly Black: 
The primers for 120 amplicons were designed according to the Fluidigm Access Array protocol 
(Fluidigm).  The primers amplified the coding regions of these five genes, excluding a total of 
312bp of coding sequence across the five genes, due to primer design constraints.  The 
Fluidigm Access Array was used for amplification.  The amplicon library was sequenced on an 
Illumina MiSeq with 2×150-bp reads. Each batch of 48 samples included at least one water 
blank as a negative control. The positive control samples were each run in two independent 
batches.  Quality control of the amplicon sequencing data was performed using FastQC 
(version 0.11.2)[338].  Primer sequences were removed from the 5′ ends of reads using the 
cutadapt tool (version 1.7.1) with the ‘anchor’ option[339]. The maximum error rate for 
primer sequences was set to 10%.  Reads were mapped to the human genome reference 
sequence hs37d5 using BWA MEM (version 0.7.10)[340]. Picard (version 1.85)[341] and 
DepthOfCoverage GATK tool (version 3.3–0)[342] were used to collect alignment and 





was used to determine the threshold for including samples from the same batch in further 
analysis.  Only samples with a median coverage that was >10× that of the negative control 
were included.  This removed seven cases and 11 controls, leaving 434 cases (432 
independent) and 389 controls for further analysis.  The UnifiedGenotyper tool, as 
implemented in GATK version 2.6 [342], was used for variant calling.  ANNOVAR (version 2014 
Nov 12) was used to provide functional annotation of the variants[343].   
Intronic and synonymous variants, variants with a population frequency greater than 1% in 
either the 1000 Genomes (October 2014 release)[344] or ExAC v0.2[345] data sets and 
variants with a frequency >5% in our cohort were excluded from further analysis.  Per-sample 
variant calls were filtered to exclude calls with a read depth <50 or an allele balance <0.3.  
Filtered variants were validated by Sanger sequencing.  One sample failed to amplify using 
PCR at variant validation stage and was excluded from further analysis, leaving 433 (431 
independent) cases.  Nine false positives were identified in SOD1 exon 1, and this exon was 
excluded from the analysis.  Following exclusion of this exon, five false positives remained, 
which were excluded from downstream analysis.  Validated variants were submitted to 
ClinVar.  The known variants in the positive controls were identified in both assays in which 
they were tested. 
 
 
Assessing variant pathogenicity 
 
Stop-gain, frameshift, and splice site variants were categorized according to their predicted 
effect on protein function.  Missense variants reported as disease-causing in association with 
MND in the Human Gene Mutation Database[346] were categorized as pathogenic.  The 
remaining missense variants were categorized according to in silico scores of pathogenicity 
and conservation.  The scores used are listed below, with the thresholds for supporting 
pathogenicity/conservation in brackets: SIFT (=D), PolyPhen HDIV (=P/D), LRT (=D), Mutation 
Taster (=D), Mutation Assessor (=M/H), FATHMM (=D), CADD phred (>15), GERP (>2), phyloP 
(>2), and SiPhy (>10).  Variants for which 7–10 in silico measures supported 
pathogenicity/conservation were categorized as likely pathogenic, variants with 4–6 





and variants with 0–3 measures supporting pathogenicity/conservation were categorized as 
likely benign.  
 
The ExAC v0.3.1 reference exome data were used to provide an additional, larger control 
population. It contains exome-wide variants identified in 60,706 individuals. For 
both TBK1 and NEK1, the total number of loss-of-function or loss-of-function + missense 
alleles in ExAC were recorded (including filtered [non-pass] variants), excluding variants 
found in >1% individuals.  The number of ExAC individuals was reduced to reflect the average 
percentage of individuals covered at 30× across each gene.  For TBK1, an average of ∼69% of 
individuals was covered at 30×, giving 41,848 individuals assumed to have sufficient depth 




Fisher's exact tests were used in comparisons between the number of variants in cases and 
controls.  One-tailed tests were used because of the prior assumption that cases contain 
more pathogenic variants than controls.  Genotype-phenotype association testing was used 
to compare clinical phenotypes with different MND genotypes. Only unrelated individuals 
(n = 431) were included in the analysis, with the first individual recruited to the SMNDR from 
each pair retained for analysis. Variables were examined for collinearity using Pearson's 
correlation coefficient.  Age of onset and age at diagnosis were highly correlated (Pearson's 
correlation r=0.98, p<5 ×10−7), as were duration of disease from onset and duration of 
disease from diagnosis (r=0.87, p<5×10−7).  Disease onset is more important to disease 
biology than date of diagnosis, which relies on clinical services; therefore, variables related 
to diagnosis were excluded from genotype-phenotype association testing.  Time to diagnosis 
was also excluded from genotype-phenotype analysis, as this is a derived variable. Univariate 
analysis was carried out for the following variables: sex, age of onset, duration of disease 
from onset, site of onset, and family history.  Two-tailed Fisher's exact test was used for 
categorical data and t-test or Mann Whitney U test was used for parametric and non-
parametric continuous data, respectively. Variables with significant univariate association 
at p ≤ 0.1 were inputted into binomial logistic regression models dependent on gene.  Logistic 





independently associated with having a pathogenic or loss-of-function variant in one of the 
genes tested.  For the purposes of the model, age of onset was grouped by decade. Results 
from logistic regression modelling were considered significant if p<0.05. SPSS Statistics 







After sample filtering, 433 MND cases (431 independent) remained, of which complete 
phenotypic data were obtained for 428 (99%) (Table 14).  Site of onset was unrecorded for 
one case.  Family history was unrecorded for three cases and was unknown for one case, who 
was adopted.  The cohort had a male-to-female ratio of 1.4:1 (Table 14).  The mean age of 
onset was 59.5 years.  Of the 443 cases in this cohort, 367 (85%) had died before censorship 
date; median duration of disease from onset for all the cases was 42 months.  Of the 430 
independent cases for which site of onset was recorded, 304 (71%) had spinal onset MND.  









































12 (6, 22) 
0-386 
 






42 (25, 73.5) 
4-583 
 






25 (12, 55.5) 
0-309 
 












Table 14 Phenotypic Characteristics of MND cases (n=433) 
 
 
Identification of variants in MND genes 
 
Targeted sequencing with the MND gene panel achieved a mean coverage of 6280× per 
amplicon per sample.  Following variant filtering and validation, at least one rare stop-gain, 
splice site, frameshift, or missense variant was identified in 57/433 cases and 19/389 
controls. Following sample filtering, the case population contained two pairs of related 
individuals.  The first pair (brothers) both carried the SOD1 G94R variant, whereas the second 
pair (first cousins) did not carry any variants in the MND gene panel that passed variant 
filtering.  Therefore, the results for the related individuals were concordant. 
Thirty-seven unique variants were identified in either cases or controls across the MND 
gene panel; of these, three were stop-gain, three were splice site, three were frameshift, 
and 28 were missense variants.   All stop-gain, splice site, and frameshift variants were 





in TARDBP was categorised as uncertain significance, as it is in the final exon of the gene 
and therefore not expected to result in nonsense-mediated decay.  There were also two 
splice site variants in NEK1 predicted to result in the in-frame loss of a single exon[347], 
which were categorized as uncertain significance.  Therefore, of the 37 unique variants 
identified, six were categorized as loss-of-function, seven pathogenic, 11 likely pathogenic, 





Gene Variant Variant type Pathogenicity classification Number of cases Number of controls 
NEK1 c.1948delC;p.Q650fs frameshift Loss-of-function 1 0 
NEK1 c.T386G;p.I129S missense Likely Pathogenic 1 0 
NEK1 c.G695A;p.R232H missense Likely Pathogenic 0 1 
NEK1 c.G782A;p.R261H missense Likely Pathogenic 5 2 
NEK1 c.G827T;p.C276F missense Uncertain significance 0 1 
NEK1 c.G1021A;p.A341T missense Uncertain significance 4 3 
NEK1 c.T1137A;p.D379E missense Likely Benign 0 1 
NEK1 c.T1789A;p.F597I missense Likely Pathogenic 0 1 
NEK1 c.G2137A;p.V713M missense Likely Benign 1 1 
NEK1 c.T2235G;p.N745K missense Likely Pathogenic 3 4 
NEK1 c.A2306G;p.H769R missense Likely Benign 0 1 
NEK1 c.G2368A;p.A790T missense Likely Benign 0 1 
NEK1 c.C2392G;p.L798V missense Likely Benign 1 0 
NEK1 c.C3140T;p.S1047L missense Likely Pathogenic 1 0 
NEK1 c.214+1G>A splice site Loss-of-function 1 0 
NEK1 c.1750-5T>C splice site Uncertain significance 1 0 
NEK1 c.1911+1->TATA splice site Uncertain significance 1 0 
NEK1 c.C481T;p.R161X stop-gain Loss-of-function 1 0 
OPTN c.A280C;p.K94Q missense Likely Pathogenic 0 1 
OPTN c.A941T;p.Q314L missense Pathogenic 1 1 
OPTN c.A1337G;p.E446G missense Uncertain significance 1 0 
OPTN c.T1403G;p.M468R missense Likely Pathogenic 2 0 
SOD1 c.G112A;p.G38R missense Pathogenic 1 0 
SOD1 c.G280C;p.G94R missense Pathogenic 2* 0 
SOD1 c.A302G;p.E101G missense Pathogenic 1 0 
SOD1 c.T341C;p.I114T missense Pathogenic 18 1 





TARDBP c.G859A;p.G287S missense Pathogenic 3 0 
TARDBP c.G1043T;p.G348V missense Pathogenic 1 0 
TARDBP c.T1122G;p.Y374X stop-gain Uncertain significance 1 0 
TBK1 c.1427delA;p.E476fs frameshift Loss-of-function 1 0 
TBK1 c.2114_2126del;p.A705fs frameshift Loss-of-function 1 0 
TBK1 c.C452T;p.S151F missense Likely Pathogenic 1 0 
TBK1 c.C829G;p.L277V missense Likely Pathogenic 1 0 
TBK1 c.A1135G;p.I379V missense Uncertain significance 0 1 
TBK1 c.C1508T;p.T503I missense Uncertain significance 1 0 
TBK1 c.C1330T;p.R444X stop-gain Loss-of-function 1 0 
 * pair of brothers 
 






In total, 31 MND cases and two controls carried at least one loss-of-function or pathogenic 
variant across the MND gene panel (Fisher's p=1.761×10−7) (Table 16).  Taken together with 
prior findings that 44 of the 431 independent cases contain a pathogenic intronic 
hexanucleotide repeat expansion in C9orf72, 74 independent cases (17%) carried at least one 
pathogenic or loss-of-function variant. This represented 26/42 (62%) of cases with a family 













Likely benign Total^ 
Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls 
SOD1 0 0 22* 1 1 0 0 0 0 0 23* 1 
TARDBP 0 0 4 0 0 0 1 0 0 0 5 0 
OPTN 0 0 1 1 2 1 1 0 0 0 4 2 
TBK1 3 0 0 0 2 0 1 1 0 0 6 1 
NEK1 3 0 0 0 10 8 6 4 2 4 21 16 
 








Figure 14 Proportion of cases with a pathogenic or loss-of-function variant in genes on the MND gene panel or in C9orf72. (A): cases with a family history; (B): 





Variants in SOD1, OPTN, and TARDBP 
 
After C9orf72, the largest genetic contributor to cases in our study was SOD1, with 
pathogenic or likely pathogenic variants observed in 22/431 independent MND cases (5%) 
and 1/389 controls (0.3%) (Table 15, Table 16).  The p.I114T Scottish founder mutation was 
observed in 18 cases (4%) and one control (0.3%).  Of all cases, 29% of familial and 2% of 
sporadic cases carried a pathogenic variant in SOD1. 
Pathogenic variants in TARDBP were observed in 4/431 (1%) cases and no controls.  This is in 
addition to a stop-gain variant of uncertain significance, observed in one case.  For OPTN, at 
least one pathogenic or likely pathogenic variant was observed in 3/431 (1%) cases and 1/389 
controls (0.3%). The single pathogenic variant in OPTN, p.Q314L, was observed in one case 
and one control.  There is no functional evidence to support the association of this variant 
with MND and, although in previous studies, in silico evidence has suggested a pathogenic 
role for the variant in MND[348], the occurrence of the variant in one case and one control 
in our data suggests that the variant either has variable penetrance or is not pathogenic for 




Variants in TBK1 
 
Several previous studies have reported dominant variants in TBK1 in cases of MND, FTD, and 
MND-FTD, accounting for approximately 1% of all cases[85,87,159,248,349–355].  In our 
study, we observed six cases and one control with a rare stop-gain, splice site frameshift, or 
missense variant in TBK1 (Fisher's p=0.080).  When compared with the ExAC reference data 
set, this result is not significant (Fisher's p=0.238).  When looking only at loss-of-function 
variants, 3 cases and no controls contained a loss-of-function variant 
in TBK1 (Fisher's p=0.145).  When compared with the ExAC reference data set, where the 
frequency of loss-of-function variants was 0.03%, this represents a statistically significant 






Variants in NEK1 
 
Loss-of-function variants in NEK1 have been associated with MND in two recent studies of 
both familial and sporadic MND cases[88,89], following an earlier study of mostly sporadic 
cases that highlighted NEK1 as a candidate gene[159].  These three studies estimate that 
loss-of-function variants in NEK1 contribute to approximately 1% of cases.  In this study, we 
observe three cases and no controls with a variant predicted to result in loss-of-function 
of NEK1 (Fisher's p=0.145) (Table 15, Table 16).  When compared with the ExAC reference 
data set, where the frequency of loss-of-function variants was 0.3%, our result remains 
nonsignificant (Fisher's p=0.143).  Regarding missense variants in NEK1, we observe 16 cases 






There are several reports of MND cases that carry MND-associated variants in more than one 
gene[92,94–97,356].  We observed five cases and one control carrying two different rare 
stop-gain, frameshift, splice site, or missense variants either across the MND gene panel or 
in C9orf72  (Table 17).  Two cases, MND-0040 and MND-0434, and no controls carry two 
variants that are predicted to be either pathogenic or loss-of-function; these will be referred 
to as digenic cases. Both digenic cases have an age of onset within two standard deviations 
of the mean and a typical disease duration.  However, as discussed, the pathogenicity of the 
variant p.Q314L in OPTN in MND-0040 is unclear. 
Of the remaining cases with two rare variants in MND-associated genes, case MND-0119 
carries one pathogenic variant and one variant of uncertain significance (VUS) and has a 
typical age of onset and disease duration.  Case MND-0158, who carries one pathogenic and 
one likely pathogenic variant, had a young age of onset (26 years, >2.5 standard deviations 
from the mean) and long disease duration (142 months, above 90th percentile).  MND-0211 





but disease duration at the lower end of the spectrum (16 months, equal to the 10th 
percentile).  Interestingly, three of the five cases (60%) carrying two rare stop-gain, splice 
site, frameshift, or missense variants in MND genes (including C9orf72 expansions) had a 
bulbar site of onset, which is higher than the 29% observed across all MND cases in the 
cohort. 
 
CONTROL-0325, who was aged 56–60 at the time of collection, carries two missense variants 
in OPTN; one considered pathogenic; and one likely pathogenic.  The pathogenicity of variant 
p.Q314L, as discussed, is unclear.  The data available do not allow confirmation of whether 
the two OPTN variants are found in cis or in trans and, therefore, if both allelic copies 
of OPTN carry a variant.  It is also unclear whether both variants are expected to contribute 
to MND pathogenesis; if so, they would be expected to be associated with variable 
penetrance.  As no follow-up information is available for controls, there is a small chance the 
control developed MND after sample donation, although this is unlikely given the lifetime 































MND-0040 Case 46 23 Bulbar No OPTN 
c.A941T; 
p.Q314L 

































MND-0119 Case 64 44 Bulbar No TARDBP 
c.G859A; 
p.G287S 








Control N/A N/A N/A N/A OPTN 
c.A941T; 
p.Q314L 














Genotype-phenotype association testing was used to determine the relationship between 
carrying a variant in a specific gene and five phenotypic markers (Table 18).  MND cases 
carrying the SOD1 p.I114T founder variant were also analysed independently of 
other SOD1 variants in view of the high incidence of this specific variant in the Scottish 
population.  Only unrelated cases were included in the analysis (n=431). 
Univariate analyses comparing cases with a pathogenic or loss-of-function variant 
(including C9orf72expansions) to cases without such a variant found associations between 
carrying a pathogenic or loss-of-function variant and a family history of MND 
(Fisher's p<5×10−7), a younger age of onset (t-test p=0.018), and female sex (Fisher's p=0.028) 
(Table 18).  A logistic regression model evaluating the possible independent associations of 
these variables with variant status explained 21% of the variance between cases with and 
without a pathogenic or loss-of-function variant (Nagelkerke R2).  Independent associations 
were found for positive family history (p<5×10−7, OR 10.88, 95% CI 5.38–22.01), decreasing 
age of onset by decade (p=0.018, OR 0.77, 95% CI 0.62–0.96), and female sex (p=0.028, OR 
1.88, 95% CI 1.07–3.30) (Table 19). 
A high proportion of cases carrying a pathogenic SOD1 variant had spinal-onset disease (95%) 
compared with the frequency of spinal-onset in all other case (Fisher's p=0.012).  Carrying a 
pathogenic SOD1 variant was also associated with having a family history of MND, compared 
to all other cases (Fisher's p<5×10−7) (Table 18).  When examining SOD1 p.I114T carriers in 
isolation, these two factors remained significant (site of onset Fisher's p=0.031, family history 
Fisher's p=9×10−6) (Table 18). Twenty-seven percent of the variance 
between SOD1 pathogenic variant carriers and all other cases was explained by the model 
(Nagelkerke R2).  Spinal onset disease (p=0.044, OR 8.25, 95% CI 1.06–64.49) and family 
history of MND (p<5×10−7, OR 16.21, 95% CI 6.21–42.33) were independently associated with 
carrying a SOD1 pathogenic variant.  After initial modelling for the SOD1 p.I114T variant 
(using sex, site of onset, and family history), sex and site of onset did not achieve significance 
at the p=0.1 threshold and were removed.  On revised modelling, family history remained 






Univariate analysis showed carrying a C9orf72 expansion was associated with having a family 
history of MND (Fisher's p=1×10−5) (Table 18).  Site of onset did not reach statistical 
significance (p<0.05), but met the criteria required for inclusion in the logistic regression 
model (Fisher's p=0.082).  The logistic regression model explained 12% of the variance 
between carriers of C9orf72 expansions and those without (Nagelkerke R2).  Bulbar onset 
disease (p=0.021, OR 2.23, 95% CI 1.13–4.42) and family history (p =1×10−6, OR 6.86, 95% CI 
3.19–14.77) were significantly and independently associated with carrying 
















































































































































































































































Variant type Predictor 
 








1.88 (1.07-3.30)  
(n=74) Age of Onset (decade) 0.018 0.77 (0.62-0.96) 




















8.25 (1.06-64.49)  










   
 
Table 19 Logistic regression modelling of genotype-phenotype tests of association 
 
 
The influence of carrying a pathogenic or loss-of-function variant in one of the MND genes 
on survival was visualized using a Kaplan-Meier plot (Figure 15). Cases were grouped by 
genotype.  Survival was plotted for all cases, including the 15% of cases for whom duration 
of disease was calculated from onset to date of last contact/study truncation.  No significant 


















Genetic epidemiology of MND in Scotland 
 
This study provides a description of the genetic pathology of MND in Scotland using a six-
gene panel.  We have identified 31 independent cases carrying a pathogenic or loss-of-
function variant across our MND gene panel.  The identification of pathogenic variants in two 
controls (0.5%) is comparable to previous studies and is explained by the variable penetrance 
observed with variants in genes associated with MND[94,144]. 
 
The historical Scottish MND population were comparable with other European MND 
populations on demographic and disease characteristics[357–359].  A positive family history 
in 10% of Scottish MND cases was comparable recent population estimates (16% in the Irish 
population and 9% in a US population of European ancestry[67,68].  Our data show that, 
after C9orf72, variants in SOD1 contribute to the largest proportion of MND cases (5%) in the 
Scottish population, which is in the upper range compared with other populations of 
European ancestry[102,360].  This reflects the high frequency of the p.I114T variant, which 
had previously been identified as a founder mutation with variable penetrance in the Scottish 
population[144,214,219,336].  Although this variant is less frequent than was observed 
previously in a smaller cohort[219], it is still found in 4% of cases when assessed across our 
larger cohort and is found in 24% of those cases in which a pathogenic variant was identified. 
In comparison, pathogenic variants in TARDBP contribute to <1% of cases, comparable to 
previous estimates in populations of European ancestry[102], and pathogenic variants 
in OPTN are extremely rare, which is similar to a previous study of the UK population[361]. 
Our data support a growing literature associating loss-of-function variants in TBK1 with MND. 
Several previous studies have associated dominant coding variants in TBK1 with MND.  The 
first study reported a significant excess of variants in TBK1, excluding those predicted to be 
benign, in mostly sporadic cases compared to controls[159].  However, the biggest excess 
was observed for loss-of-function variants.  This was supported by a second study, which 
found a significant excess of loss-of-function variants in TBK1, but only in familial cases[85].  
Several other studies, looking at MND, frontotemporal dementia (FTD) and MND-FTD cases 





of-function[248,349–351,353–355,362].  In our study, although the number of loss-of-
function variants identified in TBK1 was not statistically significant when compared with our 
389 controls, a significant difference was observed when compared with the larger ExAC 
reference data set and the percentage of cases carrying a loss-of-function variant in TBK1 was 
comparable to previous studies (0.7% vs. <1% in previous studies[85,159]).  Therefore, our 
data support the association of loss-of-function variants in TBK1 with MND. 
 
Similarly, the frequency of NEK1 loss-of-function variants in our cases (0.7%) is comparable 
to previous studies (1%)[88,89,159]; however, the observation of three loss-of-function 
variants in NEK1 in our cases was not significantly different to that of our 389 controls or the 
ExAC reference data set.  Although the result does not provide formal statistical significance 
for the association of loss-of-function variants in NEK1 with MND, as the frequency is 
comparable to other studies, our result is supportive of these previous findings.  We observed 
the same number of missense variants in NEK1 in both cases and controls, with little 
difference in the assigned pathogenicity classifications.  This is comparable to a recent study 
which showed that, although one specific missense variant, p.R261H (classified as likely 
pathogenic in our study), was associated with MND, collectively, missense variants showed 
very little difference in frequency between sporadic cases and controls[88].  In addition, the 
other variants in NEK1 causally related to the development of MND in previous studies are 
loss-of-function variants.  There may therefore be some specific missense variants that result 
in impaired NEK1 function, but collectively, this appears not to be the case. 
 
We identified two cases each carrying two variants classified as pathogenic or loss-of-
function in different MND genes (digenic cases).  As controls were not screened for 
hexanucleotide repeat expansions in C9orf72, we were biased against identifying digenic 
controls, so it is not clear whether our two digenic cases represent a statistically significant 
excess.  As each digenic case has a different variant combination, it is not possible to obtain 
a detailed assessment of how digenicity influences MND phenotype.  Further investigation 
of a larger number of digenic cases is required to determine whether each variant contributes 
to disease pathogenesis, whether variants have an additive effect and to determine how 








Our genotype-phenotype analysis confirms the expected association that MND cases with a 
family history of MND are more likely to carry a pathogenic or loss-of-function variant than 
cases with no family history.  The results also indicate that a young age of onset of MND is a 
significant independent predictor of carrying a pathogenic variant.  Although this finding 
requires replication, it suggests that, in addition to the presence of a family history, clinicians 
should use a lower threshold for genetic testing in cases developing symptoms of MND 
before the mean age of onset.  The analysis also suggests that female sex is significantly 
associated with carrying a pathogenic or loss-of-function variant.   This most likely reflects 
the equal number of males and females carrying variants pathogenic for MND, within an 
MND case population which overall has a male bias.  This result is also consistent with the 
liability threshold genetic model, which would suggest that, as females have an overall lower 
risk than males of developing MND, they must accumulate a larger burden of risk factors to 
pass the threshold for disease onset[363].  The logistic regression model concerned only 
explains 21% of the difference between cases with a pathogenic or loss-of-function variant 
and those without, suggesting that additional phenotypic markers are acting as confounders. 
Our study confirms that C9orf72 expansion carriers are more likely to present with bulbar 
disease than other MND cases[132,163,364].  However, our model explained only 12% of the 
variance, and substantial phenotypic heterogeneity among C9orf72 carriers, particularly in 
terms of cognitive symptoms, is widely recognized[75].  Cognitive profile may be an 
important parameter to explore further in characterizing this cohort of cases.  SOD1 variant 
carriers in our cohort were relatively homogeneous in terms of site of onset, with a bias 
toward spinal onset MND.  This mirrors clinical accounts of lower limb onset disease as a 
common presentation of SOD1 MND[365].  A high proportion of p.I114T carriers also had 
spinal onset disease, despite failing to achieve statistical significance on logistic regression 
modelling.  However, heterogeneity in p.I114T carriers for age of onset (range 42–84 years) 
and duration of disease from onset (11–172 months) was notable and suggests any biological 









Patients were recruited for this study between 1989 and 2014.  Although demographics are 
comparable with other population cohorts, it is likely that this cohort is enriched for patients 
who are more interested in genetic research (for example, those with a family history of 
disease).  Some patients were previously recruited for SOD1 studies in Scotland[214,336].  
Analysis of an incident cohort of new, unselected patients might give a more accurate 
estimate of the true genetic epidemiology in Scotland.  This will be explored in Chapter 6.   
 
Our methods for interpretation of variant pathogenicity are outlined – these are based on 
arbitrary rules guided by available evidence from research and genetics communities.  
However, there is clearly a need for standardisation of methods.  The recent American 
College of Medical Genetics guidelines[366] sought to address this; however, they may 
require additional consideration for complex disorders such as MND, where there is a 
preponderance for sporadic cases and considerable variability in the penetrance of 
pathogenic variants.  The lack of segregation data and large number of singleton variants 
meant that using in silico predictors of variant pathogenicity and conservation were most 
appropriate for assessing variant pathogenicity in this particular study, although it is clear 
that standardisation of the methods used to assign pathogenicity for potential MND-
associated variants is required.  This will also be explored in Chapter 6. 
 
One limitation of the combined use of the Fluidigm Access Array and Illumina MiSeq is the 
number of false positives we observed.  The large number in SOD1 exon 1 is most likely due 
to the high GC content of this exon (Timothy J Aitman, unpublished data).  Exclusion of this 
exon could have reduced the overall variant detection rate for SOD1, as many pathogenic 
missense variants have been reported in this exon[346].  After excluding this exon, 6% of the 
remaining variants also failed to validate. This could be due to the high number of cycles in 
the two rounds of PCR (35 and 15 cycles respectively) required to generate the sequencing 
library.  Therefore, it is essential to use Sanger sequencing to validate variants identified 
through this protocol, as is typically applied following high-throughput sequencing. 
 
Survival analysis between MND cases carrying pathogenic or loss-of-function variants in 





include sample size and lack of data relating to interventions that influence survival (e.g., 






In summary, we identified a pathogenic or loss-of-function variant in an MND gene in 17% of 
our cohort of MND cases from the Scottish population.  Our data give supporting evidence 
for the association of loss-of-function variants in TBK1 and NEK1 with MND.  Genotype-
phenotype association testing has highlighted that MND cases with a family history or with a 
young age of onset are significantly more likely to carry a genetic variant pathogenic for MND 
and suggests that cases presenting with a young age of onset should be referred for genetic 
testing, in addition to cases with a family history. 
 
Study of an existing historical cohort of pwMND (Chapter 5) has provided us with pilot data 
from which I can generate hypotheses to test using an incident cohort of newly diagnosed 
patients.  New hypotheses include the following and will be addressed in Chapters 6 and 7: 
 
i) The incident cohort will have a similar or lower proportion of patients with 
familial MND (as the historical cohort may have been enriched for patients with 
a family history). 
ii) The proportion of patients genotyped with an extended gene panel with a 
mutation will be higher than those genotyped with a limited six-gene panel 
(greater than 17%).  TBK1 and NEK1 mutations will be found in the incident 
population.   
iii) A systematic variant classification system will provide greater certainty regarding 
the pathogenicity of MND-associated variants. 
iv) Having a gene mutation will be associated with a family history of MND and 
younger age of onset.  We expect that the association with female sex may not 
be stable in future models of genotype-phenotype correlation.   
v) Having a C9orf72 expansion will be associated with bulbar-onset disease; 





C9orf72 expansions and cognitive impairment.  Having a SOD1 mutation may be 











6. GENOTYPING 2015-2017 
 





Work leading up to this part of the project suggests that genetics appears to be an important 
factor in MND, with the potential for genetic testing to elucidate genotype-phenotype 
associations and inform prognosis.  Seventeen percent of Scottish pwMND (both familial and 
apparently sporadic cases) had a potential genetic cause of their disease using a limited gene 
panel only (Chapter 5)[243].  In 2014, a neurodegenerative gene panel comprising 11 genes 
was incorporated into clinical practice in Scotland; this was available for clinical testing of 
pwMND and at risk relatives (details described in Chapter 1.3).  However, with the emergence 
of new discoveries regarding genetic associations in MND as a consequence of advances in 
next generation sequencing techniques and large-scale population analyses (Chapter 1.1), 
this has quickly become outdated and may not capture the breadth of potential causative 
genes in an MND population.   
 
As outlined in Chapter 1.2, pwMND are becoming increasingly aware of, and interested in, 
pursuing genetic testing.  For individuals who proceed with genetic testing, interpretation of 
variant implications brings significant challenges.  The majority of MND genetics variants are 
autosomal dominantly inherited but there is evidence for recessive disease in carriers of 
OPTN, SPG11, FUS and SOD1 mutations[169].  Mutations in the UBQLN2 gene are X-linked 
but can affect males and females[138].  Variant penetrance is variable and often age-
dependent; study of an extended pedigree of individuals with the SOD1 p.I114T variant 
calculated penetrance of 50% by age 60 and 88% by age 80[144].  Indeed, this can result in 
inherited MND skipping generations[100].  Even having a C9orf72 repeat expansion does not 
guarantee manifestation of MND[100] and quoted inheritance is about 50%[103].  Quality of 
evidence may be limited or restricted to certain geographical locations[123,350].  The 
possibility of oligogenic MND also has significant implications for genetic testing, requiring 






Classification of variant pathogenicity is a problematic domain for many genetic diseases but 
becomes particularly difficult within the scope of a rare disease with multiple genetic links 
such as MND[367].  Typical classification systems include variants that are Pathogenic, Likely 
Pathogenic, Benign, Likely Benign and Variants of Uncertain Significance (VUS)[366].  VUS are 
inevitable and bring their own diagnostic difficulties.  For diseases in which invasive 
interventions are currently available, such as breast cancer, a VUS result presents a 
management dilemma[368].  For example, 11% of individuals undertaking BRCA1 and BRCA2 
gene testing for breast or ovarian cancer were carriers of a VUS[369].  Ten percent of the 
women in this cohort subsequently opted to undergo prophylactic mastectomies, 21% 
bilateral salpingo-oopherectomies.  The extrapolated implications for MND are clear when 
we consider the imminent advent of genetic stratified therapies, which have the potential to 
involve prolonged inpatient and intravenous treatments[173,176,370].  On a more 
immediate level, however, there is the concern of burdening patients and their relatives with 
the anxiety of an uncertain future risk[169].  For many pwMND who have impaired cognition, 
FTD, or other neuropsychiatric comorbidities the possibility of discovering a VUS requires 
additional consideration.   
 
Barriers to firm classification have been acknowledged, including the relative paucity of 
functional studies and large pedigrees for assessment of co-segregation[371].  In spite of this, 
as mentioned in Chapter 5.4, there remains no consensus classification system for 
assessment of MND variant causality[372].  Many population-based genotype studies have 
reported expected pathogenicity of novel variants by considering the following criteria: i) 
presence of variant in control populations, ii) presence of variant in public databases such as 
the ExAC database of genetic variants[352], 1000 Genomes[344], ESP6500[373] or ALS Online 
Database[335], and iii) assessment of variant using a varying number of in silico functional 
predictions[374–377].  More arbitrary methods have included publication of the variant in 
more than one study[378] and publication consensus combined with minor allele frequency 
(MAF)[372].  Latterly, the American College of Medical Genetics (ACMG) guidelines have 
been adopted[243,366,379].  The ACMG workgroup devised standards and guidelines for the 
interpretation of variants in disease.  The utility of these recommendations for MND is yet to 






The cumulative evidence indicates a growing need for improved resources for genetic testing 
and risk assessment, and consequent better communication with patients.  It is the duty of 
the multidisciplinary team of MND specialists, geneticists and counsellors to address these 
requirements, in parallel to, and perhaps as a priority over, ongoing discovery.  The 
importance of these efforts to clinicians and patients will only become clearer with emerging 
genetic stratification of pwMND and treatments.    
 
Chapter 5 outlined the genetic epidemiology in Scotland using six key genes only.  However, 
the burden of MND-associated rare genes in this population is unknown.  This information is 
required to inform clinical and diagnostic testing and to outline priorities for future disease 
modelling studies.  Crucially for pwMND, we need to be aware of the proportion of gene 
carriers in Scotland for which there might be genetically-targeted treatments in the near 
future.  Accessibility to research is a key barrier to population-based genetic studies.  
However, with the revival of the Scottish MND Register through CARE-MND, prospective, 






i) To develop a new and updated neurodegenerative disease gene panel for 
testing pwMND in a research and clinical capacity. 
ii) To review existing methods for variant classification in MND genomes and to 
outline a framework for disease and gene-specific classification. 
iii) To describe the genetic epidemiology of the Scottish MND population in 2015-









Gene Panel Selection 
 
 
A review was undertaken to update the existing 11-gene neurodegenerative disease gene 
panel.  In addition to a review of the literature (Chapter 1.1), existing UK-based MND-related 
gene panels and resources were examined.  Resources included: FTD and/or ALS and 
dementia disorders gene panels from the Institute of Neurology in London the King’s College 
London[380],  the ALS with or without FTD gene panel from the Sheffield Diagnostic Genetics 
Service[381], the ALS panel from the National Centre for Biotechnology Information (NCBI) 
Gene Testing Registry[382], the list of major genes from the King’s College London ALS Online 
Database[72,335] and genes related to ALS and FTD according to the OMIM database[383].  
The final panel consisted of 49-MND associated genes for research study.  Figure 16 
illustrates the components of both the original clinical gene panel and the extended research 











DNA was acquired for this national genotypic study through the Scottish Regenerative 
Neurology Tissue Bank.  For the majority of samples, DNA was acquired by the author by 
travelling to patients in all 14 health boards in Scotland, meeting them at home, in clinic or 
during inpatient hospital/hospice stays.  DNA collection was supported by an MND Research 
Nurse and, latterly, by the MND Nurse Consultant and local clinical nurse/allied health 
specialists.  We provided training for local specialists in DNA acquisition and consent and by 
the end of the study period, DNA acquisition was maintained sustainably at a local level.  
Third sector parties, in particular MND Scotland, publicised this research through their 
website and magazines to generate interest.  I also delivered talks and interactive question-
and-answer sessions at charity-led support group meetings for patients and carers 
throughout Scotland.   
 
The consent process involved a period of discussion regarding the benefits and implications 
of research genetic testing, before the patient was invited to provide written consent and 
donate a DNA sample (See Appendix 5 for DNA Bank information sheet and consent form).  
During these discussions, it was emphasised that patients would not receive results from 
genetic testing from these research samples.  This is a stipulation of the ethical approvals for 
the Scottish Regenerative Neurology Tissue Bank for the following reasons: i) discoveries in 
MND genetics are emerging and dynamic and the implications of genetic mutations as yet 
unclear; ii) genetically-targeted treatments are not yet available for MND and the benefits of 
relaying this information to patients is as yet unclear; iii) genetic services for MND in Scotland 
are not get equipped to provide counselling for routine testing of pwMND – this may require 
provisions for extended family counselling, preimplantation genetic diagnosis counselling 
and review appointments to reassess variants of uncertain significance (VUS).   
 
DNA was acquired from all consenting patients for: i) testing against the neurodegenerative 
disease panel and ii) storage for potential future studies.  All data recorded for the DNA 
database was anonymised using a non-identifiable patient code. DNA was stored in the 
Scottish Regenerative Neurology Tissue Bank, which also has approval from the Scotland A 





Neurone Disease DNA Bank” and the “Cognitive Disorders Clinic – Diagnosis, Audit, Research 
and Treatment (CDC-DART) DNA Bank.  
 
   
Genotyping 
 
Samples were genotyping using QiaSeq Amplicon Sequencing.  The following methods were 
employed and sequencing was carried out by Dr Morad Ansari in the South East Scotland 
Genetics Service, Western General Hospital, Edinburgh: 
 
Sequence analysis of a panel of 48 genes causally associated with neurodegeneration was 
carried out using a custom-designed QIAseq assay for library construction as per 
manufacturer’s instructions (QIAGEN).  In brief, 80ng of DNA was fragmented followed by 
adaptor ligation. Target enrichment was carried out by single primer extension, followed by 
sample indexing and amplification.  Equal volumes of libraries were combined, and quantified 
using a Quantus™ Fluorometer as per manufacturer’s instructions.  Paired-end sequencing of 
the resulting DNA library (at a concentration of 10pM) was performed using an Illumina 
MiSeq instrument.  Alignment and variant calling was performed using the QIAGEN CLC 
Genomics Workbench as per in-house standard operating procedure.  Sequence read 
coverage was assessed against a browser extensible data (BED) file containing the genomic 
regions of interest.   
 
Coding regions of the genes were covered with -15 bp and +10 bp at exon-intron boundaries 
with the exception of hnRNPA1 and hnRNPA2 (where sequencing was limited to specific 
known hotspots: hnRNPA1 gene (NM_031157_exon_8_10_chr12_54677596 and 
NM_031157_exon_9_10_chr12_54678042), hnRNPA2 gene 
(NM_031243_exon_2_10_chr7_26232871)).  Further, MAPT was given wider boundaries to 
account for known intronic variants (NM_001123066_exon_1_10_chr17_44039687, 
exon_2_44049225, exon_3_44051751, exon_4_44055741, exon_5_44060544, 
exon_6_44064406, exon_7_44067244, exon_8_44068826, exon_9_44071290, 
exon_10_44073765, exon_11_10_chr17_44087676, exon_12_44091609, 






All samples were also screened for C9orf72 hexanucleotide expansions using repeat-prime 
PCR methods published by Cleary et al[215].  Expansions >30 repeats were considered 
pathogenic.    
 
 
Variant Classification – Framework Development  
 
There is no consensus classification system for assessment of causality of MND-associated 
genetic variants.  American College of Medical Genetics (ACMG) Guidelines have been 
employed but their use has not been validated in MND[366].  I therefore aimed to validate 
the ACMG criteria for MND-associated variants and to assess the potential benefits and 
limitations of adopting this classification system.  The following work outlines methods and 
results of the development of a framework of recommendations for clinicians assessing novel 
and established variants in MND-associated genes.  This summary aims to aid clinicians in 
difficult discussions with patients about genetic testing in MND.   
 
This part of my PhD was undertaken in collaboration with clinicians and academics at 
Columbia University, New York.  During my PhD, I undertook a training period at the Institute 
for Genomic Medicine, Columbia University as the Inaugural International Rowling Fellow for 
ALS/MND Genomics.  The fellowship was under the supervision of Dr David Goldstein, 
Director of the Institute for Genomic Medicine and Professor of Genetics and Development, 
and Dr Matthew Harms, assistant professor of neurology in the Division of Neuromuscular 





Based on clinical consensus, 10 genes were considered securely causative for MND: ALS2, 
CHCHD10, FUS, OPTN, PFN1, SOD1, TARDBP, UBQLN2, VAPB and VCP.  Newly associated 
genes TBK1, CCNF, NEK1 and ANXA11 were also considered for exploratory post-hoc analysis.  
The C9orf72 mutation was excluded as it is an intronic repeat expansion.  For each of the 10 





following three public databases in March 2016: Human Gene Mutation Database 
(HGMD)[346], National Center for Biotechnology Information (NCBI) ClinVar database[384] 
and the King’s College London ALS Online Database (ALSoD)[72,335].  To ensure assembly 
compatibility, ClinVar variants were converted from GRCh38 to GRCh19 using the University 
of California, Santa Cruz (UCSC) Genome Bioinformatics Liftover Tool[385].  Datasets were 
merged using Galaxy Project tools[386].  Prediction data were assigned to each single 
nucleotide variant (SNV) using the SeattleSeq Annotation online tool[387] for PolyPhen, 
Grantham, GERP and CADD scores, Mutation Assessor[388] for Functional Impact (FI) and FI 
score, and PROVEAN (v1.1.3)[389] for SIFT and PROVEAN scores.  Splice site impact was 
assessed using MaxEntScan and dbscSNV obtained from ANNOVAR[343,390] (Figure 17).   
 
 
Figure 17 Variant sourcing methods 
 
 
Variant Classification Methods 
 
Each variant was systematically reviewed using the ACMG 28-point guidelines; criteria were 
combined to give a level of evidence (Pathogenic, Likely Pathogenic, Benign, Likely Benign, 





(using HGMD PubMed ID and a subsequent literature search to ensure all publications 
captured).  Details of methods for ACMG classification can be found in Appendix 6.  A team 
of three clinician-scientist variant classifiers (the author being the primary rater) adopted a 
modified Delphi method[391,392], to develop a consensus approach to variant classification 









Genes associated with MND after initial study design (TBK1, NEK1, CCNF, ANXA11) were also 
evaluated.  Variants were sourced as described above.  No variants for NEK1 and ANXA11 
were reported in the ALSoD or HGMD databases, leaving only case-reports with minimal 
evidence in ClinVar.  They were therefore excluded from further analyses.  Variant lists for 
the original 10 genes were also updated by sourcing newly reported variants in ALSoD and 






Our methods generated many VUSs and so further analysis looked at whether the variant 
was trending towards pathogenic or benign despite not achieving requirements for ACMG 
classification.  VUS with pathogenic potential were referred to as VUS-P variants; variants 
that trended towards being benign VUS-B.  For a variant to be classified as a VUS-P, >1 criteria 
suggesting pathogenicity needed to be met, with the absence of any criteria suggesting that 
the variant was benign.  The reverse was true for VUS-B variants.  Variants meeting both 
pathogenic and benign criteria remained VUSs.     
 
The ACMG methods use in silico prediction algorithms in classification of pathogenicity.  We 
assessed each SNV variant using three methods: i) multiple prediction algorithms and a 
‘leave-one-out’ approach, ii) meta-LR and iii) meta-SVM.  Meta-LR and Meta-SVM are 
ensemble-based prediction approaches which integrate multiple scoring methods using 
logistic regression (LR) and support vector machine (SVM) models[393].  We aimed to test if 
we could simply our testing approach to use these predictions only, as a surrogate for 





Rater classification data were collected using an online Google Form 
(https://goo.gl/forms/5RvB8B0HNVMH18It1).  Data were formatted and analysed using R 
version 3.4.3.  Krippendorff’s alpha (k-alpha) statistic (R package “irr”) was used to assess 
formally inter-rater reliability; k-alpha score ranges from 0 (no concordance) to 1 (complete 
concordance) with good agreement considered ≥0.80[394].  In view of the small n-numbers 





Table 20 summarises the number of variants sourced for each gene.  Consensus on variant 
classification was initially assessed using 20 OPTN gene variants.  Concordance between all 
three raters was achieved for 50% of the variants, with an error rate of 7.0% of all criteria 





(95% CI 0.63, 0.71).  Lowest k-alpha statistics resulted from the assessment of loss of function 
variants (mean k-alpha 0.56) and informed the next round of the Delphi procedures.  Key 
disagreements concerned: interpretation of functional studies and degrees of cosegregation; 
having no pre-agreed cut-offs for allele frequencies of Pathogenic and Benign variants; and 
interpretation of multiple prediction and splice site algorithms.  Consequently, we adopted 
rules for assessment of PS3, PP1, PP3 and BP4 (see Appendix 6); these rules reflect recognised 
classification difficulties[393,395,396].   
 
On second round of the Delphi process, concordance rose to 63%, with an error rate of 6.7% 
and a mean k-alpha of 0.77 (95% CI 0.72, 0.82).  Areas of concern included definition of a 
variant “hotspot” (PM1), and how best to determine if a gene which has a low rate of benign 
missense variants (PP2).  This led to the refinement of these classification rules (Appendix 6).  
On third round, the concordance was 84%, with an error rate of 3.0% and a mean k-alpha of 
0.91 (95% CI 0.87, 0.95).  In a recent review of use of the ACMG criteria among nine 
laboratories, average intra-laboratory k-alpha was 0.91[397].  As our third-round k-alpha was 
≥0.80 and compatible with clinical sequencing laboratory agreements, the Delphi procedure 





Gene ALS2 CCNF CHCHD10 FUS OPTN PFN1 SOD1 TARDBP TBK1 UBQLN2 VAPB VCP 
Number of variants  60 10 18 76 45 8 190 57 96 26 6 25 
% of all MND-
associated variants 
identified  
10 2 3 12 7 1 31 9 16 4 1 4 
 





All remaining variants were reviewed by an individual rater and assigned an ACMG 
classification.  Results are presented in Figure 19.  Only 19% of all variants met criteria for 
Pathogenic/Likely Pathogenic.  Seventy eight percent of all variants were VUS.  These VUS 
were further examined for direction of pathogenicity, to identify VUS-P and VUS-B (Figure 











Figure 20 Direction of 'trend' of variant 
 
 
We plotted frequency of use of individual ACMG criteria by gene (Figure 21).  The top four 
classification criteria (used >100 times) were i) PM2 (absence from ExAC reference database), 
ii) PP2 (novel missense variant), iii) PP3 (computational evidence of pathogenicity) and iv) 
PM1 (variant located in a mutational hotspot).  In contrast PS1 (amino acid change seen in a 
previously reported pathogenic variant with a different nucleotide change), BS2 (variant 
observed in a healthy individual in a fully penetrant disease), BS3 (functional studies showing 
no effect of protein function) and BP3 (in-frame indel in a repetitive region with known 
function) were not used for any of our MND-associated variants.  The plots (Figure 21) were 














Figure 21 ACMG classification criteria use by gene; green genes = loss of function genes; red genes = 







Finally, our prediction algorithm assessment methods were analysed.  PP3 and BP4 
classifications were compared against meta-LR and meta-SVM values for each SNV.  Fisher’s 
exact tests showed strong association between meta-methods and our methods for 
assessing PP3 and BP4: meta-LR compared more favourably than meta-SVM (meta-LR 
p=0.0004 (PP3) and p=<0.00001 (BP4); meta-SVM p=0.017 (PP3), and p<0.00001 (BP4). 
 
 
Review of Methods 
 
Our results present a comprehensive and systematic review of the ACMG classification 
system for MND-associated variants.  Using multiple raters and stages of ‘learning’ using a 
modified Delphi approach, we identified key challenges in assessment.  One particular area 
was assessment of cosegregation (PP1).  Interpretation of inheritability of variants is fraught 
with subjectivity.  Recommendations in original ACMG recommendations are unclear[366].  
However, a follow-up report suggested methods for calculating probability of inheritance of 
a variant occurring due to chance, which acts as a surrogate for likelihood of 
cosegregation[396].  The authors suggested cut-offs for level of evidence (supporting, 
moderate and strong) using a simplified Bayes Factor method.  We found these calculations 
of probability easy to apply to our process and removed subjectivity.  Difficult pedigrees were 
discussed between raters to ensure accurate calculation.   
 
Another problematic area was interpretation of in silico prediction algorithms (PP3, BP4).  We 
included nine algorithms (including splice site algorithms).  There are no consensus cut-offs 
for these predictions.  We use a combination of suggested cut-offs[393] and clinical 
experience to generate relatively strict thresholds aiming to capture true pathogenic and 
benign variants  for the purposes of clinical practice.  Assessment of seven algorithms for 
SNVs is time-intensive and might be a barrier to clinician interpretation.  The meta-LR score, 
however, is easy to interpret (output: damaging or tolerant) and was strongly associated with 
our assessments.    
 
We encountered potential difficulty in interpretation of PM5: Novel missense change at the 
same site as a different pathogenic amino acid missense change.  This criterion can only be 





of all variants at this site.  Our methods made this possible but it is an additional consideration 





We propose that the ACMG system is appropriate for use in MND.  Specific recommendations 










Animals models of disease PS3 
Reliable models include rodent models that recapitulate disease (motor or cognitive symptoms, 
impact on survival, or proven loss of motor neurones pathologically) 
Co-segregation of variant 
with disease 
PP1 Extended and well-documented pedigrees are helpful 
   Methods proposed by Jarvik and Browning[396] correctly identify familial clustering of MND variants  
    
Consider DNA banking in proband and relevant family members to allow future co-segregation 
studies 
Prediction algorithms PP3, BP4 
Meta-LR can be used a simple and easily interpretable surrogate for variant pathogenicity instead of 
using multiple algorithms with subjective cut-offs 
Specificity of disease 
phenotype 
PP4 Relevant for mutations in: 
   VCP - inclusion body myositis, frontotemporal dementia and/or Paget’s disease 
    ALS2 - infantile ascending hereditary spastic paraplegia (IAHSP). 
Reputable source recently 
reports variant as 
pathogenic/benign 
PP5, BP6 
ClinVar reports acceptable but only if sample if from clinical testing independent to literature 
evidence and which reflects recent evidence-base   
 





A potential criticism of this work is that ACMG guidelines are suitable only for Mendelian 
disorders, and are ineffective for diseases with incomplete variant penetrance, such as MND.  
We observed that extensive pedigrees provided strong evidence for cosegregation of 
variants, thereby identifying “familial clustering” typically seen in MND[26].  However, well-
documented pedigrees are relatively rare and are additionally confounded by late onset 
disease, absence of living relatives and, in view of the terminal nature of disease, variable 
uptake of genotyping by extended family members.  Interestingly, only one SOD1 variant 
(p.H80R) met criteria for PS2: De novo variant (both maternity and paternity confirmed) in 
patient with the disease and no family history, suggesting that there is a notable absence of 
trio studies in apparently sporadic MND cases.  Lack of segregation (BS4) could not be applied 
in this disease in view of incomplete penetrance.  In view of these challenges, we propose 
that DNA banking should be explored in all pwMND and relevant family members to facilitate 
future testing should disease emerge in later life[169].   
 
We sourced reliable reviews of animal models of MND (PS3)[395,398,399].  However, many 
models in MND fail to recapitulate key disease markers such as motor symptoms[26].  To 
detect true clinically relevant disease-causing variants, we limited our use of this criterion to 
rodent models which resulted in an MND-spectrum disease phenotype (total use of criterion 
= 29).   
 
Specificity of disease phenotype (PP4) is challenging for a heterogeneous spectrum-disorder 
such as MND.  We only determined this relevant for patients with VCP mutations who had 
typical disease syndrome features (inclusion body myositis, FTD and/or Paget’s disease) and 
for juvenile patients with ALS2 mutations who had features of infantile ascending hereditary 
spastic paraplegia (IAHSP). 
 
Finally, we agreed that classification of a variant by a clinically reputable laboratory that was 
reported in ClinVar was sufficient evidence for PP5/BP6.  Often classification methods are 
not described for ClinVar reports and so there is likely to be great variability in interpretation 
of pathogenicity.  However, this criterion provides supporting evidence only and so ACMG 
methods, appropriately, do not rely heavily on external or prior classification.  Timing of 
report is crucial as some predate recent evidence, particularly for long-recognised genes such 









Gene-Specific Review  
 
The following is summarised in Table 22. 
 
ALS2  
Many MND-associated mutations in this gene result in a premature stop codon in the 
transcript, creating a truncated protein (48% of all reported variants and 100% of 
Pathogenic/Likely Pathogenic variants).  Missense variants can therefore be considered as 
probably benign (BP1).  ALS2 mutations are also highly specific for development of autosomal 
recessive forms of three early-onset neurodegenerative diseases: juvenile ALS (JALS), juvenile 
primary lateral sclerosis (JPLS), and infantile ascending hereditary spastic paraplegia (IAHSP).  
In view of the young-onset of disease, this is the only gene for which BS2 (disease is fully 
penetrant at an early age) can be considered.  Homozygous and compound heterozygous 
variants are more common in this gene than other MND-associated genes.  The ACMG 
criteria do not sufficiently take into consideration homozygous variants and so variants in 
this gene failed to meet pathogenicity in spite of apparently convincing evidence.   
 
CCNF 
CCNF is a gene newly associated with MND: all reported variants are from the same 
study[400].  ACMG evidence was limited and consequently all variants were VUS.  Multiple 
prediction algorithm agreement was met.  Accounting for this, however, only two variants 
trended towards pathogenicity.   
 
CHCHD10 
Many variants in CHCHD10 were VUS (72%) and remained VUS on further assessment of 
trend.  Explanation of this includes the gene’s recent association with MND and absence of 








Thirty six percent of MND-associated variants in the FUS gene were found at the nuclear 
localization sequence in exon 15 which is considered to be a hotspot[401].  There is strong 
evidence for in vitro modelling of cytoplasmic localization/nuclear exclusion of FUS variants 
and these were considered exceptional evidence for criterion PS3[79,401,402].  
 
OPTN 
OPTN is associated with both MND and primary open angle glaucoma (POAG).  Many 
reported variants in the public databases are in fact associated with POAG, leaving only 12% 
of Pathogenic/Likely Pathogenic variants in MND-associated variants.  The majority of 
reported MND-associated variants are SNVs (65%) but all of the Pathogenic/Likely 
Pathogenic variants are loss-of-function variants, suggesting that this is the true mechanism 
of disease.    
 
PFN1 
In the context of a relatively high Z-score (2.97), all reported variants in PFN1 were SNVs.  
Two variants in particular (p.C71G and p.M114T) met pathogenicity due to recent robust 
mouse models and strong cosegregation data[403,404].     
 
SOD1 
Since its association with ALS in 1993[65,66], 190 variants have been reported.  Variants are 
found throughout the gene and so there are no hotspots, although there are multiple 
variants within the same domain eg. Cys6.  Many of the earlier reports of rare variants are 
limited by lack of sufficient information regarding pedigrees, paternity or maternity.  Further, 
some novel mutations have not been replicated.  Several SOD1 animals models exist but are 
difficult to interpret – for example the p.A4V variant causes early and rapid onset disease in 
humans but late onset disease in mice[399].  In spite of these indeterminate factors, 
prediction algorithms tend to favour pathogenicity: 86% of SNVs, with meta-LR and meta-
SVM values “Damaging” for all.  In light of this conflicting evidence, no SOD1 variants met 
criteria for pathogenicity using ACMG guidelines (11% are Likely Pathogenic).  Eighty eight 








The majority (84%) of MND-associated TARDBP mutations are in exon six, which is considered 
a mutational hotspot[405,406].  TARDBP has a high Z-score (4.33): 88% of reported variants 
are SNVs (including all Pathogenic/Likely Pathogenic variants).  Prediction algorithms are 
problematic in TARDBP – most algorithms trend towards benign, but the gene is highly 
conserved.  Meta predictions are equally difficult to interpret with meta-LR and meta-SVM 
in disagreement in 12% of SNVs.  Our recommendation would therefore be to rely on other 
components of the guideline over in silico modelling.   
 
TBK1 
Many TBK1 variants have been associated with MND and ALS-FTD since 2016 [159].  Thirty 
percent of variants are loss-of-function.  A significant proportion of missense variants (75%) 
trended towards pathogenicity, in spite of not fulfilling full ACMG criteria.  The potential for 
disease-causation of this gene is therefore apparent.   
 
UBQLN2 
Mutations in UBQLN2 are found in patients with dominant X-linked MND, and MND with FTD.  
The PXX domain is considered a hotspot[407].  No UBQLN2 variants met criteria for 
pathogenicity, primarily due to conflicting evidence regarding allele frequency and prediction 
algorithms.  Three variants with strong cosegregation evidence met criteria for likely 
pathogenicity (p.P497H, p.P497S and p.T487I).  Stronger literature evidence is needed to 
classify variants in this gene.     
 
VAPB 
Only six MND-associated variants were identified in VAPB.  It is a small and tolerant gene and 
evidence is limited for classification – individual ACMG criteria were met on only nine 
occasions.  Based on strong segregation and prediction data, the p.P56S variant was Likely 
Pathogenic.  Further sequencing of this gene in MND populations is required to determine 
disease-association.   
 
VCP 
The VCP gene had the highest frequency of Pathogenic/Likely Pathogenic variants (56% of all 





domain[408], a defined syndromic phenotype and well-documented extended pedigrees.  It 
is an intolerant gene, with multiple concordance of prediction algorithm data.  One caution 
in interpretation is that several papers report novel variants, when in fact the variant is a new 
missense change at the same site as a previously reported amino acid change.  Systematic 
use of ACMG guidelines (specifically, PM5) helps to make sense of these variants.   
 










ALS2 PVS1, BS2, BP1 
Pathogenic variants results in a truncated 
protein. 
While variant penetrance can be variable, 
young-onset disease is best characterised. 
Missense variants are probably benign. 
CCNF   
All reported variants are VUS. 
All variants are from the same study – 
replication required. 
CHCHD10   Paucity of evidence and functional studies. 
FUS PS3, PM1 
Evidence for in vitro modelling of cytoplasmic 
localization/nuclear exclusion of FUS variants. 
1/3 of variants are found at the nuclear 
localization sequence in exon 15. 
OPTN PVS1 
Pathogenic variants tend to be loss-of-function 
but caution as many missense variants are 
reported. 
Caution regarding evidence as variants 
associated with alternative phenotypes (POAG). 
PFN1 PS3, PP1, PP2 
Few variants reported but all are missense. 
Good emerging evidence for cosegregation and 
gene function. 
SOD1 PS3, PP3, PP5 
Caution regarding animal models which do not 
recapitulate disease.  
Caution regarding historically reported variants 
with little robust evidence which have not been 
replicated. 
Prediction algorithms favour pathogenicity. 
TARDBP PM1, PP2, PP3 
Hotspot in exon 6. 





Prediction algorithms are conflicting. 
TBK1 PVS1, PM5 
Loss-of-function and missense variants are 
potentially disease-causing. 
UBQLN2 PM1, PP3 
PXX domain is a hotspot. 
Prediction algorithms are conflicting. 
VABP   
Few MND-associated variants in this gene – 
insufficient to make recommendations. 
VCP 
PM1, PM5, PP1, 
PP4 
Mutational hotspots (exons 3-5 and the N-
terminal domain). 
Novel missense variants at the same site as a 
previously reported amino acid change. 
Strong cosegregation evidence. 
Phenotype highly specific. 
 





Variant Classification – Application  
 
 
This framework was applied to classify incident samples collected in Scotland 2015-2017.  To 
streamline methods, VarSeq Golden Helix software was used for variant filtering and 
annotation of variant call filter (VCF) files[409].  Filters were selected based on the learned 
framework and are summarised in Table 23.  Variants were annotated using multiple in silico 
prediction algorithms from the Database for Nonsynonymous SNPs and their Functional 
Predictions (dbNSFP)[410] and included: SIFT, PolyPhen2 HDIV and HVAR, Mutation Taster, 
Mutation Assessor, FATHMM, PROVEAN, GERP and PhastCons.  MetaLR and MetSVM were 
also sourced as a simplified approach to classification.  However, individual algorithms were 
reviewed in addition to ensure that they did not differ significantly from Meta classification.  
For mutations where prediction information was not available (all except SNVs, but 
particularly intronic variants with missing splice site predictions), variants were reviewed 
using the Variant Effect Predictor (VEP) tool[411].  Measures of impact on splice site were 
also extracted from VarSeq and included scores derived from adaptive boost (Ada) and 
random forest (RF) models[412].   
 
Variant interpretation procedures and cut-offs for each ACMG classification point are 
described in Appendix 6.  For this analysis, the more up-to-date population reference 
database gnomAD (Genome Aggregation Database)[413] was used instead of the Exome 
Aggregation Consortium (ExAC)[352].  Probability of loss of function (pLI) scores and Z-scores 
for missense variants for each gene were extracted from gnomAD.   
 
The control population for this study was the Lothian Birth Cohort of 1921 and 1936, 
comprising of 1383 individuals.  As per ACMG guidelines, this is considered an appropriate 
population in view of its being i) a large cohort (>1000 individuals) and ii) race-matched[366]. 
 
As outlined in the ACMG-guided framework, the proportion of MND-associated variants 
being classified as Pathogenic or Likely Pathogenic are low.  However, some variants are 
“hot” VUS, or VUS with pathogenic potential (VUS-P).  Instead of making assumptions about 
their pathogenicity (ie. assuming they are Likely Pathogenic or rejecting them as unqualified 





Filter VarSeq Source Inclusions Exclusions 





Sequence ontology RefSeq Genes 105 
Intermin v1, NCBI 
3’ UTR variant 
5’ UTR premature start codon gain variant 
5’ UTR variant 






Splice acceptor variant 
Splice donor variant 
Splice region variant 
Stop gained variant 
Synonymous variants 
Effect RefSeq Genes 105 
Intermin v1, NCBI 






























Functional Predictions dsNSFP Functional 
Prediction Voting 
0/6 Predicted as Tolerated 
1/6 Predicted as Tolerated 
2/6 Predicted as Tolerated 
2/6 Predicted as Damaging 
3/6 Predicted as Damaging 
4/6 Predicted as Damaging 
5/6 Predicted as Damaging 
6/6 Predicted as Damaging 
Missing 
3/6 Predicted as Tolerated 
4/6 Predicted as Tolerated 
5/6 Predicted as Tolerated 
6/6 Predicted as Tolerated 
0/6 Predicted as Damaging 









Ada Score dbscSNV Splice Altering 





RF Score dbscSNV Splice Altering 













The number of samples donated by incident pwMND 2015-2017 was 339; this is 
representative of 54.8% of the incident MND cohort 2015-17.  All samples underwent gene 






Sequencing for the C9orf72 expansion identified 29/339 (8.6%) individuals with >30 
expansions.  Of these, one patient had an unusual intermediate-length expansion (70 
repeats).  One further patient had 28 expansions which was initially considered abnormal but 
of indeterminate significance.  Examples of unexpanded repeats (two and eight repeats, a 
typical combination in the Scottish population[215]) and a typical repeat prime expansion 








Figure 22 Top figure: a normal, unexpanded C9orf72 trace with 2 GGGGCC repeats on 1 allele, 8 on the other; Bottom Figure: an abnormal C9orf72 trace with 2 





Panel Sequencing: MND-Associated Genes  
 
On gene panel sequencing, depth of coverage (≥ 20X) was, on average, 98% across the 
regions of interest.  After VarSeq variant filtering and ACMG-based classification, 503 variants 
were identified in 339 samples; the median number of variants per sample was one (range 
0-5).  Post-filtering variants were identified in 277/339 (81.7%) of samples; 103 individuals 
(103/339, 30.4%) had a Pathogenic or Likely Pathogenic variant or VUS.   Fifty three (53/339, 
15.6%) individuals had a Pathogenic or Likely Pathogenic variant or a potentially pathogenic 
VUS (VUS-P); of these 5/339 (1.5%) had two variants of interest.  The variants identified in 
this cohort are presented in Table 24.  However, some of these variants were in genes which 
typically have a recessive inheritance in disease-causing states (ALS2, BSCL2, HTRA1 and 
SPG11); the significance of these variants is therefore significantly diminished when they are 
present on one allele only.  Excluding these variants, 47/339 (13.9%) of individuals had a 
potential genetic explanation for their disease.  The phenotypes of variant carriers will be 






After the C9orf72 expansion, the most common variant in this MND cohort was the SOD1 
p.I114T variant (n=9), previously described as a founder mutation in the Scottish population 
(Chapter 5).  Three further SOD1 variants were identified.  One of these had previously been 
seen in our pilot study (p.A146D; Chapter 5) – using the newer classification system this is a 
VUS-P but we previously described it as Likely Pathogenic.  In view of its recurrence in the 
Scottish MND population and the absence of the variant in control populations (as well as its 
being absent in gnomAD) the pathogenic potential of this variant is strong.  Two further SOD1 
missense variants were found in cases: the p.Q23H variant was first described in a Japanese 
patients with ALS[414], the p.G73C described in a patient with an usual ALS phenotype 
mimicking a myopathy[415].  These variants have not previously been identified in the 







FUS, OPTN, TBK1 and VCP 
 
Variants were also identified in FUS, OPTN and TBK1, genes that were previously included in 
our pilot gene panel (Chapter 5).  FUS variants included a missense variant and a loss of 
function frameshift variant, both on exon 14.  The missense variant (p.R485W) has been 
reported in a sporadic ALS patient, has a low MAF in gnomAD and most prediction algorithms 
suggest pathogenicity (including meta-SVM and meta-LR)[96].  The loss of function variant 
(p.Y479Mfs*50) is a novel variant in a genomic location near to previously described MND-
associated frameshift mutations.  Although the impact on protein function is unclear due to 
the absence of functional studies, this variant is potentially causative of disease.   
 
Only one OPTN variant was seen in this cohort (p.V572M).  This variant was absent from 
controls, had a very low MAF in gnomAD and 8/9 in silico predictions suggested pathogenicity 
(meta-SVM and meta-LR damaging).  However, this is a missense variant in a gene in which 
truncating variants primarily cause disease (Chapter 6.2) and so its pathogenic potential is 
attenuated.  Similarly, there was one variant found in the TBK1 gene (p.Q565P) in exon 15.  
This novel variant has a low MAF in gnomAD and is in a conserved region but remains a 
missense variant in a gene for which the mechanism of disease is unclear, but thought to be 
loss of function[416].   
 
Another confirmed MND-associated gene is VCP and, indeed, a pathogenic variant in this 
gene was identified in one case (p.R155C).  This missense mutation, located at a mutation 
hotspot on exon 5, has been previously described and is reported in clinical cases on 
Clinvar[384,417,418].  All in silico predictions suggest pathogenicity.   
 
 
NEK1, CCNF and ANXA11 
 
Variants were identified in genes newly associated with MND: NEK1, CCNF and 
ANXA11[89,400,419].  Two individuals were found to have loss of function variants in exon 
21 of NEK1, which were classified as Pathogenic (p.E634Kfs*11).  As far as we can determine 
from patient histories, they were unrelated.  Four further NEK1 variants were identified, 





variants were absent in controls, had low MAF or were absent from gnomAD and were 
located in conserved regions with multiple prediction algorithms supportive of pathogenicity.  
The final NEK1 variant was a loss of function splice donor variant associated with exon 10, 
which was present in two cases and zero controls.  The variant had a very low MAF in gnomAD 
and splice impact scores indicated a significant impact on protein function (Ada score 0.999, 
RF score 0.94).   
 
Both variants identified in the CCNF gene were novel missense variants (p.G161R and 
p.D51N), absent in controls and gnomAD and in conserved regions.  Information regarding 
this gene’s role in MND is emerging, but a recent study suggests that a single missense 
mutation can adversely affect the autophagy degradation pathway which is implicated in 
MND pathogenesis[420].   
 
One mutation in the ANXA11 gene (p.L337H) was considered to have pathogenic potential 
due to a low MAF, some supportive in silico prediction evidence, and being located in a 
conserved region.  Patients with ANXA11 mutations have been found to have A11-positive 
protein aggregation in spinal cord motor neurones[419].  Similar missense variants have been 
more recently described in Chinese populations[421,422].  Seven other variants were 
identified in this gene but these were considered VUS or VUS-B.  These comprised an intronic 
variant found in four samples (c.1029+13C>G), an intronic variant in one sample and one 
control (c.561+14C>T), a splice site variant with low impact found in two samples (c.745-
7C>G), a missense variant with a MAF of 0.002 found in 14 controls (p.T244M), another 
missense variant in four samples and 31 controls (p.P8L; European non-Finnish MAF 0.009), 
a missense variant in two samples and 12 controls (p.E369L; European non-Finnish MAF 
0.006) and a missense variant with a MAF of 0.01 in the South Asian population (p.R452W).  
Overall, there were 16/339 (4.7%) ANXA11 variants in cases and 58 /1383 (4.2%) controls.   
 
 
Rare MND-syndrome Genes: DAO, DCTN1, ERBB4, MATR3, NEFH, PRPH, SETX, SQSTM1 
 
A variant in the DAO gene (p.R115W) was absent from controls and all prediction algorithms 
suggested pathogenicity.  This variant has not previously been described in relation to MND.  





which has been more extensively studied in disease models[423].  A variant at the same site 
but with a different amino acid change - p.R199Q - was seen in our MND cohort and was 
classified as a likely benign VUS because of its relative high population MAF (0.003 in South 
Asian and 0.002 in Ashkenazi Jewish populations).  Prediction indicators were conflicting and 
the variant was present in two control samples.  This variant has been described in a previous 
cohort of patients of European origin[378].   
 
Three mutations were found in the DCTN1 gene.  This gene is associated with Perry 
syndrome, characterised by parkinsonism, depression and central respiratory 
hypoventilation, but is also rarely associated with neurodegenerative diseases such as MND, 
FTD and Parkinson’s disease[424].  The previously reported variants do not segregate with 
disease; due to this and its rarity in MND populations, DCTN1 remains a tentative gene with 
pathogenic potential only.   
 
One variant in the ERBB4 gene was identified in cases (p.I892V), with a low MAF and 
supportive in silico predictions.  Z score for this gene is 3.25.  Few MND-associated ERBB4 
mutations have been described but recent immunohistochemistry studies of spinal cord 
pathology samples from MND patients suggest that activity of ErbB4 correlates with TDP-43 
mislocalisation[425,426].   
 
The MATR3 gene interacts with TDP-43; heterozygous missense variants are thought to be a 
rare cause of both familial and apparently sporadic pwMND of European origin[427–429].  Z 
score of this gene is 2.73.  One individual carried a missense variant (p.P776S) of pathogenic 
potential – although this has not been reported in MND previously, it was absent from 
controls and had a low MAF.   
 
A novel frameshift loss of function variant was identified in the NEFH gene (p.F15Vfs*83); 
this variant was absent from gnomAD and controls.  However, the NEFH gene is tolerant of 
mutations and several VUS are reported[378].  NEFH mutations associated with increased 
MND risk are typically deletions affecting the tail end of the protein[430].   
 
In contrast, the PRPH gene encodes an intermediate filament protein involved in peripheral 





last exon.  While in silico predictions were supportive, the impact of this variant on protein 
function remains uncertain.   
 
Dominant missense variants which segregate in families with MND have been described in 
the SETX gene and cause juvenile onset ALS[431]; however, this gene is normally associated 
with spinal cerebellar ataxia with axonal neuropathy.  A novel missense variant in this cohort 
(p.L1111W) is potentially pathogenic.  However, an observed intronic variant (c.6843-5delT) 
is most certainly a single nucleotide polymorphisms (SNPs) (Table 26).  Recent literature 
suggests that many previously described SETX are indeed SNPs/benign[162].   
 
SQSTM1 missense variants are described in familial and apparently sporadic MND[432], as 
well as in FTD without MND.  The first variant observed (p.P146L) is rare and all predictive 
algorithms suggested pathogenicity.  The second (p.R267H) was seen in two of our MND 
cases and zero controls and has been described in an MND case previously as a VUS[433].   
 
 
FTD Genes: GRN, MAPT 
 
Mutations in two genes which are normally associated with FTD were seen in our panel 
screen.  In spite of the phenotypic overlap, GRN mutations are almost exclusively seen in 
people with FTD, rather than MND[434].  Missense variants, as seen in this cohort, can be 
pathogenic.  Our two observed variants are close in location, near to other previously 
described variants in gnomAD (p.C475R; p.R478C) and have low MAFs and supportive 
prediction algorithms.  Similarly, missense mutations in MAPT are found in people with FTD.  
The variant in this cohort (p.G107V) has previously been described in a patient with FTD[435].   
 
 
Other Dementia Genes: APP, CSF1R, NOTCH3, PSEN1, PSEN2 
 
Several genes normally associated with other cognitive phenotypic profiles were identified 
in this cohort.  One missense variant in the amyloid precursor protein (APP) gene was seen 
(p.D219V) – this variant was found on exon 5 in a conserved region and all bar one prediction 





APP gene is causative in early-onset Alzheimer’s disease (<65 years onset).  A missense 
mutation was also observed in the CSF1R gene – missense variants in this gene are normally 
associated with hereditary diffuse leukoencephalopathy with spheroids.  Presentations of 
gene carriers can include phenotypes similar to FTD[436].  Several variants were seen in 
NOTCH3, the gene associated with cerebral autosomal dominant arteriopathy with 
subcortical infarcts and leukoencephalopathy (CADASIL).  These were all missense variants 
at various locations throughout the gene that were absent from controls and had low 
population MAFs.  The Z-score for NOTCH3 is 3.53 implying a low rate of benign missense 
mutations.   
 
PSEN1 and PSEN2 mutations are seen in patients with early-onset Alzheimer’s disease.  The 
two variants observed in this cohort (PSEN1 p.S132A; PSEN2 p.T128I) have low MAFs and 
supportive in silico markers.  The latter was present in controls (n=1) but it is not possible to 





Two samples had C9orf72 expansions plus another variant of interest.  A further five samples 
harboured two VUS-Ps.  These are described in Table 25.  Overall, digenic cases comprised 












Gene Genomic Position Variant DNA Change  Variant Protein 
Change 







Pathogenic and Likely Pathogenic Variants 
SOD1 21:33039672T>C c.341T>C p.Ile114Thr Missense Pathogenic 9 0 
NEK1 4:170428210TC>- c.1900_1901delGA p.Glu634Lysfs*11 LoF frameshift Pathogenic 2 0 
VCP 9:35065361G>A c.463C>T p.Arg155Cys Missense Pathogenic 1 0 
 
Variants of Uncertain Significance with Pathogenic Potential (VUS-P) 
ANXA11 10:81923309A>T c.1010T>A p.Leu337His Missense VUS-P 1 0 
APP 21:27423322T>A c.656A>T p.Asp219Val Missense VUS-P 1 0 
CCNF 16:2487264G>A c.481G>A p.Gly161Arg Missense VUS-P 1 0 
CCNF 16:2481265G>A c.151G>A p.Asp51Asn Missense VUS-P 1 0 
CSF1R 5:149441322C>T c.1717G>A p.Glu573Lys Missense VUS-P 1 0 
DAO 12:109283278C>T c.343C>T p.Arg115Trp Missense VUS-P 1 0 
DCTN1 2:74605284C>T c.122G>A p.Arg41Gln Missense VUS-P 1 0 
DCTN1 2:74595092A>C c.2015+5G>A  Intronic splice site VUS-P 1 0 
DCTN1 2:74593111C>T c.2795G>A p.Arg932His Missense VUS-P 1 0 
ERBB4 2:212293178T>C c.2674A>G p.Ile892Val Missense VUS-P 1 0 
FUS 16:31202343C>T c.1453C>T p.Arg485Trp Missense VUS-P 1 0 
FUS 16:31202325T>- c.1435delT p.Tyr479Metfs*50 LoF frameshift VUS-P 1 0 
GRN 17:42429718T>C c.1423T>C p.Cys475Arg Missense VUS-P 1 0 
GRN 17:42429727C>T c.1432C>T p.Arg478Cys Missense VUS-P 1 0 
MAPT 17:44055753G>T c.320G>T p.Gly107Val Missense VUS-P 1 0 
MATR3 5:138661306C>T c.2326C>T p.Pro776Ser Missense VUS-P 1 0 
NEFH 22:29876289->C c.41dupC p.Phe15Valfs*83 LoF frameshift VUS-P 1 0 
NEK1 4:170510659A>C c.403T>G p.Phe135Val Missense VUS-P 1 0 
NEK1 4:170398485G>A c.2140C>T p.Arg714Cys Missense VUS-P 1 0 
NEK1 4:170501992C>G c.868+1G>C  LoF splice donor  VUS-P 2 0 
NEK1 4:170511956A>G c.317T>C p.Leu106Ser Missense VUS-P 1 0 
NOTCH3 19:15272414G>A c.6025C>T p.Arg2009Trp Missense VUS-P 1 0 
NOTCH3 19:15298776C>T c.1522G>A p.Val508Met Missense VUS-P 1 0 





NOTCH3 19:15302615C>G c.743G>C p.Gly248Ala Missense VUS-P 1 3 
OPTN 10:13178846G>A c.1714G>A p.Val572Met Missense VUS-P 1 0 
PRPH 12:49691776C>T c.1303C>T p.Arg435Trp Missense  VUS-P 1 0 
PSEN1 14:73640329T>G c.394T>G p.Ser132Ala Missense VUS-P 1 0 
PSEN1 1:227073265C>T c.383C>T p.Thr128Ile Missense VUS-P 1 1 
SETX 9:135203653A>C c.3332T>G p.Leu1111Trp Missense VUS-P 1 0 
SOD1 21:33040863C>A c.437C>A p.Ala146Asp Missense VUS-P 1 0 
SOD1 21:33032151G>C c.69G>C p.Gln23His Missense VUS-P 1 0 
SOD1 21:33038809G>T c.217G>T p.Gly73Cys Missense VUS-P 1 0 
SQSTM1 5:179250993C>T c.437C>T p.Pro146Leu Missense VUS-P 1 0 
SQSTM1 5:179260077G>A c.800G>A p.Arg267His Missense VUS-P 2 0 
TBK1 12:64889529A>C c.1694A>C p.Gln565Pro Missense VUS-P 1 0 
 
Heterozygous Variants in Recessive Genes 
ALS2 2:202614512C>T c.1738G>A p.Val580Ile Missense VUS-P 1 0 
ALS2 2:202574703T>C c.4181A>G p.Tyr1394Cys Missense VUS-P 1 0 
ALS2 2:202626404C>T c.313G>A p.Ala105Thr Missense VUS-P 1 0 
BSCL2 11:62458810A>C c.755T>G p.Phe252Cys Missense VUS-P 1 0 
HTRA1 10:124266357C>T c.928C>T p.Arg310Cys Missense VUS-P 1 0 
SPG11 15:44949428AT/- c.733_734delAT p.Met245Valfs*2 LoF frameshift Pathogenic 1 0 
SPG11 15:44855329A>G c.7322T>C p.Leu2441Pro Missense VUS-P 1 0 
SPG11 15:44925771A>G c.1667T>C p.Phe556Ser Missense VUS-P 1 0 
SPG11 15:44876486C>T c.5392G>A p.Glu1798Lys Missense VUS-P 1 0 
 





Gene 1 Variant Protein 
Change 1 
Gene 2   Variant Protein 
Change 2 
C9orf72 Expansion SOD1 p.Ile114Thr 
C9orf72 Expansion ALS2 p.Val580Ile 
SOD1 p.Ala146Asp SETX p.Leu1111Trp 
MATR3 p.Pro776Ser SQSTM1 p.Arg267His 
NEK1 p.Arg714Cys DCTN1 p.Arg932His 
FUS p.Tyr479Metfs*50 SPG11 p.Glu1798Lys 
ALS2 p.Ala105Thr NOTCH3 p.Pro1317Arg 
 






Single Nucleotide Polymorphisms 
 
Four variants were found in multiple MND case samples and were thought to be single 






Gene Genomic Position Variant DNA Change  Variant Protein 
Change 







Single Nucleotide Polymorphisms in MND population 
SETX 9:135152544A>- c.6843-5delT  Intronic splice site Benign 143 317 
FIG4 6:110053825T>- c.447-3delT  Intronic splice site Benign 46 0 
NEK1 4:170506525C>T c.782G>A p.Arg261His Missense VUS-B 9 7 
DCTN1 2:74590116C>T c.3529+5G>A  Intronic splice site Likely benign 9 31 
 






Genetic Epidemiology 2015-17 
 
 
In summary, 22.4% of individuals carried a potentially pathogenic variant.  This percentage 
includes people with C9orf72 expansions, Pathogenic or VUS-P variants as assessed using the 
extended gene panel and those individuals carrying more than one pathogenic or potentially 
pathogenic expansion or variant (digenic carriers).  This is illustrated in Figure 23.  The 
proportion of Pathogenic and VUS-P by gene name is illustrated in Figure 24.  Although 
different variant classification methods were adopted in this analysis compared with our 
published analysis in Chapter 5, the proportion of potentially pathogenic mutations in the 
incident cohort is significantly more (1989-2014 74/431 cases; 2015-2017 82/339 cases; Z-
test of proportions p=0.021 (95% CI 0.13-0.0097).  As described in Chapter 5, the genetic 
epidemiology of MND is often described by sub-categorising “familial” (n=28) and 
“apparently sporadic” (n=305) cohorts and this is illustrated in Figure 25.  In those considered 
to have familial MND, 67.9% had a potentially pathogenic mutation, whereas 20.3% of 













































We have shown the utility of the ACMG guidelines for 12 MND-associated genes and have 
outlined a framework for focused interpretation of variants.  To our knowledge, this is the 
first systematic analysis of classification of MND genomic data.  We applied the framework 
to an incident cohort of MND patients diagnosed in 2015-2017.  Just over half of the incident 
MND population (54.8%) contributed to this genetic study.  Reasons for not achieving higher 
ascertainment might include patient choice, limited discussions regarding research options 
prior to the CARE-MND initiative (prior to August 2015) and rapidly deteriorating disease, 
meaning that patients were less willing to devote time and efforts to research.  Currently, 
genetic research in Scotland does not offer feedback of results and does not lead to 
treatment modification and so benefits to patients at an individual level are limited.  Allowing 
for these factors, we consider our recruitment figures to be appropriate and reflective of the 
generosity of the Scottish MND patient community. 
 
The proportion of patients found to have a potentially pathogenic mutation/expansion was 
22%; this is significantly higher than the proportion obtained using a limited gene panel 
(17%), as hypothesised.  However, the figure obtained in the incident cohort includes VUS-P 
mutations.  By using a systematic ACMG-guided framework, we aimed to outline a 
framework that might lead to improved increased accuracy of variant classification.  
However, ACMG-guided methods are in fact more stringent and result in a more conservative 
estimation of pathogenicity.  One benefit of this is that, on reviewing previously described 
MND-associated variants, we can identify with certainty those that are Pathogenic and those 
that are Benign.  This can be used as a reference for future MND genetic work.  We tried to 
provide some clarity by qualifying VUS by describing VUS-P and VUS-B.  Ideally, future MND 
genetic studies should make reference to VUS-P to inform the research community better.  
This would help in the identification of ACMG criteria that might help to change this 
classification to Likely Pathogenic (eg. Focus research towards trio or segregation studies or 
animal/cell models of disease).  Clinician understanding of VUS-P is also essential, as this may 
better facilitate informed discussions regarding potentially inheritability of disease (even in 






The disease-specific and gene-specific use of the ACMG guidelines parallels that adopted by 
the colorectal cancer community.  The International Society for Gastrointestinal Hereditary 
Tumours (InSiGHT) adopted similar methods to ours (modified Delphi) but on a wider and 
more collaborative scale[392].  Research and clinical groups were invited to submit 
unpublished variants, which were recognised by microattribution.  This resulted in an open-
access annotated database for active and ongoing variant interpretation.  Although 32% of 
variants remained unclassifiable at the end of the study, public availability of this information 
has facilitated ongoing reassessment.  This group also found that missense VUSs were 
problematic.  However, by putting an increased weight on highly accurate in silico predictors, 
they could potentially reclassify ~50% of VUSs into Likely Pathogenic variants[392].  Elements 
of this platform are echoed in the ALS Online Database; however, in the current ALS website, 
nuances of variant pathogenicity are not outlined[71,72].  While generic variant databases 
(such as ClinVar) do exist, the InSiGHT database highlights the benefits of a disease specific 
platform to which experts can continuously contribute emerging knowledge.       
 
The most important regions of interest in this incident Scottish cohort are: the C9orf72 
expansion, the SOD1 gene and the NEK1 gene.  The proportion of C9orf72 expansion carriers 
(8.6%) was lower than in our pilot study (Chapter 5; 10.2%).  However, the 2015-17 cohort is 
more unselected and population-based than our historical cohort, and so this figure is likely 
more representative.  We identified two individuals with intermediate-length repeat 
expansions (70 repeats and 28 repeats).  Previous studies regarding intermediate repeat-
length expansions are conflicting.  A case of an 89 year old man without MND or FTD who 
had a 70-repeat expansion has been described[437].  However, more recently, a meta-
analysis suggested that intermediate expansions 24-30 repeats in length are associated with 
MND (p=0.02)[438].  In view of this new evidence, our intermediate length samples were 
both considered pathogenic giving a final population frequency of 30/339 (8.9%).  The 
C9orf72 expansion is the commonest cause of familial MND affecting 32.1% of cases, but also 
6.2% of apparently sporadic cases.  In a large study of people of European, USA and Australian 
origin, higher figures were identified (expansions in 39.3% familial and 7.0% of apparently 
sporadic pwMND)[439] but in a more recent study of Italian patients, only 6.9% of patients 






SOD1 mutations were identified in 3.5% of cases overall, but 17.9% of familial cases.  This is 
lower than expected relative to findings in our pilot study 1989-2014 cohort (5% of all cases, 
29% of familial cases) though figures are still higher than global population estimates (12% 
familial and 1-2% sporadic cases[102,440]).  As before, the p.I114T variant is the biggest 
contributor to this observation though clearly other SOD1 variants are found in the Scottish 
population.  The relative ethnic homogeneity of the Scottish MND population (Chapters 3, 4, 
7) is likely a factor in the persistence of this variant.  This has significant implications as 
antisense oligonucleotide (ASO) gene-modifying treatments for SOD1 carriers appear 
promising[441].  Functional studies of the p.I114T variant may be particularly beneficial to 
the Scottish population – if this variant results in toxic-gain-of-function pathophysiologically, 
then ASOs may be a potential treatment for 3-4% of the Scottish MND population.  The p.A4V 
mutation – the most common SOD1 mutation in the USA – does not appear to be present in 
the Scottish population[65,113,114].    
 
As hypothesised in Chapter 5, our population also appeared to be enriched for potentially 
pathogenic NEK1 mutations, present in seven cases (2.1%) versus zero controls.  None of 
these individuals had a family history of MND.  Four of these were loss-of-function mutations 
(two frameshift, two splice donor); loss of function is considered mechanistic for this 
gene[90].  Loss of function variants were present in 1.2% of cases, which parallels previous 
population studies (rates 0.7-1.2%)[88,90].  Of all the potentially pathogenic NEK1 variants 
identified, none were seen in the pilot study cohort (Chapter 5).  Two mutations were 
identified in both cohorts (p.R261H and p.A341T).  The former is described in other studies: 
first identified in an isolated community in the Netherlands, it is now thought to be a risk 
variant for ALS using meta-analysed data (p=4.8 x10-5, OR 2.4 in cases versus controls)[88].  
In the 1989-2014 cohort, five cases and two controls had this variant and it was considered 
Likely Pathogenic.  In the 2015-17 cohort, it was present in nine cases and seven controls.  
Other clinical samples reported to ClinVar suggest that the variant may be a VUS, Likely 
Benign or Benign.  In view of this information, we would now classify this variant as a VUS-B, 
present in a total of 1.8% of cases and 0.7% of controls (1989-2017).  The p.A341T variant 
was previously identified in the Scottish population as a VUS, present in four cases and three 
controls (Chapter 5).  In the latest cohort, we identified the variant in four cases and 14 
controls.  In silico predictions suggest that it is benign and it has a MAF in the European non-






Similarly, the previously described DAO p.R199Q variant is a VUS-B based on our analysis but 
previously thought to be potentially pathogenic[378].   
 
Potentially pathogenic rare variants were identified in several MND-associated and 
dementia-associated genes.  Phenotypic characterisation of these cases will be important to 
identify any correlations with specific MND phenotypes (eg. Those seen in those with VCP 
and DCTN1 mutations) and with cognitive profiles.  This will be discussed in Chapter 7.  No 
loss of function variants were identified in the TBK1 gene, contrary to results in Chapter 5.  
Recent studies suggest that TBK1 variant population frequencies range from 0.5%-9%[416]     
No pathogenic variants were identified in genes related to hereditary spastic paraparesis 
(HSP).  By extension, we can be confident that the CARE-MND platform reliability identifies 
patients with a diagnosis of MND, as opposed to MND mimics.   
 
Finally, 2.1% of the population were oligogenic gene carriers, although some of the variants 
were in recessive genes.  This is similar to other population rates[94,442].  None of these had 
TBK1 variants, in spite of recent research suggesting that TBK1 variants are found in 
oligogenic cases[416].  Again, phenotypic correlation of these cases is key.  Interestingly, we 
identified one patient with a C9orf72 expansion and the SOD1 p.I114T variant.  We might 
expect this individual’s disease to manifest at an earlier age with a more aggressive course 
due to the burden of pathogenic variants.   
 
As with other published MND genotype studies, our findings highlight that there is an 
increasing number of MND-associated genes but that variants in these genes are rare.  The 
novelty of these genes means that insufficient information is available to allow conclusive 
classification of pathogenicity.  As we have seen, further study necessitates reclassification 
of variants.  As clinical diagnostic testing of MND genomes because more established in 
Scotland, provisions will need to be made to allow reassessment and revision of an 
individual’s gene status. 
 
Some variants have changed classification between the 1989-2014 and 2015-2017 analysis.  
We therefore recommend that all pwMND undergoing genetic testing should be counselled 





proportion of VUS.  Trends towards pathogenic or benign status, as outlined in our methods, 
may be useful to aid explanations.  Our analyses are up-to-date as of August 2017 but the 
dynamic nature of the field necessitates continuous review of each variant.  The requirement 
to follow-up individuals with VUS and reassess the variant of interest at regular intervals 
should be explained[443].  In view of cognitive impairment in MND, careful assessment of 
capacity and involvement of family members is crucial.  When faced with results of MND 
genotyping, we suggest referring to our disease and gene-specific considerations.  We have 
outlined key areas that are clinically relevant and interpretable, and hope that it can be used 





The ACMG-guided framework adopted for this part of the thesis is more strict than the 
approach taken in the pilot study.  One major limitation of this is that it generates more 
uncertainty, by classifying most variants as VUS.  This makes the translation of our results 
into clinical practice difficult.  The argument for a more stringent and transparent approach 
is: i) that is provides a more realistic estimate of the number of true pathogenic, causative 
gene mutations, ii) it highlights the uncertainty and lack of information within the field and 
identifies areas for future collaborative research and knowledge building; iii) it avoids the 
blanket dismissal of potentially clinically relevant variants.  
 
We also acknowledge that that we have not confirmed variants identified in the incident 
cohort using Sanger sequencing.  While the concordance between next generation 
sequencing (NGS) and Sanger techniques is now excellent, the risk of false positives with NGS 
may be 1.3%[444].  One reason that this was not pursued was that sequencing was 
performed as part of a research study only, with results not being fed back to patients.  In 
Scotland, all patients with MND are encouraged to consider storing a DNA sample in an NHS 
clinical-approved laboratory.  Research participants were reminded of this option at point of 
recruitment to the Scottish Regenerative Neurology Tissue Bank.  Theoretically, if a drug were 
to become available for an MND-associated gene, the patient or their family members could 





intensive compared with NGS techniques and, although this was not possible during the 






In summary, we have tested an updated and comprehensive gene panel on an unselected 
cohort of incident pwMND.  We have shown that the ACMG classification system can be 
applied to MND genomes.  However, certain classification criteria are more relevant than 
others, and so a disease or even gene-specific approach should be adopted to avoid ignoring 
potentially pathogenic VUS.  We have proposed changes to classifications of previously 
described variants, highlighting the importance of continuous reassessment in genes for 
which evidence is emerging.  Our results suggest that, while the C9orf72 expansion is 
important in the Scottish MND population, it should certainly not be the only target for future 
genetically-stratified treatments.  SOD1 p.I114T carriers (3%) and NEK1 loss of function 
variant carriers (1%) make up a small but important subset of patients.  As NEK1 carriers were 
all apparently sporadic cases, future work into functional and pathological correlates is 
certainly merited.  Potentially pathogenic rare variants in MND and dementia-associated 
genes are found in the Scottish population. Further exploration of their phenotypes may 
provide justification for their inclusion in a diagnostic panel.  Digenic cases are found in the 
Scottish population; the SOD1 p.I114T variant and the C9orf72 expansion can co-exist and so 
anyone considered pursuing genotyping to inform patients or families of risk of heritability 
should ensure that both screening for C9of72 expansions and MND panel genes occurs 










7. GENOTYPE-PHENOTYPE CORRELATION AND 
PROGNOSTIC MODELLING 
 






As described, it has been possible to achieve deep clinical phenotyping of an unselected 
population cohort of pwMND at and around diagnosis, and subsequently genotype a subset 
of these individuals using a comprehensive gene panel.  Gene carriers of sufficient number 
can be studied for genotype-phenotype associations.  The benefit of the CARE-MND platform 
is the broad selection of variables which can be studied.  However, in this case, the number 
of variables are high relative to the number of individuals with the outcome of interest.   As 
described in Chapter 5.2, one way to determine association between variables and a binary 
outcome of interest it to perform multiple univariate analyses of all variables against the 
outcome, and then to input near-significantly associated variables into a multivariable model 
such as a logistic regression model.  These methods can be applied but they are generally 
now considered to be undesirable because they do not take into account between-variable 
association[445].  A preferred approach is to undertake multivariable modelling from the 
start.  However, this limits the number of predictors that one can include in the analyses due 
to the ‘one in ten’ rule[195,316].  Machine learning methods, however, can be used to select 
the most appropriate predictors (feature selection), where the number of predictors (p) is 





1. To identify genotype-phenotype associations in mutation carriers. 
2. To test the use of machine learning methods for feature selection of phenotypic 
variables in CARE-MND. 





4. To appreciate the impact of having a genetic mutation in a multivariable survival 









All patients studied in Chapter 6 (n=339) were included for genotype-phenotype analysis.  
The variables considered for prognostic modelling in Chapter 4.4 (Table 12) were revisited 
and some minor modifications were undertaken.  The variable examining El Escorial 
Classification of disease was expanded to include Primary Lateral Sclerosis (PLS), Progressive 
Muscular Atrophy (PMA) and Progressive Bulbar Palsy (PBP), rather than grouping these into 
one variable (“Other”) in case specific genetic mutations were related to these phenotypes.  
Variables previously found to be correlated with others (Time to Neurology Clinic, Time from 
Onset to MND clinic, Number of Comorbidities) were excluded from the outset.  Although 
the ECAS ALS Non-Specific Score was previously removed from the prognostic models due to 
its correlation with the ALS Specific Score, this was reconsidered for genotype-phenotype 
studies in view of their being several genes related to cognitive phenotypes.  In summary, 26 
phenotypic variables were considered for genotype-phenotype analyses. 
 
 
Genotype-Phenotype Correlations Analyses 
 
 
In view of the relatively small sample sizes in this study, gene carriers were summarised based 
on frequency of mutation.  Thereby, the following groups were studied: i) pwMND carrying 
Pathogenic or potentially pathogenic mutations (including C9orf72 expansions and VUS-P); 
ii) pwMND carrying Pathogenic mutations (including C9orf72 expansions), iii) pwMND 
carrying C9orf72 expansions only, iv) pwMND carrying SOD1 mutations only, v) pwMND 
carrying the SOD1 p.I114T variant only, vi) pwMND carrying NEK1 mutations, and vii) pwMND 
who carried more than one mutation (digenic carriers).  Descriptive statistics for phenotypic 





proportion of patients had the outcome of interest, statistical modelling was explored to 
determine if significant phenotypic predictors were associated with the outcome using 
multivariable analyses.   
 
Machine learning methods were incorporated using elastic net regularisation with variable 
selection[446].  The aim was to undertake penalised regression to reduce the variability of 
the regression estimates.  The machine learning algorithm selects the best penalisation 
hyperparameter (lambda (λ)) over a range of alpha (α) hyperparameters (ranging between 
ridge (α=0) and lasso (α=1)) which minimises both variance and bias, and therefore 
overfitting.   
 
The process for this analysis involves pre-processing to remove variables with near-zero 
variance and dummy coding of categorical variables, as described in Chapter 4.2.  A nested 
leave one site out cross-validation (LOSOCV) approach was taken, whereby the model was 
trained on part of the dataset and then tested on unseen data.  The data were split by “Health 
Board”; 15 health board sites were included accounting for the 14 health boards in Scotland 
plus a proportion of patients who moved out of Scotland after receiving initial care in 
Scotland.  By training the data on each combination of 14 sites and testing on the unseen 
site, it is internally-externally validated[447].  This process is repeat 10 times (10-fold cross-
validation) over a 10x10 grid of λ and α hyperparameters to identify the optimal model.  
Single imputation was used to account for missing data using the k-nearest neighbour 
method[191].  The stability and significance of the model is checked and, if satisfactory, the 
features common to all models (the most generalisable and stable features) are extracted.  
These features can then be taken forward for regression modelling.   
 
The selected variables were then tested for independent association with the outcome of 
interest using a binomial logistic regression model.  Comparison was made against the more 
traditional method of inputting near-significant (p≤0.1) variables from univariate analyses 
into a logistic regression model.  For groups (iii)-(vi), where the number of individuals with 
the outcome of interest was small, univariate analyses only were performed using two-tailed 
Fisher's exact tests for categorical data and t-test or Wilcoxon Rank-Sum/Mann Whitney U 
test for parametric and non-parametric continuous data, respectively.  Correction for 






Finally, genotype (group (i)) was included in the Cox regression models described in Chapter 
4.2 to test the hypothesis that having a genetic mutation is an independent predictor of 
survival.   
 
All statistical analyses were undertaken using R statistical programming[240], in particular 





Pathogenic or VUS-P carriers 
 
Individuals carrying a Pathogenic variant, C9orf72 expansions or VUS-P were studied (n=82) 
and compared against those who did not have one of these types of mutations (n=257).  
Descriptive statistics are summarised in Table 28.  Across 29 variables, the median proportion 
of missing data was 1.8% (range 0-44.5).  An elastic net regularised regression with nested 
cross-validation split by health board site (n=15) was undertaken.  These models were 
significant (p=0.0013).  The simplest model within one standard error of the model with the 
‘best’ tuning parameters was selected to avoid over-fitting (Breiman’s one standard error 
rule).  This selected out seven features which were common to all models (listed in order of 
importance): Family History of MND, Family History of Other Neurological Conditions, 
ALSFRS-R Preslope, Classification: Progressive Bulbar Palsy, Feeding Tube Inserted, Sex and 
Time to Diagnosis.  A logistic regression model was undertaken using these seven variables 
(p=8 predictors taking into account all levels of the Classification variable included after 
removing for near-zero variance).  After modelling, variables significantly associated with 
having a genetic mutation were: Family History of MND (p<0.00001), Classification: PBP 
(p=0.018) and Family History of Other Neurological Conditions (p=0.027).  Significantly fewer 
mutation carriers underwent Feeding Tube Insertion compared with non-mutation carriers 
(p=0.017).  The pseudo-R2 for the model was 0.141 (95% CI 0.135-0.147) implying that these 
variables explained 14% of the variance between mutation carriers and non-mutation 
carriers.  The Akaike information criterion (AIC) (an estimate of relative quality of models) 








Figure 26 Logistic Regression Model of Variables Associated with a Pathogenic Variant, C9orf72 





These results can be compared with those obtained using the more traditional method of 
selecting features from univariate analysis, as described in Chapter 5.  Variables with 
univariate p-values ≤ 0.1 (Sex, Classification, Family History of MND, Family History of Other 
Neurological Conditions and Feeding Tube Insertion) were included in a second logistic 
regression model.  After controlling for near-zero variance there were p=6 predictors.   As 





of Other Neurological Conditions (p=0.034) were significantly associated with having a 
pathogenic mutation/VUS-P.  In this model, there was no significant association with Feeding 
Tube Insertion (p=0.067).  The pseudo-R2 was 0.116 (95% CI 0.113-0.119) explaining 12% of 
the variance and the AIC was 345.5 (95% CI 344.4-346.6).  These results are illustrated in 





Figure 27 Logistic Regression Model of Variables Associated with a Pathogenic Variant, C9orf72 
expansion or a VUS-P using univariate statistics for feature selection 
 
 







Patients with convincing Pathogenic/disease-causing mutations were studied separately to 
see if increasing certainty of pathogenicity was associated with different phenotypic markers.  
This group included C9orf72 expansion carriers (n=30), SOD1 p.I114T carriers (n=9), NEK1 
pathogenic carriers (n=2) and the VCP pathogenic mutation carrier (n=1) (total n=41).  The 
same methods were adopted to identify predictors.  These individuals were compared 
against the rest of the cohort (n=297).  However, to limit the number of predictors to fulfil 
the ‘one in ten’ rule, a ‘tolerance’ cut-off was applied to select the simplest model within a 
percentage of the model with the ‘best’ tuning parameters.  The models were significant 
(p=0.004).  The models generated twelve relevant predictors (Family History of MND, ALS 
Specific Score, Family History of Other Neurological Conditions, Sex, Time to Diagnosis, 
History of Head Injury, Ever Smoking, Use of NIV, Exercise Participation, Age of Onset, 
Feeding Tube Insertion and Past Medical History of Malignancy).  When selected for logistic 
regression modelling, there were remained 12 predictors.  Considering there were only 41 
individuals with the outcome of interest, this violated the ‘one in ten’ rule and so the logistic 
regression model could not be used.  Instead, univariate statistics with Bonferroni correction 
only could be tested, revealing that only a Family History of MND was associated with having 
a pathogenic mutation (Table 28).  
 
 
C9orf72 expansion carriers 
 
 
The same methods were again applied to carriers of C9orf72 expansions only (n=30).  These 
individuals were compared against the rest of the cohort (n=309).  The models were 
significant (p<0.0001).  The models generated seven significant features (Use of NIV, Family 
History of MND, ALS Specific Score, History of Blood Transfusion, Time to Diagnosis, Family 
History of Other Neurological Conditions and Site of Onset: Other).  When selected for logistic 
regression modelling, there were eight predictors (taking into account different levels of Site 
of Onset).  Considering there were only 30 individuals with the outcome of interest, this also 
violated the ‘one in ten’ rule.  Univariate statistics with Bonferroni correction revealed that 
a Family History of MND and lower ECAS: ALS Specific Score were associated with having a 





There were two individuals with intermediate-length repeat expansions.  Both individuals 
were diagnosed in their early sixties with upper limb onset disease and had diagnoses of ALS 
with cognitive impairment identified via ECAS measurements (ECAS total score 73 in patient 
with 28 repeats, 79 in patient with 70 repeats).  Neither had a family history of MND nor past 
medical or family history of psychiatric conditions.  The individual with 28 repeats died 2.6 
years after symptom onset whereas the individual with 70 repeats was alive at censorship 




SOD1 carriers, SOD1 I114T carriers 
 
 
Due to the low number of SOD1 variant carriers (n=12), multivariable analysis was not 
possible.  However, univariate analysis showed a significant genotype-phenotype association 
between SOD1 carriers and having a Family History of MND (p=0.0001) (Table 28).  SOD1 
p.I114T carriers were studied separately and, on univariate testing, they were also 
significantly associated with having a Family History of MND (p=0.0003) (Table 28).  Family 
































2 64 Limb 3 Sisters x2, parental 
cousin – disease site and 
onset unknown 
 
3 67 Limb 1 Father – site and onset 
unknown 
Niece – diagnosed 
with MS 
4 57 Limb 2 Father, Sister – limb 
onset 
 
5 48 Limb 1 Stepsister – site and 
onset unknown 
 
6 55 Limb 0 - Parental 
grandfather – 
diagnosed with 
MS in 40s 
7 67 Limb 0 -  
8 68 Limb 0 -  
9 64 Limb 0 -  
   
Table 27 Family histories of SOD1 p.I114T carriers; MS = multiple sclerosis 
 
 
NEK1 carriers, Digenic carriers 
 
 
There were no statistically significant genotype-phenotype associations for NEK1 or digenic 
carriers (Table 28).  The individual with both the C9orf72 expansion and SOD1 p.I114T variant 





as assessed by ECAS.  Interestingly, he had no family history of MND or other neurological 

















































































































































































































































































































































































































































































































































































































































































Age of onset 
(years) 










































































































































































































































































































































































































































































































Key phenotypic characteristics of rare gene carriers are described in Table 29.   
 
FUS, OPTN, TBK1 and VCP 
 
Both patients with FUS mutations had young-onset ALS with short survival (20 months from 
onset, compared with 32 months for the genotyped cohort overall).  Both also had family 
histories of MND, reinforcing the likely pathogenicity of these variants.  Neither underwent 
cognitive assessment, perhaps related to their rapid rate of decline, but cognitive impairment 
was not a documented feature of disease.  As such, both patients met expected phenotypic 
profiles for FUS carriers[79].  The pwMND with a variant in OPTN had a very young onset of 
disease (30 years) with bulbar-onset ALS but no family history.  Patients with OPTN variants 
tend to have more slowly progressive disease and, indeed, this individual survived to point 
of censorship (33 months).  The patient with a TBK1 missense mutation had very rapidly 
progressive ALS (survival 10 months from onset).  In view of this, it was not possible to 
undertake cognitive assessment.  However, during the course of disease, she developed 
anxiety and low mood and was commenced on antidepressant therapy.  She also had a 
premorbid history of depression, perhaps suggesting that this was a prodromal feature or 
disease feature of TBK1 MND.  This individual did not have a family history of MND; indeed, 
all previously described TBK1 variants in Italian cohorts had sporadic disease[416].  A 
hypothesis is that TBK1 variants alone have low disease penetrance; this is supported by 
reported digenic cases involving TBK1[416].   
 
The individual with the Pathogenic VCP mutation had a two-generation family history with 
her mother being diagnosed with limb-onset MND (presumed ALS) and her maternal 
grandmother having had dementia.  There was no documented history of Paget’s disease or 
inclusion body myositis.  This individual actually had relatively slowly progressive ALS, 








New MND Genes: ANXA11 and CCNF 
 
The patients with ANXA11 and CCNF mutations had late age of onset of disease and no family 
history of MND.  While they had typical ALS presentations, it is not possible to draw any 
further conclusions about the pathogenicity of these variants from the phenotypes.   
 
 
Rare MND-syndrome Genes: DAO, DCTN1, ERBB4, MATR3, NEFH, PRPH, SETX, SQSTM1 
 
People with DAO mutations are thought to have shorter survival[86].  However, our patient 
with a potentially pathogenic DAO variant had relatively long survival from onset (52 months) 
compared to the overall median for the cohort (32 months).  Three DCTN1 carriers were all 
males with lower limb-onset ALS.  While DCTN1 mutations in MND are rare, this perhaps 
hints at a link with a more classical ALS phenotype.  No specific characteristics were linked 
with carriers of ERBB4, MATR3, NEFH or PRPH mutations.  The individual with the SETX 
mutation had young onset (age 43 years) familial ALS.  However, this patient also had a SOD1 
variant (p.A146N).  The young age of onset might be related to the compound heterozygosity 
observed in this individual.  Neither patient with SQSTM1 variants had multisystem disease 
suggestive of Paget’s disease or myopathy; however, one individual did have cognitive 
impairment.   
 
 
FTD Genes: GRN, MAPT, PSEN1, PSEN2 
 
When examining individuals carrying variants in FTD-associated genes (GRN, MAPT, PSEN1, 
PSEN2), we see that 3/5 individuals had evidence of some cognitive impairment; the 
remaining two did not have cognitive assessments.  Of these five individuals, one had a family 
history of early-onset dementia, one a family history of MND and two had family histories of 
Parkinson’s disease.  As cognitive impairment is a feature of all these neurodegenerative 
disease, it is possible that the variants are contributing to an inheritable dementia 







Other Dementia Genes: APP, CSF1R, NOTCH3 
 
Genes associated with other dementia processes (APP, CSF1R, NOTCH3) were also variably 
associated with cognitive impairment (2/6; 3/6 not assessed) and family histories of 
dementia (2/6) and Parkinson’s disease (2/6).   
 
 
The median Time to Diagnosis for these rare gene carriers was 16 months (IQR 8-28 months).  











































Ethnicity A1A A1A A1A A1A  
A1A 






















Age of onset 
(years) 
41 85 71 78 
63 







44 16 9 1 
7 




Site of onset Lower limb Lower limb Bulbar Bulbar 
Lower limb 




Classification ALS ALS PBP ALS 
ALS 





















75 27 25 7 
20 




















































































































































































































































8 10 56 7 
16 
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7.4 PROGNOSTIC MODELLING: ADDING GENETIC DATA 
 
 
The final process in the genotype-phenotype study was to assess the contribution of genetics 
to survival, in the context of other phenotypic variables.  The “Pathogenic/VUS-P” group (n= 
82) was considered the most informative genotype split as the most stringent statistical 
methods could be applied to this sample to obtain genotype-phenotype associations.  This 
variable (Pathogenic Variant/VUS-P, Yes or No) was therefore as added to the prognostic 
model outlined in Chapter 4.3 with all missing data imputed (Figure 13 (iii)).  Applying the 
same correlation matrix as previously, the only correlation was ECAS: ALS Non-Specific Score 
with ECAS: ALS Specific Score (0.61) and so the former was excluded.  After excluding 
variables with near-zero variance and correlated variables, there remained 26 predictors.  
One hundred and seventy six individuals had the outcome of interest (death at follow-up).  
While this did not fulfil the ‘one in ten’ rule, there is certainly precedent for relaxing these 
rules in linear regression models[448].  Using all 26 predictors, a Family History of MND 
(p=0.039) and increasing ALSFRS-R Preslope (p=0.0039) predicted death whereas increasing 
Time to Diagnosis (p<0.00001), Classification: Other (p=0.0032) and a history of Ever Smoked 
(p=0.047) predicted survival (Figure 28).  Having a Pathogenic Mutation or VUS-P did not 
influence survival (p=0.12).  Further, Age of Onset (p=0.081) and Heavy Metal or Pesticide 
Exposure (p=0.16) were no longer significant.  The overall R2 for the model was 0.511 (95% 
CI 0.500-0.522) which was lower than the model which did not include genetic data, perhaps 
due to the higher number of predictors.  Hazards ratios and confidence intervals for the 
genotype-phenotype prognostic model are summarised in Table 30, ranked by hazard ratio 







Figure 28 Cox Regression Model predicting survival with Pathogenic Mutation/VUS-P status (all 













Finally, patients with pathogenic mutations only (including C9orf72 expansions; n=41) were 
also studied within the same prognostic model.  Again, 26 predictors were included in the 
model.  Increasing ALSFRS-R Preslope (p=0.0011) predicted death.  Family History of MND 
was no longer significant (p=0.081).  Time to Diagnosis (p<0.00001), Classification: Other 





ALSFRS-R Preslope 1.31 1.09-1.57 
Age of Onset 1.20 0.98-1.48 
Family History of MND 1.19 1.01-1.41 
Heavy Metal or Pesticide 
Exposure 
1.17 0.94-1.45 
Pathogenic Mutation or VUS-P 1.14 0.97-1.35 
Family History of Psychiatric 
Disorders 
1.13 0.96-1.34 
PMH Cardiovascular Disease 1.08 0.90-1.30 
Blood Transfusion 1.06 0.88-1.28 
Family History of Dementia 1.05 0.88-1.26 
Classification: MND-FTD 1.05 0.86-1.28 
Feeding Tube Insertion 1.02 0.84-1.24 
Site of Onset:Other 1.02 0.84-1.24 
Non-Invasive Ventilation 1.01 0.85-1.21 
PMH Psychiatric Disease 1.00 0.85-1.19 
Sex (Male) 0.95 0.79-1.15 
Site of Onset:Limb 0.95 0.79-1.14 
Exercise Participation 0.94 0.78-1.14 
Head Injury 0.94 0.75-1.18 
Riluzole 0.92 0.78-1.09 
Family History of Other 
Neurological Disorders 
0.91 0.76-1.09 
PMH Malignancy 0.87 0.73-1.03 
PMH Autoimmune Disease 0.85 0.71-1.01 
Ever Smoked 0.83 0.68-1.00 
ECAS: ALS Specific Score 0.82 0.63-1.06 
Classification: Other 0.73 0.59-0.90 





Having a Pathogenic Mutation Only did not influence survival (p=0.087).  The overall R2 for 
the model was 0.517 (95% CI 0.509-0.525) which was higher than the model which included 
all potentially pathogenic mutations.  Hazards ratios and confidence intervals for this model 
































Table 31 Hazard ratios of prognostic modelling predictors using genotype-phenotype model 





ALSFRS-R Preslope 1.36 1.13-1.63 
Age of Onset 1.22 0.97-1.52 
Heavy Metal or Pesticide 
Exposure 
1.20 0.95-1.51 
Family History of MND 1.17 0.98-1.40 
Pathogenic Mutation Only 1.16 0.98-1.38 
Family History of Psychiatric 
Disorders 
1.14 0.97-1.35 
PMH Cardiovascular Disease 1.08 0.89-1.29 
Family History of Dementia 1.05 0.87-1.26 
Classification: MND-FTD 1.04 0.85-1.27 
Blood Transfusion 1.03 0.86-1.25 
Non-Invasive Ventilation 1.03 0.86-1.23 
PMH Psychiatric Disease 1.02 0.85-1.22 
Site of Onset:Other 1.01 0.83-1.23 
Feeding Tube Insertion 1.00 0.82-1.21 
Exercise Participation 0.97 0.79-1.18 
Sex (Male) 0.95 0.78-1.15 
Head Injury 0.95 0.75-1.20 
Site of Onset:Limb 0.94 0.77-1.14 
Riluzole 0.92 0.78-1.09 
PMH Malignancy 0.90 0.76-1.06 
Family History of Other 
Neurological Disorders 
0.90 0.75-1.08 
PMH Autoimmune Disease 0.85 0.71-1.01 
Ever Smoked 0.82 0.69-0.98 
ECAS: ALS Specific Score 0.82 0.61-1.10 
Classification: Other 0.73 0.59-0.90 











In this part of the analysis, I have used stringent statistical modelling with machine learning 
elements to identify genotype-phenotype associations.  Machine learning approaches for 
feature selection were similar to univariate methods but the pseudo-R2 and AIC were better.  
Similarity between the two methods suggests model stability and implies that we can make 
conclusions about the Scottish cohort based on the results.      
 
With deeper phenotyping and genotyping, and an evolution in understanding of statistical 
methods, different predictors of having a genetic mutation were identified compared with 
our pilot analysis in Chapter 5, contradicting the hypothesis.  In the latter analysis, Age of 
Onset and Female Sex loses significance.  The male-to-female ratio in the gene carrying 
population remains low, although this did not reach Bonferroni-corrected significance on 
univariate testing (p=0.03).  The differences between cohorts are likely related to more 
stringent statistical methods adopted latterly.  A Family History of MND is strongly associated 
with having a genetic mutation, as predicted.  However, a Family History of Other 
Neurological Conditions is also associated (p=0.027 in the logistic regression model).  As 
described in Table 11, many patients in this category had family histories of Parkinson’s 
Disease (PD) (34.6%) and multiple sclerosis (MS) (19.6%).  There are also family histories of 
these other neurodegenerative diseases in rare gene carriers (Table 29).  This may imply a 
shared genetic pathology.  Indeed previous studies have observed higher incidences of PD in 
apparently sporadic MND and FTD kindreds[164,449,450].   
 
Significantly fewer gene carriers undergo Feeding Tube Insertion, in spite of there being more 
people with PBP in this group.  Factors which might impede gastrostomy placement include 
presence of cognitive impairment and rapidly progressive disease.  More gene carriers than 
non-gene carriers were were cognitively impaired and had poorer survival and ALSFRS-R 
Preslopes, although this did not reach statistical significance.  Individuals with PBP were 
significantly more likely to have a genetic mutation.  As described in Chapter 1, PBP may be 
an artificial subtype of ALS: the majority of patients will progress to develop a more classical 





measure of bulbar-onset disease.  The Site of Onset variable is complicated by patient recall 
and ‘mixed’ onset presentation.  By extension, we may hypothesise that gene-carriers are 
more likely to have bulbar-onset disease.  This would support our previous link with C9orf72 
expansion carriers and bulbar-disease (the C9orf72 expansion being the biggest monogenic 
contributor to Pathogenic/VUS-P cohort).  However, these assumptions require validation 
using larger Scottish cohorts and an external validation cohort.    
 
Univariate association testing of C9orf72 expansion carriers showed that they have 
significantly poorer ALS-Specific ECAS scores, confirming the hypothesis.  This finding 
parallels other studies and supports a link between C9orf72 and MND-FTD spectrum 
disorders[75,128,132,133]. This highlights the utility and importance of early cognitive 
assessment using the ECAS assessment tool following diagnosis of MND.  The penetrance for 
the C9orf72 expansion is incomplete but is thought to be higher in MND than in pure FTD; it 
is also unaffected by prior family history of disease and increases with age[451].  Antisense 
oligonucleotide therapy trials are currently recruiting C9orf72 expansion carriers[452].  Early 
identification of cognitive impairment will be crucial in the near future to guide appropriate 
genetic testing and ensure that patients are offered therapeutic intervention before they lose 
capacity.      
 
While it did not meet Bonferroni-corrected threshold for significance, C9orf72 expansion 
carriers in our population have poorer outcomes in terms of survival (p=0.006), as has been 
described in other studies[132,136].  Fewer people with C9orf72 expansions were initiated 
on NIV, though, again, this did not meet the significance cut-off (p=0.003).  C9orf72 expansion 
carriers are thought to have fast respiratory decline[135].  From this we might infer that this 
population might not have had opportunity to commence on NIV due to inability to consent 
and comply with treatment (because of cognitive impairment) and because of rapidly 
progressive disease.  Inclusion of Forced Vital Capacity respiratory measures in a longitudinal 
survival study might help to validate these findings.  In the meantime, early assessment of 
C9orf72 status and ECAS cognitive assessment in a clinical setting could guide intervention 
strategies and help to maximise patient access to available intervention.  The male-to-female 
ratio in C9orf72 expansion carriers was 50:50, ie. more females that would be expected in a 
typical MND cohort.  In our study of a whole population cohort of patients in Chapter 3, we 





was unexplained but, on reflection, C9orf72 status might be a contributor.  However, neither 
female sex nor NIV affects overall survival (Chapter 4).   
 
We identified two patients with intermediate-length repeat expansions who both had 
classical ALS phenotypes and cognitive impairment. Intermediate repeats are more common 
in those with neuropsychiatric disease (including FTD) and our results provide further 
evidence of this phenotype.   
 
In contrast to C9orf72, proportionally more SOD1 carriers commenced  NIV, though this did 
not reach Bonferroni-corrected significance (p=0.007).  This may be due to their having more 
predictable limb-onset ALS disease.  ECAS scores and survival of SOD1 carriers were reflective 
of the population as a whole, suggesting that the mutation does not influence these factors.  
Patients with SOD1 mutations tend not to have significant cognitive impairment[108] and so 
these findings were anticipated.  Individuals who had the p.I114T mutation did not have any 
statistically significant phenotypic markers; however, all had limb-onset ALS suggesting that 
the variant may result in a more ‘classical’ form of MND.  Indeed, none required gastrostomy 
insertion by the time of censorship, suggesting that bulbar disease is not a prominent feature.  
Family histories of individuals with the p.I114T variant revealed histories of limb-onset MND 
age similar ages to the proband, although details about disease site and onset are missing for 
some individuals.  Family histories of MS were also apparent, perhaps implying either a 
shared genetic aetiology, or perhaps a misdiagnosis of phenotype.     
 
While proportionally more patients with the C9orf72 expansion had bulbar-onset disease and 
more patients with the SOD1 mutation had limb-onset disease, this was not statistically 
significant.  This contradicts predictions from the historical analysis in Chapter 5.  This 
observation may relate to the more conservative statistical methods adopted in Chapter 7 
and suggests that our initial findings are not necessarily stable or replicable.    
 
Oligogenic patients also had no significantly different phenotypic markers.  The sample size 
is very small and so this is unsurprising.  Contrary perhaps to expectations, they appeared to 
have a slower rate of ALSFRS Preslope decline (p=0.004).  However, this did not influence 






Rare gene mutations were observed in this Scottish cohort, including a pathogenic mutation 
in VCP.  These are rare in the UK population and are often associated with other diseases 
such as inclusion body myositis, FTD and Paget’s disease[126].  Our patient had a family 
history of MND and dementia (there was insufficient information to determine if this was 
FTD) but no other diseases typical of the phenotype.  The presence of rare potentially 
pathogenic mutations in MND and FTD/dementia-associated genes in the Scottish population 
suggests that these require further study.  The median Time to Diagnosis for these rare gene 
carriers was 16 months (IQR 8-28 months).  This is longer than the overall median for the 
cohort (n=339; median 12 (IQR 8-23).  Early genetic testing of these individuals might have 
resulted in earlier diagnosis, better prognostication and more quality time for the patients 





Rare variants have been shown to influence survival in a smaller study[453].  However, our 
larger study, which controls for a wide breadth of endogenous and exogenous variables, 
suggests that while genotype may influence disease onset, it is not an independent predictor 
of survival.  A similar observation was seen in an Italian survival study which included C9orf72, 
SOD1 and TARDBP status[178].  Clinical variables related to speed of progression of disease 
remained influential.  It is possible that these factors overwhelm other biological hallmarks 
of disease once a patient has reached the critical threshold for disease manifestation.  Age 
of Onset loses its significance in predicting death in the model that includes genetic data (HR 
1.20 (95% CI 0.98-1.48) in model including genotype; HR 1.28 (95% CI 1.06-1.56) in model 
excluding genotype).  We would expect increasing Age of Onset to be associated with worse 
prognosis and so the insignificance of this predictor is counter-intuitive.  The confidence 
intervals are close to 1.0 and so this variable is vulnerable to instability when the number of 
predictors are high.  Indeed, the R2 of the model with genotyping is lower than the one 
without (0.51 versus 0.54) and the model does violate the ‘one in ten’ rule (26 predictors, 
176 people with the outcome of interest).  A solution would be to adopt a machine learning 






Two groups of gene carriers were explored in the prognostic models: i) those with all 
potentially pathogenic gene mutations, and ii) those with clearly pathogenic/disease-causing 
mutations by strict ACMG-guided standards.  Predictors of outcome remain relatively stable 
between the two models.  However, Family History of MND loses its significance when 
combined with the Pathogenic Only gene variable.  This reflects the raw data as definite 
pathogenic mutations are more highly correlated with family history than all potentially 







The main constraint of these genotype-phenotype analyses are the small sample sizes, 
limiting the number of permitted multivariable analyses.  Ways to overcome this would be i) 
to genotype more samples in the Scottish population, ii) to collaborate with other 
populations to increase sample sizes, and iii) to adopt machine learning methodology 
throughout the analysis, using methodology which might cope better with small numbers of 
event per variable.  Options (i) and (iii) are achievable within the framework of CARE-MND 
and should be explored for future study.  Option (ii) should also be explored, providing that 







From this genotype-phenotype study using a wide variety of phenotypic variables and an 
extended gene panel, we can conclude that having pathogenic and VUS-P mutations may be 
associated with a shared pathological process with other neurodegenerative diseases.  The 
C9orf72 expansion is associated with cognitive impairment.  Having a gene mutation did not 
influence survival when controlled for other phenotypic markers.  Early clinical gene testing 
using an extended gene panel may help in the diagnostic process by shortening time to 
diagnosis.  It may also guide management, either by prompting consideration of NIV prior to 






8. SUMMATIVE CONCLUSIONS 
 
8.1 THESIS OBSERVATIONS 
 
This thesis demonstrates what we can learn from a cohesive population-based study of a rare 
and life-limiting disease.  Using the strengths of the Scottish healthcare system and Scottish 
government infrastructure, we have been able to create a harmonised platform for 
longitudinal assessment of pwMND.  Through this, we have achieved 99% capture of incident 
pwMND over a three year period, allowing me to make conclusions about this population’s 
phenotypes and genotypes though my PhD study.  Unknowns relevant to Scottish pwMND 
and their care-providers have been elucidated and will now be summarised.   
 
 
Question 1: Has the incidence of MND in Scotland changed over time? 
 
The incidence of MND in Scotland is rising, in-keeping with anticipated global trajectories[21].  
In the Scottish population, we suspect that this is due to better awareness of the broader 
phenotype of MND (including cognitive phenotypes), an increase in the number of MND 
clinical specialists and improved healthcare for competing diseases such as heart disease and 
stroke disease.  The incidence of MND in Scotland is the highest reported standardised 
incidence of the disease globally[253].  This likely reflects our ascertainment processes and 
the infrastructure of CARE-MND.  However, ongoing assessment of incidence post-2017 with 
comparison against up-to-date European population statistics will be required to see if these 
observations are sustained.  An opposing argument is that they reflect recent public 
awareness of MND in Scotland, which has prompted a surge in diagnosis by healthcare 
providers.   
 
The annual prevalence of MND ranged from 7.61-7.81/100,000 population.  Compared with 
some other European populations, this is low (10.3 in the Netherlands 2008[266], 11.2 in 
Modena 2009[265], 10.5 in Piemonte and Valle D’Aosta 2014 (although this rose to 12.3 with 
the inclusion of 78 prevalent patients who had undergone tracheostomy)[257]).  Survival 





survival had improved over time, likely due to better multidisciplinary care[265,266].  In this 
thesis, I have observed a median survival from onset of 3.5 years in the historical cohort 
(diagnosed 1989-2014).  However, in the incident cohort (mean follow-up time 1.9 years), 
55% of patients were deceased.  Longer follow-up of the 2015-17 incident cohort is required 
to study longer survivors in this group but our observations so far, combined with the low 
prevalence of disease, are discouraging and suggest that current interventions for MND do 
not have a significant survival benefit in Scotland (see Question 2).   
 
Nevertheless, current awareness of incidence and prevalence will now allow us to anticipate 
service needs better.  The MND Nurse Consultant for Scotland is able to use this information 
as evidence for economic and healthcare investment.  Estimated annual incidence is 
important for power calculations for future clinical trials.  Knowledge of epidemiology is 
important for long-term services planning, particularly in the climate of imminent drug 
therapies.  The implementation of genetically targeted treatments, particularly those for 
C9orf72 expansion carriers, is expected to result in a rise in prevalence of MND by up to 50% 
by 2066[454].  Such predictions should justify ongoing investment into MND care in Scotland.     
 
 
Question 2: Can deep clinical phenotyping of the Scottish MND population reveal 
predictors of survival? 
 
During this population study, I initially undertook limited phenotypic characterisation of an 
incident population cohort and a historical cohort of genotyped individuals with MND.  These 
analyses revealed hypothesis generating questions which were explored further on deep 
clinical phenotyping of an incident research cohort of patients (n=437) using the CARE-MND 
platform.  Using this information, I can summarise that Scottish individuals with MND are 
predominantly male and of White Scottish ethnicity, with a male-to-female ratio of 1.7:1.  
They tend to develop symptoms of disease age 64 years and receive a diagnosis age 66 years.  
The average time to diagnosis is 12 months.  Lower limb is the most common site of disease 
onset and ALS the most typical manifestation.  Six percent of the population are diagnosed 
with MND-FTD from the outset; however, cognitive impairment of some degree is present in 





a feeding tube inserted and 27% being commenced on NIV at time of censorship (median 
follow-up 23 months).    
 
I have shown that survival can be predicted at diagnosis and that models with multiple 
imputation for missing data perform better than those that exclude missing data.  Using a 
fully imputed model, I found that steeper decline in the ALSFRS-R slope (ALSFRS-R performed 
within six months of diagnosis) and a shorter time to diagnosis predicts poorer survival.  
Median rate of decline is 0.6 points per month and median time to diagnosis 12 months.  
Patients with PLS, PMA and PBP have better outcomes.  Older age at onset also predicts 
death.  In summary, these findings suggest that increased burden of upper and lower motor 
neurone degeneration in older, vulnerable patients results in faster progression to death.  A 
family history of MND suggests poorer outcome; however, having a pathogenic or potentially 
pathogenic mutation did not predict survival.  This might suggest that there are, as yet, 
undiscovered genetic influences of disease.  Another possibility may relate to the “gene-time-
environment (GTE)” hypothesis as described in Chapter 1[160].  Once a patient with a genetic 
predisposition has reached a critical threshold, or accumulated the required risk burden for 
disease manifestation, there is a rapid cascade of decline related to the patient’s innate 
vulnerability.  In our models, post-onset factors may overwhelm the influence of premorbid 
characteristics.   
 
Interventions such as riluzole, gastrostomy and NIV did not influence survival when 
controlled for other variables.  The overall median survival from onset was 30 months (2.5 
years); by two years, 49% of this research cohort were deceased.  This is unchanged 
compared to a Scottish study published in 1993, in spite of the fact that uptake of riluzole 
and gastrostomy has increased substantially (5.6% vs 40.0% and 11.6% vs 31.3% 
respectively)[203].  Although longer follow-up time is required (as described above), it 
suggests that current interventions for MND in Scotland do not have significant survival 
benefit.      
 
Exogenous variables - heavy metal/pesticide exposure and smoking – may negatively and 
positively influence survival, respectively.  Case-controls studies in the Scottish population 





in all models studied through this PhD.  Potential theories underlying this observation relate 
to its effects on inflammation and the gut microbiome.   
 
While the derived prognostic models do not violate the ‘one-in-ten’ rule, there are a high 
number of predictors in the context of a small sample size.  As such, there is a high chance of 
overfitting of the data.  Ways to overcome this will be explored in Chapter 8.3.  The prediction 
observations are also only derived from the Scottish population; we have not yet validated 
them on an external cohort and so findings are not generalisable.  However, close parallels 
have been seen in similar analyses from Italian registry studies[178].  This study examined 
the influence of similar phenotypic markers and clinical interventions and found that age of 
onset, diagnostic delay, ALS phenotype, presence/absence of dementia, riluzole use, BMI and 
El Escorial classification predicted survival using multivariable Cox regression.  However, in 
this analysis, non-significant variables were ‘dropped’ from the model.  Results must 
therefore be interpreted with caution as non-inclusion of non-significant variables may 
inflate the significance of remaining variable (or, reduce the suppression effect of these non-
significant variables[190]).   
 
 
Question 3: What is the genetic epidemiology of MND in Scotland?  In particular, are 
there mutations unique to the Scottish population and are rare/newly described 
mutations present in this population? 
 
Following a hypothesis-generating pilot study, we used an adapted MND-specific ACMG 
framework to test a comprehensive gene panel on an unselected cohort of incident pwMND 
in Scotland.  To our knowledge, this is the first complete, manual application and assessment 
of utility of the ACMG guidelines for MND genomic data.  This has highlighted classification 
criteria that are relevant and irrelevant to MND-specific genes, thereby identifying targets 
for improvement (eg. Focus on functional studies and sourcing of segregation data).   
 
Using this framework, up to 22% of patients have a potentially causative gene mutation.  This 
is higher than previously described estimates[77].  Two percent were oligogenic, in-keeping 
with other population estimates[94,378,442].  In the MND community, monogenic causes of 





individuals[455].  In this study, 68% of familial cases and 20% of apparently sporadic were 
thought to have potential pathogenic mutations.  However, only 54% of familial cases and 
10% of apparently sporadic cases had definite Pathogenic mutations.  The C9orf72 expansion 
is the biggest contributor, affecting 32% of familial and 6% of sporadic patients, matching 
current estimates of frequency (35% and 5% respectively)[455].  However, SOD1 mutations 
are also important, particularly the p.I114T variant.  SOD1 variants were found in 2% of 
sporadic individuals and 18% of familial.  These number are similar to quoted estimates[455] 
but, to our knowledge, Scotland has the highest frequency of p.I114T variant.       
 
Between the historical and incident Scottish cohorts, six loss of function NEK1 variants 
(absent from controls) were identified.  As loss of function is the presumed mechanism of 
disease causation in this gene[90], our data provide evidence for association of this gene with 
MND in the Scottish population and suggest that it should be included in future clinical gene 
panels.  Loss of function variants in TBK1 were identified in the historical cohort but not in 
the incident cohort, where only one potentially pathogenic missense TBK1 variant was 
identified in a patient with limb-onset ALS and short survival (10 months from onset).  This 
collective information neither confirms nor discounts TBK1 as a disease-causing gene in the 
Scottish population; we therefore recommend that clinical panels include this gene to further 
knowledge of its role and avoid missing a potentially inheritable cause of MND.   
 
There remains considerable uncertainty regarding VUS-P and VUS in rare genes and genes 
associated with dementia phenotypes.  Sharing of these data with public databases and 
collaboration with other population cohorts may help to clarify their significance within the 








Question 4: Can deep clinical phenotyping and extended genotyping of an incident 
MND cohort identify genotype-phenotype correlates (particularly with regard to 
C9orf72 and SOD1)? 
Question 5: Does genotype influence survival in a multivariable prognostic model of 
MND in Scotland? 
 
Genotype-phenotype study of these individuals shows a significant relationship between 
having a mutation and having a family history of other neurological conditions, including 
Parkinson’s disease and multiple sclerosis, perhaps suggesting a genetic spectrum across 
these neurodegenerative diseases.  Having a C9orf72 expansion is associated with an 
increased risk of cognitive impairment and, perhaps, poorer survival, and these factors may 
preclude NIV initiation.  Alternatively, cognitive impairment provides a barrier to NIV and so 
hastens clinical deterioration.  Early genetic testing of people with suspected MND may 
provide clues towards likely prognosis and development of cognitive impairment, and guide 
early intervention.   
 
We have outlined the phenotypic characteristics of the largest series of patients with the 
SOD1 p.I114T variant to our knowledge (n=27 across both pilot and incident cohorts; 3.5% of 
cases overall).  All but one of these cases had limb-onset disease and the majority had a 
classical ALS phenotype.  They were significantly associated with having a family history of 
MND, suggesting penetrance of this variant across generations.  A previous study of this 
variant suggested phenotypic heterogeneity and variable penetrance within a family[144].  
Our study alludes to an association of MS within families with this variant and it would be 
interesting to review the phenotypic characteristics of these family members.    
 
Genotype-phenotype descriptions of rare variants are hypothesis generating.  The high 
frequency of VUS-P associated with cognitive phenotypes/dementia supports the need for 
early cognitive assessment and exploration of family histories of dementia and 
neuropsychiatric symptoms.  Genotype annotation of CARE-MND patients provides a 
valuable resource whereby individuals with specific phenotypes and genotypes can be 





for gene carriers.  For example, patients with rare variants and cognitive impairment might 
be useful targets for pluripotent stem cell models.     
 
Genetic results were not fed back to patients from this research study.  Currently, clinical 
genetic testing in Scotland is only offered routinely to those with a family history of MND.  
Following the results of our pilot study (Chapter 5), a clinic was set-up in the West of Scotland 
to offer genetic counselling and testing to individuals with young-onset (<50 years) 
apparently sporadic disease.  Similar approaches have been adopted by Northeast ALS 
Consortium members in the USA[171].  After spending time at Columbia University, I learned 
that genetic results, including those obtained from research studies, are routinely reported 
back to patients.  Although there are concerns about patient anxiety in the clinic on receiving 
information about a variant of uncertain significance, variant classification multidisciplinary 
team meetings operate to ensure that patients are given appropriately full and clear 
information.  Although this is not part of routine clinical practice in the UK, growing 
knowledge of genetics amongst clinicians and patients will likely require consideration of this 
in the near future.  This would be the only way to learn more about the implications of rare 
gene variants in the Scottish population and would more easily permit trio studies of parents.  
Further, and crucially, a non-paternalistic transparent approach to gene testing would allow 
individuals to make more informed decisions regarding family planning and pre-implantation 
genetic diagnoses.  Variable penetrance of mutations makes this area especially challenging 
but denying patients the relevant information is equally ethically questionable.   
 
Finally, inclusion of genetic data in a multivariable survival model revealed that genetic 
mutation status was not a significant predictor of death.  From this, we can hypothesise that 
genetic mutations predispose to, but do not necessarily perpetuate, disease.  However, the 
number of predictors in this model was high and so validation is required with a bigger 
sample size and using alternative statistical methods.     
 
The ultimate aim is that these observational studies will inform national guidelines of MND 
in Scotland and translate directly to the patients and families who have contributed.  Already, 
we have been able to provide patients with answers to questions about the Scottish MND 












8.2 STUDY LIMITATIONS 
 
 
This PhD benefits from a population cohort studied in 2015-17.  Data prior to 2015 (1989-
2014) were also analysed.  However, a complete longitudinal picture is not possible due to 
differences in capture of phenotypic characteristics over time.  As described in Chapter 3, the 
El Escorial classification was established during this time period and has evolved.  Recognition 
of cognitive impairment in MND has also emerged over the past two decades. 
 
Our models only include data from consenting patients on the CARE-MND Register.  Patients 
without capacity at presentation are therefore excluded; we might expect such patients to 
have more rapid progress of disease.  While research recruitment is addressed at the earliest 
opportunity in Scotland, such barriers are inevitable.  There were also insufficient data to be 
able to include body mass index (BMI), electrophysiology, spirometry or imaging biomarkers 
in these analyses.  BMI and post-diagnostic weight loss can be predictors of death[58].  
Forced vital capacity (FVC) measurements have also been shown to be key predictors of early 
decline[6,179].  However, these variables are part of the CARE-MND platform proforma and 
should be included in future studies dedicated to specific exploration of each modality, whilst 
controlling for our predictive variables.  One factor, which is not yet covered by CARE-MND, 
is a measurement of quality of life.  This  is independently related to survival outcome and 
could be incorporated into patient-centred questionnaires and future survival models[58].   
 
This study provides a proof-of-concept of the viability of deep clinical phenotyping in a 
routinely-collected, population setting.  However, a trade-off for a broad set of phenotypic 
variables is the lack of detail for each variable.  For example, exogenous variables on CARE-
MND exist as screening questions (for example, history of smoking: Yes/Ex/Never, with a free 
text box for comments).  Answers are therefore crude and hypothesis generating for future 
case-control studies, which should include stratification of these factors (for example, pack 
year history, dates of starting and stopping smoking).  Variables may also be subject to recall 
bias (for example, history of heavy metal and pesticide exposure, history of blood 
transfusion).  Attempts to overcome this included a review of ISD hospital records and 







Throughout my PhD study period, my understanding of genetic variant classification and 
statistical modelling has evolved, corresponding with changes in the MND literature-base.  
Chapter 5 (genotype-phenotype study of a historical cohort) was hypothesis-generating and 
was published in 2016.  Through this part of the PhD, I identified that methods for assessment 
of variant pathogenicity were arbitrary and inadequate, which prompted a systematic review 
of the ACMG guidelines and a more transparent approach to classification.   
 
There has also been a move towards more sophisticated and systematic approaches for 
survival modelling, including machine learning[179,456].   During this PhD, univariate and 
then inclusion of near-significant variables in a multivariable model using SPSS was adopted 
in Chapter 5.  However, R programming was adopted latterly to allow for more advanced and 
flexible analyses.  This included imputation and machine learning approaches for feature 
selection.  Missing data is an expected repercussion of routinely-collected population data.  
Exclusion of missing data risks losing individuals’ valuable contributions to research.  
Although imputation resulted in clinically appropriate models, this method can come under 
criticism in medical research.  One argument for imputation is the well-established and 
validated QRISK score for cardiovascular disease.  In the development of this model, some 
variables included had up to 70% missing data, yet it is still considered an important clinical 
tool[194].   
 
As described in Chapter 7, the numbers of individuals with genetic mutations were too small 
to allow for gene-specific genotype-phenotype study using multivariable models.  We 
recognise that collaboration and contribution to larger datasets, such as Project MinE[457], 
will be a key application of this work.     
 
Finally, the follow-up times for this project were short, constrained by the time frame of the 
PhD (mean follow-up time was 23.0 months (SD 9.2, range 6.0–39.0 months)).  Longer follow-
up may change our prognostic models and highlight as yet unseen benefits of NIV or 










8.3 FUTURE DIRECTION 
 
 
The integrated MND care-research infrastructure will enable Scotland to become a leader in 
a stratified medical approach to individual patient care, resulting in better focused clinical 
trials.  Parallels with other newly–launched national registries, such as the Swedish MND 
Quality Registry, the New Zealand MND Registry and the developing MND Register of 
England, Wales and Northern Ireland, will allow us to pursue extensive collaboration for 
patient centred-discovery science[458,459].   
 
The findings in this thesis suggest that stratification of patients for clinical trials by site of 
onset is likely artificial.  Clinical trial patients in Scotland should ideally be stratified by age of 
onset, family history of MND and El Escorial classification of disease.  Time to diagnosis, 
ALSFRS-R preslope and smoking status should be controlled for when analysing outcome 
data.  Register data in isolation cannot make conclusions about environmental risk factors, 
but combining data with control data from the same population in a case-control study would 
help to assess the impact of our environmental risk factors such as smoking and heavy 
metal/pesticide exposure[227].  Scotland is in a perfect position to perform such studies, with 
the availability of the Lothian Birth Cohorts and Scottish Government ISD data[460].  While 
this could provide important answers to questions about local environmental risk factors, 
perhaps the best use of CARE-MND data would be to collaborate internationally and use our 
data on a greater scale.  Through CARE-MND we have endeavoured to make our data 
collection internationally compatible to streamline this process.   
 
The prognostic models would benefit from longer follow-up time.  This can be achieved 
through CARE-MND.  I have demonstrated the use of machine learning methods for feature 
selection.  However, other feature selection approaches could be explored, such as principle 
component analysis (PCA).  PCA methods were not undertaken during this thesis as it is often 
difficult to make clinically-relevant assumptions from PCA groupings.  Novel approaches 
include “concept-based” variable reduction whereby variables are grouped by clinical 
interaction[188].  It would be interesting to apply this to our Scottish dataset.  Machine 
learning methodology also has the capability to perform cross-validated regression models.  





previously in ALS cohorts, with random forest models performing superiorly[179,188].  These 
models have the advantage of being able to cope with datasets where the number of 
predictors approaches the number of variables.  Additional granularity could therefore be 
incorporated into our models, including FVC measures, a separating out of MND subtypes, 
and the inclusion of ALSFRS-R and ECAS subscores.  ALSFRS-R motor and bulbar subscores 
have been found to provide additional information to recalled site of onset data.   
 
Further dissection of our results could be achieved through a causal mediation analysis to 
elucidate the potential interactions between predictors in the multivariable models[461].  
For example, there is clearly an interaction between family history of MND and the presence 
of pathogenic mutations but I have not yet been able to prove if the influence of family 
history on survival is mediated by results of our gene panel testing, or if there are other 
unknown genetic modifiers.   
 
While the models described in this thesis are only relevant to the 2015-17 incident Scottish 
population, machine learning models would be more generalisable to other populations.  
Internal validation on a new Scottish dataset (eg. 2018-19 incident cohort) would be the next 
step.  Gold-standard external validation on another population cohort would be ideal, 
perhaps through our collaborators at Columbia University or through other UK population 
databases such as the new MND Register for England and Wales.  These analyses will be 
explored over the coming year.  While the methods and results of the prognostic models are 
reported in this thesis with reference to TRIPOD guidelines, clear clinical applications of a 
model are not yet delineated, pending the above modifications[195,196].  The final model 
will ensure that full TRIPOD recommendations are met.         
 
We recommend that the extended 49-gene panel be considered as a diagnostic panel for 
Scotland.  Results from the research study will be communicated to the South-East Scotland 
laboratories to inform future variant interpretation.  Ideally, Scottish variants would be 
uploaded into a centralised database so that we can learn more about the implications of 
rare variants in the Scottish population, determine heritability through family segregation or 
trio studies, and perhaps even identify new founder mutations.  Scottish genetics 
laboratories are currently exploring this possibility and plan to work with our clinical 





By setting up this kind of infrastructure, anchored through CARE-MND, we would have access 
to a rich resource for selection of participants for disease modelling/stem cell studies and for 
genetically stratified drug trials.  Ideally, this would also contribute to, or act as a stepping-
stone, for a multi-site open-access database of annotated MND-associated gene variants 
through which the MND research and clinical community can continue to reassess variants, 
and identify missing classification criteria and targets for future research.   
 
 
In conclusion, this PhD has set the scene for the future of MND discovery and treatment in 
Scotland.  Through a population-wide model of participation, personalisation, prediction and 
prevention, we can move towards further advancement in the field and set precedent for 
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Appendix 2: CARE-MND Platform Standard Operating 






































































































preproc_pheno = read_csv("PhenoGeno1517_Simplified3.csv") 
 
#Only include columns of interest (including outcome) 
pheno = preproc_pheno[,c(2:33)] 
 
#Visualise and count missing data 
aggr_plot = aggr(pheno, numbers=TRUE, sortVars = T, labels = names(data), 
cex.axis = .7, gap=3, ylab=c("Histogram of missing data", "Pattern")) 
 
#dummyCode (for categorical variables) 






dummies = dummyVars(~.,data=phenoPreproc, fullRank=T) 
phenoPreproc = data.frame(predict(dummies,newdata = phenoPreproc)) 
 
#Remove variables with 0 variance 
nzv_cols = nearZeroVar(phenoPreproc) 
if(length(nzv_cols) >0) phenoPreproc = phenoPreproc[,-nzv_cols] 
 
#Standardise 
preprocvalues = preProcess(phenoPreproc,method=c("center", "scale")) 
phenoPreproc = predict(preprocvalues, phenoPreproc) 
 
# Identify correlated variables 
corrMatrix = corr.test(phenoPreproc) 
corrMatrix005 = corrMatrix 
corrMatrix005$r[corrMatrix005$p>0.05] = 0 
png(file="corr.png", res=300, width=4500, height=4500) 
corrplot(corrMatrix005$r, method="color", type="lower", addCoef.col = 
"white", number.cex = 0.5) 
dev.off() 
 
# Remove correlated variables 
 
#Cox regression 
#Remove columns with <=25% missing data 
pheno25 = phenoPreproc[, colMeans(is.na(phenoPreproc)) <= .25] 
 
#Add outcome back in 
pheno25cox = pheno25 
pheno25cox$Survival = pheno$Survival_Onset_Days 
pheno25cox$Censor = pheno$Censor_or_Death 
 
#Create "temporary" imputed dataset. m=10 = 10 sets of imputed data 















r2_cox25 = NULL 
for(i in seq(1:10)) 
{ 




#Code for box/whiskers 
boxLabels_ep = c("Sex (Male)","Time to Diagnosis", "Age of Onset","Site of 
Onset:Limb", "Classification: MND-FTD", "Classification: Other", "PMH 
Malignancy", "PMH Autoimmune Disease", "PMH Cardiovascular Disease", "PMH 
Psychiatric Disease", "Ever Smoked", "Exercise Participation", "Family 
History of MND", "Family History of Dementia", "Family History of Other 
Neurological Disorders", "Family History of Psychiatric Disorders", 
"Riluzole", "Feeding Tube Insertion", "Non-Invasive Ventilation", "ALSFRS-R 
Preslope") 
 
#manually extract each column exp(coef) which is the OR (not the intercept) 
boxOdds_ep = NULL 
boxCILow_ep = NULL 
boxCIHigh_ep = NULL 
 
for(i in seq(1:20)) 
{ 
  boxOdds_ep = c(boxOdds_ep, exp(summary(pool(cox25model))[,1][[(i)]])) 
  boxCILow_ep = c(boxCILow_ep, exp((summary(pool(cox25model))[,1][[(i)]])-
(1.96*(summary(pool(cox25model))[,2][[(i)]])))) 





df_ep <- data.frame(boxLabels_ep, boxOdds_ep, boxCILow_ep, boxCIHigh_ep) 
 
png("hr_coefs_cox_25_2.png",res = 300, width = 30, height = 45, units = 
'cm') 
(p <- ggplot(df_ep, aes(x = boxOdds_ep, y = df_ep$boxLabels_ep)) + 
    geom_vline(aes(xintercept = 1), size = .25, linetype = 'dashed') + 
    geom_errorbarh(aes(xmax = boxCIHigh_ep, xmin = boxCILow_ep), size = .7, 





                     .2, color = 'gray30') + 
    geom_point(size = 3.5, color = '#00BFC4') + 
    theme_bw() + 
    theme(axis.text.y = element_text(face = "bold", color = "gray30", size 
= 12)) + 
    theme(panel.grid.minor = element_blank()) + 
    scale_x_continuous(breaks = c(0.05,0.1,0.2,0.4,0.7,1,1.5,3,6,12,24) ) + 
    coord_trans(x = 'log') + 
    ylab('') + 
    xlab('Hazard Ratio 95% CI (log scale)') + 
    labs(title = "i) Prognostic Variables in MND Cox Proportional Hazards 
Model (<=25% Missing Data)") 
  + annotate("text", x=0.05, y=-0.5, label = "R2 = 0.51") 
  + theme(plot.title = element_text(hjust = 0.5)) 




# Repeat above for <=50% missing data and 0 missing data 
 
#Adding in Genetic data 
 
preproc_geno = read_csv("PhenoGeno_GenotypeOnly_Simplified2.csv") 
 
#Univariate Analyses by Mutation Type (not shown) 
#Logistic regression model with imputation for genotyping  
#PathVUSP vs no PathVUSP 
#select variables using regularisation 
 
#Only include columns of interest (including outcome) 
genoPath = preproc_geno[,c(4, 54, 55, 57, 59:83)] 
#Visualise and count missing data 
#dummyCode (for categorical variables) 
#Remove variables with 0 variance 
#Add outcome back in 
#Control (within 1 SE) 
control <- trainControl(method="cv", number=10, classProbs=TRUE, 






#Path_VUSP Outcome and Model 
results_Path = list() 
mods_Path = list() 
 
#15 sites 
for(i in seq(1:15)) 
{ 
  set.seed(987) 
   
  #set up leave one site out cv 
  test_set = genoPathglm[ which(genoPathglm$Health_Board == 
levels(genoPathglm$Health_Board)[i]), ] 
  train_set = genoPathglm[ -which(genoPathglm$Health_Board == 
levels(genoPathglm$Health_Board)[i]), ] 
   
  #remove site column 
  test_set = test_set[ ,!(colnames(test_set) %in% c("Health_Board"))] 
  train_set = train_set[ ,!(colnames(train_set) %in% c("Health_Board"))] 
   
  #Get the observed outcome classes for this test set 
  result = data.frame(obs=test_set$Path_VUSP)  
   
  #train model over grid of 10 by 10 lambda alpha, knn impute, standardise 
  mod <- train(Path_VUSP ~ ., data=train_set, method="glmnet", 
metric="ROC", tuneLength = 10, preProc = c("center", "scale","knnImpute"),  
 
trControl=control,na.action = na.pass) 
  result$pred = predict(mod, test_set, type = "prob", na.action = na.pass) 
  result$row = as.numeric(rownames(test_set)) 
   
  results_Path[[i]] = result 












                          
results_Path[[4]]$pred$Y,results_Path[[5]]$pred$Y, 
results_Path[[6]]$pred$Y, 
                          
results_Path[[7]]$pred$Y,results_Path[[8]]$pred$Y,results_Path[[9]]$pred$Y, 
                          
results_Path[[10]]$pred$Y,results_Path[[11]]$pred$Y,results_Path[[12]]$pred
$Y, 






                                
as.character(results_Path[[3]]$obs),as.character(results_Path[[4]]$obs), 
                                
as.character(results_Path[[5]]$obs),as.character(results_Path[[6]]$obs), 
                                
as.character(results_Path[[7]]$obs),as.character(results_Path[[8]]$obs), 
                                
as.character(results_Path[[9]]$obs),as.character(results_Path[[10]]$obs), 
                                
as.character(results_Path[[11]]$obs),as.character(results_Path[[12]]$obs), 
                                
as.character(results_Path[[13]]$obs),as.character(results_Path[[14]]$obs),a
s.character(results_Path[[15]]$obs))) 
results_Path_seq$row = c(results_Path[[1]]$row,results_Path[[2]]$row, 
results_Path[[3]]$row, 
                         results_Path[[4]]$row,results_Path[[5]]$row, 
results_Path[[6]]$row, 
                         
results_Path[[7]]$row,results_Path[[8]]$row,results_Path[[9]]$row, 
                         
results_Path[[10]]$row,results_Path[[11]]$row,results_Path[[12]]$row, 
                         
results_Path[[13]]$row,results_Path[[14]]$row,results_Path[[15]]$row) 
 
auc_Path_seq = roc(predictor = results_Path_seq$pred, response = 
results_Path_seq$obs)$auc 




#PSI = (PPV+NPV)-1 
#LR+ = sens/(1-spec) 






ci.coords(roc_Path_seq,"best", best.method = "closest.topleft", ret = 




Path_auc_null = NULL 
for(i in seq (1:10001)) 
{ 
  Path_perm = permute(results_Path_seq$obs) 
  Path_auc_null = c(Path_auc_null, roc(predictor = results_Path_seq$pred, 
response = Path_perm)$auc) 
} 
 
#get p value by taking proportion of permutated values greater or equal to 
the actual value 




getStability <- function(X,alpha=0.05) { 
  ## the input X is a binary matrix of size M*d where: 
  ## M is the number of bootstrap replicates 
  ## d is the total number of features 
  ## alpha is the level of significance (e.g. if alpha=0.05, we will get 
95% confidence intervals) 
  ## it's an optional argument and is set to 5% by default 
  ### first we compute the stability 
   
  M<-nrow(X) 
  d<-ncol(X) 
  hatPF<-colMeans(X) 
  kbar<-sum(hatPF) 
  v_rand=(kbar/d)*(1-kbar/d) 
  stability<-1-(M/(M-1))*mean(hatPF*(1-hatPF))/v_rand ## this is the 
stability estimate 
   
  ## then we compute the variance of the estimate 
  ki<-rowSums(X) 
  phi_i<-rep(0,M) 





    phi_i[i]<-(1/v_rand)*((1/d)*sum(X[i,]*hatPF)-(ki[i]*kbar)/d^2-
(stability/2)*((2*kbar*ki[i])/d^2-ki[i]/d-kbar/d+1)) 
  } 
  phi_bar=mean(phi_i) 
  var_stab=(4/M^2)*sum((phi_i-phi_bar)^2) ## this is the variance of the 
stability estimate 
   
  ## then we calculate lower and upper limits of the confidence intervals 
  z<-qnorm(1-alpha/2) # this is the standard normal cumulative inverse at a 
level 1-alpha/2 
  upper<-stability+z*sqrt(var_stab) ## the upper bound of the (1-alpha) 
confidence interval 
  lower<-stability-z*sqrt(var_stab) ## the lower bound of the (1-alpha) 
confidence interval 




   
} 
 
coefs_Path = NULL 
for (i in seq(1:15)) 
{ 




#just get numbers 
coefs_Path_extract = NULL 
for(i in seq(1:15)) 
{ 
  coefs_Path_extract = rbind(coefs_Path_extract, coefs_Path[[i]][1:28]) 
} 
 
#get matrix of coefficients presence (1) or absence (0) 
#Presence or absence of predictors across all 15 LOSOCV models 
coefs_Path_presence = NULL 
coefs_Path_presence = coefs_Path_extract[1:15,2:28] 










#work out number of predictors shared across all models 
table(colMeans(coefs_Path_presence)) 
 
#get rank of coef by importance as in sports ranking 
coefs_Path_baseline_rank = NULL 
 
for(i in seq(c(1:15))) 
{ 
  #rank absolute value excluding the intercept for each model 
  coefs_Path_baseline_rank = rbind(coefs_Path_baseline_rank, 
rank(abs(coefs_Path_extract[i,2:28]), ties.method = "min")) 
} 
 
# rank the mean ranks of each column across all models 
coefs_Path_baseline_rank_mean = colMeans(coefs_Path_baseline_rank) 
 
#Invert order of rank to identify top models 
coefs_Path_baseline_order = rank(-coefs_Path_baseline_rank_mean) 
 
#Get the column names (not the intercept) 
coef_Path_names = dimnames(coefs_Path[[1]])[[1]][2:28] 
 
coefs_Path_means = colMeans(coefs_Path_extract)[2:28] 
 
df_Path_names = data.frame(coef_Path_names, coefs_Path_baseline_order, 
coefs_Path_means, colMeans(coefs_Path_presence)) 
 




##Run the LR model with top predictors 
 
#Only include columns of interest (including outcome) 






#Visualise and count missing data 
#dummyCode (for categorical variables) 
#Remove variables with 0 variance 
#Standardise 
#Add outcome back in 
#See which variables are include 
 
#Create "temporary" imputed dataset. m=10 = 10 sets of imputed data 
tempgenoPathglm = mice(genoPathglm, m=10, maxit=5, method = 'pmm', 
seed=987) 
 
#Glm model  










#Excluding individuals with missing outcome data (n=0) 
glmPathmodelnull = genoPathglm[which(!is.na(genoPathglm$Path_VUSP)),] 
nullgenoPathglmmod = glm(glmPathmodelnull$Path_VUSP~1,family = "binomial") 
 
#pseudo R2 and AIC for each iteration of mice (10) (in a sequence, 10x) 
pseudor2_genoPathglm = NULL 
AIC_genoPathglm = NULL 
for(i in seq(1:10)) 
{ 
  pseudor2_genoPathglm[i] = (1-logLik(getfit(glmPathmodel, 
i))/logLik(nullgenoPathglmmod))[1] 










#Code for box/whiskers  





Appendix 5: Scottish Regenerative Neurology Tissue Bank 


























Appendix 6: Consensus Methodology for American College of 
Medical Genetics Classification of MND Genomes 
 
Abbreviations 
PVS = Pathogenic Very Strong 
PS = Pathogenic Strong 
PM = Pathogenic Moderate 
PP = Pathogenic Supporting  
BA = Benign Stand-alone 
BS = Benign Strong 
BP = Benign Supporting 
VUS = Variant of Uncertain Significance  
 
PVS1: Null variant (nonsense, frameshift, canonical +/- 1 or 2 splice sites, initiation codon, 
single or multiexon deletion) where loss of function (LoF) is a known mechanism of disease - 
LoF known mechanism of disease only applicable for ALS2, OPTN and TBK1 (probability of 
being loss-of-function intolerant (pLI) scores extracted from gnomAD).  Functional assays for 
splice site variants only – not needed for frameshifts or truncations. 
PS1: The amino acid change is seen in a previously established pathogenic variant (but with 
a different nucleotide change) - Ensure previous established variants meets ACMG criteria for 
Pathogenic. 
PS2: De novo variant (both maternity and paternity confirmed) in patient with the disease 
and no family history - Review of literature including supplementary materials. 
PS3: Well-established in vitro or in vivo functional studies supportive of a damaging effect on 
the gene or gene product - Rodent model of a given mutation accepted as supportive if the 
rodent had motor or cognitive symptoms, there was impact on survival, or proven loss of 
motor neurons pathologically[395,398,399].  Pathologically similar findings without 
neurodegeneration not accepted (eg. presence of DP43 mis-localization, dipeptide repeats, 
C9of72 foci).  The only accepted in vitro assay was cytoplasmic localization/nuclear exclusion 
of a FUS variant.   
PS4: Prevalence in affected individuals is significantly higher than in controls - Relative Risk 






PM1: Located in a mutational hot spot and/or critical and well-established functional domain 
(without any benign variants) - SOD1, VAPB, PFN1, CHCHD10 and ALS2 – no hot spot; FUS – 
NLS (exon 15); TARDBP – exon 6; VCP – exons 3,4 and 5 or N-terminal domain; UBQLN2 -  PXX 
domain 
PM2: Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing 
Project, 1000 Genomes Project, or Exome Aggregation Consortium – Most complete database 
at time of analysis (ExAC database) used only.  Extremely low frequency if recessive taken to 
be 0.01% MAF. 
PM3: If recessive, detected in trans with a pathogenic variant (if parental or offspring samples 
available - Review of literature including supplementary materials. 
PM4: Protein length changes as a result of in-frame deletions/insertions in a non-repeat 
region OR stop-loss variants (stop codon is changed to an amino acid) – Amino acid sequences 
visualised using UCSC and Ensembl Genome Browsers.   
PM5: Novel missense change at the same site as a different pathogenic amino acid missense 
change (eg. Trp38Ser and Tryp38Leu) - Assessed with knowledge of pathogenicity of other 
variants – if one of the variants is pathogenic, this will impact on all other variants.   
PM6: Assumed de novo but paternity and maternity not confirmed.  
PP1: Cosegregation with disease in multiple affected family members in gene definitively 
known to cause the disease - Co-segregation calculated as per methods described in parallel 
publication[396]. 
PP2: A novel missense variant in a gene that has a low rate of benign missense variants, and 
in which missense variants are a common mechanism of disease - Z-score of ≥2.00 in ExAC 
accepted ensuring that the gene would be the top 5% of missense variant intolerant genes.  
Z-scores for missense variants: ALS2 = 0.80; CCNF 0.22; CHCHD10 0.99; FUS = 2.60; OPTN = 
0.06; PFN1 = 2.97; SOD1 = 2.34; TBK1 = 1.17; TARDBP = 4.33; UBQLN2 = 1.56; VAPB = 1.13; 
VCP = 6.47. 
PP3: Multiple lines of computational evidence supports a deleterious effect on the gene or 
gene product (eg conservation, evolutionary or splicing impact etc) (NB PP3 can only be used 
once) - Review of seven in silico prediction algorithms.  Rules for pathogenic: PhastCons >0.9; 
GERP > 4.0; CADD >20; Grantham >100; SIFT <0.05; Mutation Assessor >0.65/High; Polyphen 
probably-damaging.  All algorithms must agree in order to achieve criteria.  In view of high 





disagreement.  If the remaining algorithms agreed, the criterion was accepted. Meta-SVM 
and meta-LR methods were also used (see Methods).   
PP4: Phenotype or family history is highly specific for a disease with a single genetic aetiology 
- Due to phenotypic and genotypic heterogeneity of ALS, this was only thought to be relevant 
for patients with VCP who have typical disease syndrome (inclusion body myositis (IBM), 
frontotemporal dementia (FTD) and Paget’s disease) and ALS2 for infantile ascending 
hereditary spastic paraplegia (IAHSP).  
PP5: Reputable source (eg. clinical laboratory) recently reports variant as pathogenic but the 
evidence is not available for independent evaluation - If a variant was reported clinically in 
ClinVar as pathogenic this criterion was accepted (evidence of clinical genotyping, not 
literature only).   
BA1: Allele frequency is >5% in Exome Sequencing Project, 1000 Genomes Project, or Exome 
Aggregation Consortium - ExAC database only used.   
BS1: Allele frequency is greater than expected for disorder (in any population (eg African 
American or European American) - ExAC database only used; MAF cut-off = 0.001 
BS2: Disease is fully penetrant at an early age and the variant is observed in a well-
documented healthy adult individual for a recessive (homozygous), dominant (heterozygous) 
or X-linked (hemizygous) disorder - Only applicable for ALS2 (juvenile disease) 
BS3: Well-established in vitro or in vivo functional studies show no damaging effect on protein 
function or splicing 
BS4: Lack of segregation in affected members of a family - Only applicable if complete/early 
penetrance therefore not applicable for these genes 
BP1: Missense variant in a gene for which primarily truncating variants are known to cause 
disease - Only truly applicable for ALS2 
BP2: Observed in trans with a pathogenic variant for a fully penetrant/dominant 
gene/disorder, OR, observed in cis with a pathogenic variant in any inheritance 
BP3: In-frame deletions/insertions in a repetitive region without a known function 
BP4: Multiple lines of computational evidence suggest no impact on gene or gene product – 
Methods as per PP3 
BP5: Variant found in a case with an alternate molecular basis for disease (dominant variants) 
– C9orf72 expansions were considered alternative molecular explanations for disease. 
BP6: Reputable source recently reports variant as benign but evidence is not available for 





BP7: A synonymous variant for which splicing prediction algorithms predict no impact to the 
splice consensus sequence nor the creation of a new splice site, AND, the nucleotide is not 
highly conserved - Splicing algorithms – MaxEntScan >7 for splice impact and dbscsnv >0.8 
for splice impact.  
VUS: Does not meet any of the above criteria or conflicting evidence (pathogenic and benign 
criteria met) 
 
 
